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Abstract 
Platinum-based anticancer drugs are believed to exert their action through chemical 
reactions with genomic DNA, forming adducts with DNA bases. Although the 
pharmacology of such adducts has been widely studied, the cytotoxic mechanism 
remains unclear. The possibility that non-DNA molecules have the potential to alter the 
types of adducts formed has received very little attention, and limited information is 
available on the levels of adducts formed in clinical tumours. Further understanding of 
platinum-DNA adduct formation may be important in explaining the efficacy of 
platinum-based drugs in different tumour types, providing insights into both the 
cytotoxic mechanism and the development of clinical resistance. 
  
The aims of the work described in this thesis were: a) to analyse the nature of DNA 
adducts formed by three clinically used platinum-based anticancer drugs and to 
investigate the potential intracellular formation of additional types of adducts to those 
previously characterised on pure DNA; b) to determine platinum-DNA adduct levels 
formed in solid ovarian cancer tissue following treatment of patients with carboplatin 
and test the hypothesis that these levels are comparable to the levels of DNA adducts 
formed in blood cells; and c) to determine whether sodium thiosulfate (STS), which is 
currently in clinical trials to protect against cisplatin-induced normal tissue toxicity, 
impacts on DNA adduct formation. 
 
Analysis of the properties of all DNA adducts formed in cells was made possible by 
analysing enzymatically digested DNA using anion exchange chromatography together 
with inductively-coupled plasma mass spectrometry (ICP-MS). Putative adducts 
involving deoxyguanosine monophosphate cross-linked via cisplatin to glutathione 
were prepared and the chromatographic properties determined. Studies were carried out 
to characterise the types of adducts formed following incubations of cisplatin with four 
cancer cell lines. No additional types of adducts were observed compared to those 
formed by the reaction of cisplatin with pure DNA. The chromatographic behaviour of 
adducts formed in cells incubated with carboplatin and oxaliplatin were comparable to 
those formed by cisplatin. 
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This study is the first to investigate carboplatin-DNA adduct levels induced in solid 
tumours during therapy in patients. Total DNA adduct levels in tumour biopsies and 
blood cells were measured using ICP-MS with thallium as an internal standard. Tumour 
biopsies from all four patients studied showed clearly detectable levels of treatment-
induced DNA adducts ranging from 1.9 - 4.2 nmoles Pt/g DNA. Blood cell adduct 
levels ranged from 0.15 – 3.5 nmoles Pt/g DNA. Both tumour and blood cell adduct 
levels were significantly above background measurements. No correlation was 
observed between adduct levels in DNA from biopsies and levels in DNA from 
peripheral blood cells. 
 
Concurrent incubation of four human tumour cell lines with cisplatin and STS caused 
greater than 2-fold decreases in total DNA adducts. Delayed administration of STS had 
no effect of adducts levels. STS did not appear to affect the chromatographic behaviour 
of DNA adducts formed in cells following incubation with cisplatin.  
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Chapter 1 
Introduction 
 
1.1: Cancer and Cancer Treatment 
 
1.1.1: Cancer 
 
1.1.1.1: The origin of the word cancer 
 
The Edwin Smith papyrus (c1600 B.C.) and the Ebers papyrus (c1550 B.C.) are 
believed to be two of the oldest surgical documents, and the first to describe tumours of 
the breast and uterus respectively. Furthermore, they are based on material from a 
thousand years earlier. The term cancer however is credited to the Greek physician 
Hippocrates (460-370 B.C.) who used the terms carcino‟s and carcinoma to describe 
non-ulcer-forming and ulcer-forming tumours. In Greek terminology these words refer 
to the crab, probably applied describing the spreading projections from a cancer in a 
similar manner to that of the shape of the crab (Diamandopoulos 1996). Some of the 
earliest direct evidence of cancer was found in bone tumours in ancient Egyptian 
mummies. 
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1.1.1.2: What is cancer? 
 
Cancer is a non-specific term that describes a group of diseases characterized by 
deregulated growth mechanisms. Normal cells acquire the ability to proliferate 
abnormally to form tumours, which can be benign or malignant. This “transformation” 
from normal to cancerous cells is a multi-stage process, and major advances have been 
made in demonstrating that many of the steps involved reflect genetic alterations or 
abnormalities. Normal cells acquire tumourogenic potential as a result of an initiating 
factor causing mutations, for example chemicals or radiation. Mutations can also occur 
through spontaneous DNA damage. Hanahan and Weinberg proposed that the 
transformation of cells to a cancerous genotype involves six hallmark characteristics, 
shown in Figure 1.1 (Hanahan and Weinberg 2000). A brief description of each 
proposed acquired potential is given below. 
 
 
Figure 1.1: Acquired capabilities of cancer cells (Hanahan and Weinberg 2000). 
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Acquired Capability: Self -sufficiency in growth signalling 
In normal cells, mitogenic growth signal cascades control the progression from a 
quiescent state into an active proliferative state. Oncogenes are mutated forms of proto-
oncogenes usually involved in the positive regulation of this progression. Activation of 
proto-oncogenes can occur through point mutations, amplification, translocation and/or 
epigenetic up-regulation, causing normal cells to grow uncontrollably and giving them 
a selective growth advantage. Examples of these include growth factors such as 
platelet-derived growth factor and tumour growth factor α (Fedi et al 1997) and growth 
factor receptors such as EGF-R/erb2 and HER2/neu, both up-regulated in stomach and 
breast cancers (Yarden and Ullrich 1988, Slamon et al 1987). Growth signalling 
autonomy can also arise through alterations in the downstream signalling circuitry that 
processes growth signalling, such as the SOS-Ras-Raf-MAPK cascade. The Ras protein 
has been found to be structurally altered in approximately 25% of human tumours, 
allowing continuous signalling without stimulation from their normal upstream 
regulators (Medema and Bos 1993). 
 
Acquired Capability: Insensitivity to anti-growth signalling 
Normal cells and tissues receive multiple anti-proliferative signals which act to either 
force cells into the quiescent (G0) state of the cell cycle, or to permanently relinquish 
their proliferative capabilities. Tumour suppressor genes code for proteins that function 
in the opposite manner to that of oncogenes, with a primary function of slowing cell 
division and maintaining genetic stability. At the molecular level, many, if not all anti-
proliferative signals are processed by the retinoblastoma protein (pRb) (Hanahan and 
Weinberg 1996), which in its hyperphosphorylated form, blocks progression from G1 to 
S phase in the cell cycle (Weinberg 1995). Functional impairment of tumour suppressor 
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gene signalling can be a result of reduced expression, mutation or deletion and leads to 
uncontrolled cellular growth and genetic instability. The anti-proliferative signalling 
circuit that acts through pRb is disrupted in a majority of human cancers (Dyson et al 
1989, Fynan and Reiss 1993, Markowitz et al 1995, Schutte et al 1996, Chin et al 
1998). 
 
Acquired Capability: Evasion of apoptosis 
Programmed cell death (apoptosis) is a process that maintains the healthy development 
of multi-cellular organisms, and evidence suggests the apoptotic program is present in 
virtually all cell types found throughout the body. The ability of tumour cell 
populations to expand is determined both by the ability of the population to maintain 
proliferation, and also to evade apoptosis. Acquired resistance to apoptosis is a 
hallmark of most types of cancer and can occur through a variety of mechanisms. The 
most commonly occurring loss of pro-apoptotic regulation involves mutation of the p53 
protein, and inactivation of p53 is found in greater than 50% of human cancers 
(Anthoney et al 1996, Harris 1996, Soussi and Wiman 2007), although not all cancers 
are hallmarked by p53 mutations (Peng et al 1993). Loss of the tumour suppressor 
pTEN has been linked to mitigating apoptosis (Cantley and Neel 1999), and 
mechanisms for avoiding death signals conveyed through the FAS receptor have been 
found in lung and colon cancers (Pitti et al 1998). 
 
Acquired Capability: Limitless replicative potential 
Cellular senescence is a phenomenon that stops cells from proliferating indefinitely, 
effectively giving cells a finite lifespan. Immortality genes allow cells to proliferate 
indefinitely. Cancer cells are often described as immortal, and this may be attributed to 
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up-regulation of telomerase, an enzyme that adds specific DNA repeats (3‟-TTAGGG-
5‟) to the ends of telomeres (Zakian 1995). Telomeric DNA comprises tandem repeats 
that protect the chromosome from degradation. During replication DNA is shortened 
and in normal dividing cells critical shortening of telomeres can cause cells to stop 
replicating and senesce (Harley et al 1990, Hastie et al 1990).  Up-regulation of 
telomerase enables cancer cells to overcome telomere shortening by continually 
synthesising the repeat sequence, effectively immortalizing the cells. This has been 
demonstrated in many different tumour types (Kim et al 1994, Hiyama et al 1995 (a), 
Hiyama 1995 et al (b), Langford et al 1995, Hiyama et al 1996, Shay and Wright 1996, 
Wright et al 1996). 
 
Acquired Capability: Sustained angiogenesis 
Cell function and survival is critically dependent on a constant supply of oxygen and 
nutrients provided by the vasculature. This dependence on supply obliges virtually all 
cells to reside within 100 µm of a capillary blood vessel (Hanahan and Weinberg 1996). 
This closeness is maintained during organogenesis, and the process of angiogenesis is 
closely regulated. It was initially assumed therefore that proliferating cells were 
intrinsically able to stimulate blood vessel development, but the evidence suggested 
otherwise. Proliferating cells initially lack angiogenic signalling capacity, and the 
ability to induce and sustain angiogenesis is therefore a critical step in tumour 
development. This ability is believed to be acquired during tumour development 
through an “angiogenic switch”, and this was found to be activated in mid-stage 
lesions, prior to full tumour appearance, although the mechanisms involved are poorly 
understood (Reviewed in Hanahan and Folkman 1996). Angiogenesis inhibitors have 
been found to impair the growth of human tumour cells inoculated into mice (Folkman 
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1997) and tumours in cancer-prone transgenic mice have demonstrated susceptibility 
(Bergers et al 1999), further supporting the essential role of angiogenesis in tumour 
development. 
 
Acquired Capability: Tissue invasion and metastasis 
In addition to the alterations described above, full malignancy is associated with the 
spread of tumour cells outside of the site of origin, invading neighbouring tissues and 
allowing the tumours to metastasise. Metastasis describes the movement and 
subsequent re-development of cancer cells from their primary site to secondary 
locations around the body, facilitated by transport through the vasculature. Metastasis is 
a defining event in cancer and is believed to account for 90% of human cancer deaths 
(Sporn 1996). Invasion and metastasis are complex mechanisms, and the genetics and 
biochemical processes involved are incompletely understood. 
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1.1.2: Cancer treatment 
 
Early detection of cancerous cells significantly improves outcome for patients, 
increasing the potential for complete elimination of the malignant population. However, 
in many cases by the time of diagnosis the tumour has already metastasised and 
invaded vital organs, complicating treatment and resulting in poorer prognosis. Cancer 
therapy is therefore often multi-modal, involving surgery, radiotherapy and/or 
chemotherapy.  
 
1.1.2.1: Surgery 
 
For established solid cancers, removal of the tumour by surgery is the preferred 
approach to treatment. In the early stages of tumour development surgery can be 
curative, as can cyto-reduction surgery followed by chemotherapy. However surgery 
has many limitations and excision of the full tumour from essential organs such as the 
brain or lungs is often not possible. For most haematological cancers, such as 
leukaemia, lymphoma and myeloma, surgery is not an option. Furthermore for cancers 
that have spread through metastasis, surgery is mainly of palliative value to patients.  
 
1.1.2.2: Radiotherapy 
 
There are three main divisions of radiotherapy used clinically: external beam 
radiotherapy, brachytherapy (sealed source radiotherapy) and systemic radioisotope 
therapy (unsealed source radiotherapy). Conventional external beam radiotherapy 
consists of a single beam of ionising radiation, often in the form of x-rays, being 
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delivered to the patient from several directions but is limited by collateral damage to 
surrounding tissues. Stereotactic and 3-D conformal radiotherapy were developed in an 
attempt to reduce the collateral damage, and involve focusing directed beams of 
radiation to the tumour using well defined scans and images of the tumour. Particle 
therapy is another form of external beam radiotherapy that involves directing energised 
particles (protons or carbon ions) to the tumour. Brachytherapy is delivered by placing 
the radiation source directly at the site of treatment, which limits the irradiation to a 
localized area and minimises surrounding tissue damage, allowing for higher doses of 
radiation to be used. Brachytherapy is commonly used in the treatment of cervical, 
prostate and breast cancer (Gaffney et al 2007, Morris et al 2009, Polgar and Major 
2009). Systemic radioisotope therapy generally involves infusion of isotopes either 
alone, or coupled to another molecule or antibody to target specific tissues. A major use 
of systemic radiotherapy is in the treatment of bone metastasis (Lin and Ray 2006). 
Radiotherapy however is not effective as a single modality treatment for cancer, and as 
with surgery, radiotherapy has limited application in haematological malignancies. For 
advanced metastatic cancers, radiotherapy is mainly of palliative value. 
 
1.1.2.3: Chemotherapy 
 
One of the major advantages of chemotherapy over alternative treatments is the 
potential to treat tumours that have metastasised or which are in surgically inaccessible 
locations. Chemotherapy is generally divided into two categories; cytotoxic 
chemotherapy and targeted chemotherapy. Cytotoxic chemotherapy kills cancer cells 
through the inhibition of replication and mitotic division. There are numerous classes of 
cytotoxic chemotherapeutic agents that elicit their effect in a number of ways and show 
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varying efficacy against different tumour types. The cytotoxic agents were amongst the 
earliest anticancer drugs to be discovered at a time when the underlying biology of 
cancer was poorly understood. The first cytotoxic agents to demonstrate anti-tumour 
activity were the mustards, developed after the discovery that soldiers exposed to 
“mustard gas” (1,5-dichloro-3-thiapentane) during World War One often presented 
with leukopaenia (Reviewed in Hall and Tilby 1992). Although treatment of superficial 
tumours with small quantities of liquid sulfur mustard was possible, damage to 
surrounding tissue was severe and administration was a hazard for both patient and 
clinician. During the Second World War, in an effort to create improved chemical 
warfare agents, the sulfur atom of mustard gas was replaced by an amine. These new 
“nitrogen mustards” were less reactive than their sulfur counterpart, and were entered 
into clinical trials in 1942, although no data was published until 1946 due to wartime 
secrecy constraints. Many derivatives of the nitrogen mustards were synthesised and 
tested in animal tumour systems, and it was shown that having a benzene ring coupled 
to the nitrogen mustard reduced the reactivity of the chloroethyl groups of the mustard. 
This increase in the chemical half life of the drug allowed more effective distribution 
throughout the body. After nitrogen mustard itself (mechlorethamine), chlorambucil 
was the first analogue of this type to be successful in clinical practice, and is still used 
today in the treatment of chronic lymphocytic leukaemia (CLL) (Begleiter et al 1994, 
Begleiter et al 1996). During the second half of the 20
th
 century a number of major 
cytotoxic drugs were discovered through screening programmes.  
 
The vast majority of cytotoxic agents act to kill cells by disrupting DNA function and 
synthesis, with the notable exceptions of the vinca alkaloids and the taxanes which 
disrupt microtubule dynamics. Cytotoxic agents may act through chemical reactions 
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with DNA to form adducts (alkylating and platinating agents), blocking synthesis of 
DNA precursors (anti-metabolites), blocking enzymes that control DNA structure 
(topoisomerase poisons), or by affecting microtubule metabolism (tubulin binding 
agents). The platinum-based chemotherapy drugs are sometimes described as being 
“alkylating-like” agents as they form adducts on DNA but they do not contain an alkyl 
group. 
 
It is generally thought that dividing cells are more susceptible to cytotoxic 
chemotherapy. Rapidly dividing cells, such as cells in bone marrow, hair follicles and 
the intestinal lining are frequent sites of toxicity (Corrie 2004). Dysregulation of cell 
growth and cell cycle checkpoints, both common hallmarks of many cancers, could 
potentially explain why cancer cells can be more susceptible to cytotoxic drugs 
compared to normal tissues. 
 
The cytotoxic agents have generally been used clinically with limited or no 
understanding of their mechanism of action. This contrasts to targeted agents, which are 
being developed strategically to target a specific characteristic of a tumour. The first 
successful small molecule drug of this class was the tyrosine kinase inhibitor Imatinib 
(Glivec). This works by blocking the active site of the fused bcr-abl protein, a product 
of the rearranged genes in the Philadelphia chromosome. It is used for chronic myeloid 
leukaemia (CML) and gastrointestinal stromal tumours (GISTs) (Kantarjian et al 2001, 
Kantarjian and Talpaz 2001, Eisenberg et al 2003). Trastuzumab (Herceptin) is a 
monoclonal antibody that was designed to target the HER2/neu receptor, amplified in 
breast cancer. It has had a significant impact in the treatment of metastatic HER2
+
 
breast cancer (Baselga et al 1998, Baselga et al 1999). Although there have been 
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important advances in targeting tumours for many types of cancer, cytotoxic 
chemotherapy is likely to remain the most effective treatment for the immediate future, 
and seems likely to continue to play an important role in combination with new targeted 
agents, particularly drugs that inhibit DNA repair, such as inhibitors of PARP 
(Calabrese et al 2004, Curtin 2005) and DNA PK (Salles et al 2006, Zhao et al 2006, 
Bolderson et al 2009). It is therefore important to continue to improve our 
understanding of the precise mechanisms involved in the anticancer activity of both 
newer and more established agents. 
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1.2: Platinum Complexes 
 
1.2.1: Discovery of cisplatin 
 
Diamminedichloroplatinum (DDP) is an inorganic compound with platinum (II) atom 
co-ordinated to two ammonia molecules and two chlorine atoms. It was first described 
by Michel Peyrone in 1845 and originally known as Peyrone‟s salt (Peyrone 1845). The 
chemical structure was elucidated in 1893 by Alfred Werner (Werner 1893) and is 
shown in Figure 1.2.  
 
 
Figure 1.2: The chemical structure of diamminedichloroplatinum (II) in cis- and trans- 
isomers 
 
Diamminedichloroplatinum (II) was re-discovered in 1965 at Michigan State University 
by Dr Barnett Rosenberg (Rosenberg et al 1965). Rosenberg was investigating the 
effects of electric fields on growth processes of Escherichia coli cells. Experiments 
were carried out in a continuous culture chamber in a chemically defined medium. 
Importantly this growth medium contained ammonium chloride. The electric current 
was applied using an audio oscillator generating between 50 and 10
5
 c/s frequency 
(alternating current). Platinum electrodes were chosen as they were believed to be 
chemically inert and alternating current chosen to eliminate the effects of electrolysis 
and electrode polarization. 
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Microscopic examination of the E. coli cells showed that cell division ceased after 1-2 
hours of exposure to the electric field. However the bacteria continued to elongate, 
growing unusually long and filamentous, to up to 300 times their normal length of 
between 2 – 5 µm as shown in Figure 1.3 (Rosenberg et al 1965). Further investigation 
concluded that the reason for the inhibition of bacterial cell division was not the action 
of the electric field directly on the cells, but platinum-containing chemical species 
formed between the platinum electrodes and the bacterial growth medium containing 
ammonium chloride. Many platinum-containing complexes were discovered in the 
media, with the most biologically active being the chemically neutral 
diamminedichloroplatinum (II) (Rosenberg et al 1965, Rosenberg 1967 et al (a). 
Rosenberg further concluded that it was the cis- conformation (cis-DDP) and not the 
trans- conformation that was the active species (Rosenberg 1967 et al (a), Rosenberg et 
al 1967 (b)). 
 
 
Figure 1.3: Scanning electron micrograph of E. coli grown in normal media (A) and in 
normal media containing low levels of cis-DDP (B). Figure taken from Lippert 1999 
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1.2.2: Cisplatin – from bench to bedside 
 
Following on from the interesting results found in bacteria, Rosenberg hypothesised 
that cis-DDP might be effective at inhibiting cell division in mammalian cells, and 
investigated the effects on two murine cell lines implanted into mice (Sarcoma 180 and 
Leukaemia L1210). Cis-DDP was injected i.p. at 0.5 – 2.0 mg/kg daily and 1.25 – 10.0 
mg/kg daily for mice implanted with Sarcoma 180 and L1210 cells respectively. There 
was a marked difference between the treated groups compared with the untreated, with 
cis-DDP causing tumour regression, and a complete cure in mice which were kept alive 
for 6 months (Rosenberg et al 1969). Following confirmatory in vivo investigations 
which were carried out at the Chester Beatty Institute (UK), cis-DDP was entered into 
clinical trials in 1970, with encouraging results obtained despite toxic side effects 
(Kelland 2007). The first patients were treated with cis-DDP in 1971, and the drug was 
approved for clinical use by the Food and Drug Administration (FDA) against 
metastatic testicular and metastatic ovarian cancer in 1978, under the generic name 
cisplatin. 
 
Cisplatin is currently used clinically in the treatment of a variety of different cancers as 
a single agent, or more commonly, as part of combination therapies. Administration is 
generally intravenous, and adults typically receive doses of 50 – 100 mg/m2 repeated 
every 3 to 4 weeks (McKeage 1995). Prior to the introduction of cisplatin, the cure rate 
for testicular cancer was approximately 10%. However, currently more than 90% of 
patients are cured after undergoing surgery and chemotherapy, and this improvement 
was mainly due to the introduction of cisplatin in combination therapy. Ovarian cancer 
response rate to chemotherapy prior to the introduction of cisplatin was between 30-
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60%, with 5 year survival less than 10% (Young et al 1974). Use of cisplatin as a single 
agent showed a response rate of 50% in previously untreated patients, and in 
combination with doxorubicin this rose to between 55-96% (Cvitkovic et al 1977). 
Cisplatin use in ovarian cancers however has been widely superseded by carboplatin 
(discussed in section 1.2.3). Cisplatin is also an important drug in combination therapy 
for treatment of bladder cancer (Noguchi et al 1992, Keane et al 1994, Hussain et al 
2001), and in other cancers such lung and neuroblastoma (Meczes et al 2002, Lee et al 
2004, Mishima et al 2004, Hirose et al 2006, Feliu et al 2009). 
 
Clinically, despite its broad spectrum of activity, cisplatin is very toxic and causes 
severe side effects in some patients even following single doses ≥ 50 mg/m2. These 
include nephrotoxicity, ototoxicity, myelosuppression, neurotoxicity, and also nausea 
and vomiting (McKeage 1995). Less common side effects that have been linked to 
cisplatin include pancreatitis, seizures and vision loss (Loehrer and Einhorn 1984). 
Nephrotoxicity is potentially the most severe side effect encountered in cisplatin-treated 
patients, and involves cumulative damage to both tubules and glomeruli (Weiner and 
Jacobs 1983, McKeage 1995). Saline hydration can be used to decrease nephrotoxicity, 
but it does not completely prevent the damage (Hayes et al 1977, Al-Sarraf et al 1982). 
Cisplatin induced ototoxicity is cumulative with treatment, and causes irreversible 
damage to the inner ear cells (Rybak et al 2005, Thomas et al 2006). Myelosuppression 
is considered a mild toxicity which allows combination of cisplatin with other highly 
myelosuppressive agents (McKeage 1995). Cisplatin causes leukopaenia in up to 50% 
of patients, with a typical onset of between 6-26 days, and recovery occurring between 
days 21-45 (Von Hoff et al 1979). Cisplatin also causes thrombocytopaenia in nearly 
half of all patients, with a typical onset between 10 to 26 days, whilst recovery occurs 
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between days 22 to 45 (Von Hoff et al 1979). Anaemia has also been reported in some 
patients (Von Hoff et al 1979). Neurotoxicity presents often in the form of peripheral 
neuropathy, seizures and muscle cramps (Cersosimo 1989, Harmers et al 1991). Nausea 
and vomiting can last up to 24 hours after treatment, though is easily treatable with 
anti-emetics. Toxicity limits administration of higher doses of cisplatin and can result in 
early cessation of therapy. 
 
1.2.3: Carboplatin 
 
In an effort to improve the efficacy of platinum drugs and decrease the severe toxicities 
associated with cisplatin, other platinum-containing compounds were screened for 
anticancer activity (Kelland 2007). One of the most successful of these compounds was 
cis-diammine-[1,1-cyclobutanedicarboxylato] platinum (II), (cis-Pt(NH3)2CBDCA-
O,O’) (Figure 1.4) developed in an industry-academia collaboration between the 
Institute of Cancer Research (ICR) in London, and Johnson-Matthey Plc (Reviewed in 
Kelland 1993 and Kelland 2007). Cis-Pt(NH3)2CBDCA-O,O’ proved significantly less 
toxic than cisplatin, particularly to the kidneys and nervous system (McKeage 1995, 
Ozols et al 2003), whilst maintaining comparable anti-tumour activity, especially in 
ovarian cancer (Aabo et al 1998, Sandercock et al 2002, Ozols et al 2003). It is thought 
that the more stable bound CBDCA leaving group is the reason for greater stability of 
the compound and the decrease in toxicity compared to cisplatin.  
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Figure 1.4: The chemical structure of carboplatin 
 
Cis-Pt(NH3)2CBDCA-O,O’ was approved by the FDA for palliative treatment of 
ovarian cancer following previous chemotherapy in 1989, and as a first-line agent 
against ovarian cancer in 1991, under the generic name carboplatin. Currently, 
carboplatin is widely used in the treatment of advanced ovarian cancer in combination 
with paclitaxel (Sandercock et al 2002). Carboplatin has also been used in combination 
treatments for hormone refractory prostate cancer (Urakami et al 2002), 
nephroblastoma (Kremens et al 2002) and non-small cell lung cancer (Vieitez et al 
2003).  
 
Long-term follow up studies of renal function in patients treated with carboplatin 
showed no significant effects on renal function (Mason 1991), although carboplatin at 
doses higher than 1200 mg/m
2
 has been associated with reductions in glomerular 
filtration rate in over 50% of patients (Gore 1987). Typical doses for adults receiving 
carboplatin are between 250-400 mg/m
2
 (McKeage 1995) or doses based on individual 
patient GFR (Calvert et al 1989). Haematological toxicity is the major dose-limiting 
toxicity associated with carboplatin, with thrombocytopaenia a greater problem than 
leukopaenia at conventional doses (Calvert et al 1982, Curt et al 1983). Carboplatin is 
often used in high-dose chemotherapy (greater than 1200 mg/m
2
) due to its lack of non-
haematological toxicities, although more than 90% of patient‟s present grade IV 
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neutropaenia and thrombocytopaenia in these regimes. Carboplatin has also been linked 
with ototoxicity in humans and animals (Kennedy 1990, McAlpine and Johnstone 
1990) but this is only dose-limiting when carboplatin dosing is greater than 2000 mg/m
2
 
(Kennedy et al 1990, McAlpine and Johnstone 1990, Neuwelt et al 1996). Compared to 
cisplatin, carboplatin is associated with greatly reduced neurological toxicity (Shea et al 
1989) and is considerably less emetogenic (Harvey et al 1991). 
 
 1.2.4: Oxaliplatin 
 
Oxaliplatin (1R,2R-diaminocyclohexane)oxalatoplatinum(II)) (Figure 1.5) was 
originally discovered in 1976 at Nagoya City University, Japan (Kidani et al 1978). It 
was licensed to Debiopharm for development as a treatment for advanced colorectal 
cancer. Sanofi-Avensis gained the license in 1994, and oxaliplatin became licensed for 
clinical use in Europe in 1996 under the trade name Elaxotin. The FDA initially 
approved oxaliplatin for treatment of metastatic colorectal cancer (second line) in 2002, 
and as a first line agent in 2004 (Kelland 2007). Oxaliplatin is based on the 1,2-
diaminocyclohexane carrier ligand (DACH), and is a more water soluble derivative of 
the failed drug tetraplatin (Kelland 2007). DACH compounds were thought to be 
promising as drugs development targets due to their lacking of the major toxicities of 
cisplatin and carboplatin (Burchenal et al 1979, Hoeschele et al 1994, Monti et al 
2005). Also, of particular importance, cells resistant to cisplatin have demonstrated a 
lack of cross-resistance with oxaliplatin (Fukuda et al 1995, Rixe et al 1996). 
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Figure 1.5: The chemical structure of oxaliplatin 
 
Oxaliplatin has demonstrated modest activity when used as a single agent in the 
treatment of colorectal cancer (Machover et al 1996) but greater activity when used in 
combination with 5-fluorouracil and folinic acid (Levi et al 1992). Neither cisplatin nor 
carboplatin demonstrate any significant clinical activity against colorectal cancer. 
Oxaliplatin has also been reported to have activity as both a single agent (Misset et al 
1991) and in combination with cisplatin and/or paclitaxel (Soulie et al 1997, Faivre et al 
1999, Delaloge et al 2000, Piccart et al 2000) in the treatment of ovarian cancer. 
 
The major dose limiting toxicity with oxaliplatin is peripheral neuropathy, associated 
with acute paraesthesia of the lips and extremities, and peripheral sensory neuropathy 
can develop with repeated treatment (Extra et al 1990). Other toxicities associated with 
oxaliplatin include myelosuppression, emesis and gastrointestinal tract toxicity. 
Nephrotoxicity observed following oxaliplatin treatment is far less severe than that 
associated with cisplatin allowing administration of oxaliplatin without hydration 
(Cassidy and Misset 2002). 
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1.3: Molecular mechanism of action of platinum complexes 
 
1.3.1: Identification of genomic DNA as the principle target for platinum 
complexes 
 
Platinum complexes can react with many molecules in the intracellular environment 
including DNA, RNA, proteins, membrane phospholipids and cytoskeletal 
microfilaments (Akaboshi et al 1992, Kopf-Maier and Muhlhausen 1992, Speelmans et 
al 1996, Speelmans et al 1997). It is commonly accepted that platinum binding to DNA 
is responsible for the major cytotoxic effects of platinum complexes (Jamieson and 
Lippard 1999, Wong and Giandomenico 1999) although only 5-10% of the total 
platinum binding is to DNA, with the majority (85-90%) binding to proteins (Fuertes et 
al 2003).  
 
Some of the earliest evidence that identified DNA as the principal cellular target was 
the filamentous growth of bacteria induced by cisplatin (Rosenberg et al 1965, Witkin 
1967). This is a common attribute to DNA damaging agents such as UV and ionising 
radiation. DNA damaging agents also cause lysis of E. coli cells containing 
bacteriophage λ, and this phenomenon was demonstrated with cisplatin (Reslova 1971). 
Most of this initial evidence was obtained in bacteria. Investigation of DNA, RNA and 
protein synthesis using radiolabelled precursors provided early indications that DNA 
was also the target for cisplatin in mammalian cells. DNA synthesis was inhibited when 
cells were exposed to cisplatin, but there was no effect on RNA or protein synthesis 
(Harder and Rosenberg 1970, Howle and Gale 1970), further implicating DNA as the 
principle target. Additional studies investigating the mechanisms are discussed in 
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greater detail in section 1.3.3, providing further evidence supporting DNA as the 
principle target (Roberts and Pascoe 1972, Fichtinger-Schepman et al 1985). 
 
1.3.2: Behaviour of platinum complexes in cells and tissues 
 
Once administered into the bloodstream, cisplatin is believed to remain in its non-
aquated form due to the high chloride ion (Cl
-
) concentration. Cisplatin uptake into 
cells and tissues is a much debated issue and is addressed in section 1.4. It is proposed 
that a lower intracellular chloride ion concentration facilitates the aquation of cisplatin 
to its active form, but this is a debated topic. The effects of intracellular chloride ion on 
the pharmacodynamics of cisplatin are reviewed in Jennerwein and Andrews 1995. 
 
Cisplatin reacts with biological molecules by substitution of one or both of the chlorine 
atoms. Cisplatin in its dichloro form (Figure 1.6, structure A) is not believed to be 
reactive with molecules such as DNA, and it appears that initially one or both of the 
chlorine atoms must be replaced by water molecules (Riley et al 1983, el Khateeb et al 
1999) (Figure 1.6, structures B and D). This is kinetically favourable because of the 
high concentration of water (~ 55 M). The resulting positively charged mono- or di-
aqua derivatives of cisplatin are the species which are believed to react with DNA. The 
reaction with DNA involves the substitution of a water molecule, and investigation with 
free nucleobases and short oligo-nucleotides provided evidence that platinum binds to 
the N7 atom of guanine, the N7 and N1 atoms of adenine, and the N3 atom of cytosine 
(Marcelis et al 1984, Hambley 1997, Wang and Lippard 2005). In polymeric DNA 
however it has been shown that the substitution of a water molecule occurs primarily at 
the N7 position of guanine and adenine. In DNA, the N7 atoms of the purines are 
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exposed on the surface of the major groove of DNA, making them very accessible to 
metal binding (Sherman and Lippard 1987). The aquated cisplatin molecule can also 
undergo ionisation to yield neutral hydroxy derivatives (Figure 1.6, Structures C, E and 
F), thought to be non-reactive with DNA. It seems likely that two factors contribute to 
the reactivity of the aquated form of cisplatin with DNA. Firstly, the Pt-O bond is less 
stable than Pt-Cl (Zhou et al 1994), and secondly, the overall positive charge on the 
molecule will result in electrostatic interaction to DNA. As discussed above, it is 
believed that DNA bases are unable to directly attack the non-aquated molecule. 
 
 
Figure 1.6: Different chemical species of cisplatin. Cisplatin can potentially form six 
species from aquation with water or ionisation: A, cis-Pt(NH3)2Cl2; B, cis-
Pt(NH3)2(Cl)(OH2); C, cis-Pt(NH3)2(Cl)(OH); D, cis-Pt(NH3)2(OH2)2; E, cis-
Pt(NH3)2(OH)(OH2) and F, cis-Pt(NH3)2(OH)2. These species occur in equilibrium in 
solution.  
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1.3.3: Platinum-DNA (Pt-DNA) adducts formed by platinum complexes 
 
The establishment of DNA as the major target for cisplatin led to further investigations 
to characterise the nature of platinum binding to DNA. The interaction with DNA is 
believed to be a multi-step process which involves formation of monofunctional lesions 
with the mono-aquated complex, followed by aquation of the second arm and closure to 
a bifunctional adduct. Cisplatin and carboplatin form the same bifunctional complexes 
with DNA of the general structure cis-Pt(NH3)2(R)2 where R represents individual 
bases of DNA. However, their intermediate complexes differ, with cis-[Pt(NH3)2Cl(OH 
2)]
+
 for cisplatin and cis-[Pt(NH3)2CBDCA(OH2)]
+
 for carboplatin. The diaqua form 
cis-[Pt(NH3)2(OH2)2]
2+
 is the same for both compounds but is much less prevalent 
(Kozelka et al 1999, McGowan et al 2005). As expected, aquation has been shown to 
be much slower for carboplatin than cisplatin (Knox et al 1986). The intracellular 
mechanism of removal of the oxalate ligand from oxaliplatin is unknown, but it is 
probable that, like cisplatin and carboplatin, it involves aquation. Pt(DACH)Cl2 had 
been proposed previously as a potential intermediate product, and there is evidence that 
Pt(DACH)Cl2 causes formation of two-fold more adducts than oxaliplatin in 
mammalian cells at equimolar concentrations (Luo et al 1998). However, further 
investigation showed that with Pt(DACH)Cl2 there was a 30-fold higher intracellular 
platinum level, so the conversion from oxaliplatin to Pt(DACH)Cl2 seems to make only 
a minor contribution to oxaliplatin cytotoxicity. 
 
Before the development of chromatographic methods to separate and characterise Pt-
DNA products the only specific adducts that could be detected were cross-links 
between two opposite strands of DNA. Roberts et al used a caesium chloride density 
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gradient centrifugal technique based on 5-bromo-2'-deoxyuridine (bUDR) 
incorporation to separate and study cross-linking of “light” and “heavy” strands of 
DNA (Roberts and Pascoe 1972). When incubated with cisplatin, a third chain of 
“hybrid” DNA consisting of both strands of DNA was detected. The study further 
investigated the formation of these cross-links by using concomitant radioactive and 
density labelling of DNA to achieve radiolabelled heavy chain DNA. The extent of 
formation of hybrid DNA was found to be dependent on the concentration of platinum.  
 
Early techniques to study Pt-DNA cross-links however were unable to investigate the 
formation of specific adducts. Interstrand cross-links could be analysed, but based on 
the size of DNA have been shown to account for less than 1% of the total Pt-DNA 
adducts (Roberts and Friedlos 1981). Atomic absorption spectrometry (AAS) has been 
used to study total Pt-DNA adducts, but due to its inherent lack of sensitivity for 
platinum has limited application for studying specific adducts. Pt-DNA adducts have 
also been shown to block DNA synthesis in vitro (Pinto and Lippard 1985) but such 
methods don‟t address the nature or proportions of such adducts. Pt-DNA adducts have 
also been shown to block Taq polymerase primer extension in PCR reactions (Ponti et 
al 1991). 
 
A major step forward in understanding the nature of Pt-DNA adducts other than 
interstrand cross-links was the development of suitable chromatographic techniques. 
Several studies investigated the nature of Pt-DNA complexes using chromatographic 
separation methods, with three main strategies employed for these investigations. 
Approaches involving enzymatic digestion of platinated DNA were deployed by 
Eastman (Eastman 1983, Eastman 1985, Eastman 1986) and Fichtinger-Schepman et al 
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(Fichtinger-Schepman et al 1985, Fichtinger-Schepman et al 1987). A major difference 
between the two techniques was differing end-points of enzymatic digestion, and the 
results obtained were determined by the specificity of the enzymes used in the 
digestion. The third strategy involved removal of platinum-modified adenine and 
guanine bases from DNA by acid depurination, followed by separation of free and 
platinum-bound nucleobases by cation exchange chromatography (Johnson 1982, 
Johnson et al 1985). The latter technique was found to be less informative as it involved 
removal of the sugar-phosphate linkages between platinated bases. 
 
Fichtinger-Schepman et al enzymatically digested salmon sperm DNA that had been 
incubated with cisplatin using deoxyribonuclease 1 and nuclease P1. These enzymes 
cut 3' phosphate bonds resulting in the formation of 5' deoxyribonucleotides. It is 
suggested that these enzymes were unable to cut the deoxyribose-3'-phosphate bond 
between two adjacent platinum cross-linked deoxynucleotides. Anion exchange 
chromatography was used based on the use of DEAE-Sephacel and MonoQ columns to 
separate negatively charged nucleotides. The amount of DNA-bound platinum in 
collected fractions was determined by AAS (Fichtinger-Schepman et al 1985, 
Fichtinger-Schepman et al 1987). Eastman employed a method that involved digestion 
with alkaline phosphatase, resulting in deoxyribonucleosides, which were separated 
using reverse-phase chromatography (Eastman 1983, Eastman 1985, Eastman 1986).  
 
Analyses by Fichtinger-Schepman et al (Fichtinger-Schepman et al 1985) showed the 
separation of four major products after the reaction of pure DNA with cisplatin. They 
found that the major cross-link formed was the 1,2-intrastrand cross-link involving 
adjacent guanine bases (cis-Pt(NH3)2d(GpG)), with a 1,2-intrastrand cross-link 
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involving adjacent guanine and adenine bases (cis-Pt(NH3)2d(ApG)) also identified. 
Analysis by 
1
H-NMR analysis showed the product to be cis-Pt(NH3)2d(ApG) and not 
cis-Pt(NH3)2d(GpA). A third identified product was cis-Pt(NH3)2(dGMP)2. This was 
attributed to cross-links formed between guanines on opposite strands of DNA or 
between non adjacent guanines on the same strand of DNA (cis-Pt(NH3)2d(GpXpG)) 
The fourth product was found to be cis-Pt(NH3)3dGMP, proposed to form as a result of 
the monofunctional reaction of cisplatin with the N7 position of guanine. In the above 
mentioned work the second arm of monofunctionally bound cisplatin was inactivated 
by addition of ammonium bicarbonate before enzymatic digestion. Further studies 
revealed that the 1,2-intrastrand cis-Pt(NH3)2d(GpG) adducts accounted for 
approximately 60-65% of the total adducts formed. The 1,2-intrastrand cis-
Pt(NH3)2d(ApG) adduct accounted for 20-25%, and the 1,3-intrastrand cis-
Pt(NH3)2d(GpXpG) adduct accounted for 5-10%. Only a very small percentage (less 
than 1%) was comprised of interstrand cross-links or monofunctional lesions. If 
cisplatin reacted randomly with all the guanines in DNA, only 37% of the total adducts 
formed would be expected to be 1,2-d(GpG) (Fichtinger-Schepman et al 1985). The 
fact that over 60% of the total adducts are of this type suggests that cisplatin has a 
strong binding preference for adjacent guanines. 
  
Comparative analyses to the above were performed by Eastman, analysing DNA 
modified by [
3
H]-cis-dichloro(diethylenediammine)platinum (II) (cis-DEP). This gave 
similar results (Eastman 1986). Eastman showed that the major product formed was a 
cross-link between two deoxyguanosines connected by a phosphodiester linkage 
(dGpdG), followed by a similar adduct between adjacent deoxyadenine and 
deoxyguanosine (dApdG), with adenine always 5' to the guanine. A minor product 
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involving two deoxyguanosines with no phosphate (dG-Pt-dG) was also observed. A 
similar spectral distribution was obtained.  
 
However, the extension of analyses to DNA from drug-treated cells was not possible 
due to the low sensitivity of AAS for detecting platinum. The development of 
immunochemical (Fichtinger-Schepman et al 1987, Tilby et al 1991, Meczes et al 2005, 
Liedert et al 2006) and 
32
P post-labelling assays (Blommaert and Saris 1995, Welters et 
al 1997, Pluim et al 1999) enabled investigation of adducts in DNA extracted from cells 
where the levels of platinum were too low to detect by AAS.  
 
The first antibodies used in immunochemical studies (Fichtinger-Schepman et al 1987) 
were raised against dinucleotide cross-links in collected fractions eluted 
chromatographically and used in immunoassays to detect specific Pt-DNA cross-links. 
Unfortunately there are two major problems with this approach: firstly, the antibodies 
are raised against specific dinucleotide cross-links and would be incapable of detecting 
alternative cross-links, and secondly they wouldn‟t work on high molecular weight 
DNA. Antibodies that detect Pt-DNA cross-links on high molecular weight DNA have 
also been developed for use in immunoassays (Tilby et al 1991, Meczes et al 2005, 
Liedert et al 2006), but again are limited to detection of the cross-link antigen they are 
raised against and may not recognise new cross-links altogether. 
32
P post-labelling 
techniques have also been used to study cross-links (Blommaert and Saris 1995, 
Welters et al 1997, Pluim et al 1999). Briefly, in these assays Pt-DNA adducts are 
separated by strong cation exchange chromatography after enzymatic digestion, then 
deplatinated with sodium cyanide. The resulting dinucleotides are labelled with [γ-32P] 
ATP, then further separated by thin-layer or high-performance liquid chromatography. 
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Radioactivity is detected by scintillation counting. 
32
P post-labelling techniques have 
demonstrated high sensitivity for analysis of low levels of 1,2-intrastrand cis-
Pt(NH3)2d(GpG) adducts, and a less sensitive analysis of low levels of 1,2-intrastrand 
cis-Pt(NH3)2d(ApG) adducts. However, these assays are unable to detect interstrand 
and monofunctional products due to their lack of a 3' phosphate bond. 
 
Figure 1.7: Diagrams of the known adducts formed following the reaction of cisplatin 
with DNA. The majority of adducts formed are intrastrand (greater than 90%). Adducts 
can also form between DNA and non-DNA molecules. Diagram modified from Masters 
and Koberle 2003  
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The formation of Pt-DNA cross-links structurally distorts DNA and binding of cisplatin 
has been shown to unwind the helix and to disrupt helical stability (Maeda et al 1990). 
This destabilisation is more predominant with 1,2-intrastrand cis-Pt(NH3)2d(GpG) 
adducts and flanking base sequences have been demonstrated to alter the levels of 
destabilisation (Poklar et al 1996). Cisplatin binding has been shown to induce a bend 
in the helix towards the major groove, widening the minor groove with the 1,2 
intrastrand cis-Pt(NH3)2d(GpG) and cis-Pt(NH3)2d(ApG) adducts inducing 
approximately a 30-35˚ bend in the helix (Bellon and Lippard 1990, Bellon et al 1991). 
As the major and minor grooves are important in protein binding and recognition, and 
are sites of functional group presentation, helical disturbance can hinder the ability of 
proteins to interact with DNA. 
 
Carboplatin is believed to form the same types of cross-links as cisplatin (Knox et al 
1986). Blommaert et al incubated salmon sperm DNA with carboplatin, and 
demonstrated a similar profile of Pt-DNA adduct formation to that of cisplatin, with the 
1,2-intrastrand cis-Pt(NH3)2d(GpG) adducts accounting for approximately 58% of the 
total Pt-DNA adducts, the 1,2-intrastrand cis-Pt(NH3)2d(ApG) adducts accounting for 
approximately 11% of the total Pt-DNA adducts, 9% 1,3-intrastrand cis-
Pt(NH3)2d(GpXpG) adducts and 22% monofunctionally bound lesions (Blommaert et al 
1995). Platinum was detected using AAS. However, in the same study when Chinese 
hamster ovary cells were incubated with carboplatin and platinum levels determined by 
ELISA, the ratio of adducts was different, with 30% 1,2-intrastrand cis-
Pt(NH3)2d(GpG) adducts, 16%  1,2-intrastrand cis-Pt(NH3)2d(ApG) adducts, 40%  1,3-
intrastrand cis-Pt(NH3)2d(GpXpG) adducts and 14% monofunctionally bound lesions. 
These data suggest that unlike cisplatin, carboplatin does not show an intrinsic 
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preference for formation of 1,2-intrastrand cis-Pt(NH3)2d(GpG) adducts. Similar data 
was also provided by Fichtinger-Schepman et al (Fichtinger-Schepman et al 1995). In 
this study only the levels of 1,2-intrastrand cis-Pt(NH3)2d(ApG) adducts were 
comparable. It is interesting to note that a much higher concentration of carboplatin is 
required to achieve comparable platination levels to cisplatin (Blommaert et al 1995, 
Fichtinger-Schepman et al 1985). This may be reflective of differences in the rate of 
aquation (Knox et al 1986). 
 
Oxaliplatin is also believed to form the same types of adducts as cisplatin, albeit with a 
DACH ligand in the place of two ammonia molecules. Jennerwein et al analysed DNA 
incubated with oxaliplatin and separated by reverse-phase chromatography, and 
identified the same types of adducts as cisplatin at similar ratios (Jennerwein et al 
1989). Platinum was detected by AAS and the chemical nature of the products was 
confirmed by 
1
H-NMR. Oxaliplatin has demonstrated equal cytotoxicity to cisplatin 
(Saris et al 1996), and experiments have shown that the levels of adducts for oxaliplatin 
compared to cisplatin were significantly lower, both at equimolar and equitoxic 
concentrations (Saris et al 1996, Woynarowski et al 1998, Woynarowski et al 2000). 
The structural differences of oxaliplatin adducts appear to be biologically significant 
and appear to make them more toxic than similar levels of cisplatin adducts. 
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1.4: Resistance to Platinum Complexes 
 
Platinum-based drugs are one of the most commonly prescribed classes of anticancer 
agents in clinical use. Whilst patients can show good initial responses to platinum drug 
chemotherapy, resistance develops in most cases and is a major factor in therapeutic 
failure. Resistance to platinum drugs can be either intrinsic, i.e. a property of the 
tumour at the start of treatment, or may be acquired as a result of repeated exposure to 
the drug. When tumour cells become resistant to a platinum drug, they can also become 
cross-resistant to other drugs, and this has been demonstrated with other classes of 
cytotoxic drugs including melphalan, etoposide, adriamycin, mitoxantrone and taxol 
(Hamaguchi et al 1993). Cisplatin and carboplatin have also demonstrated cross-
resistance (Hamaguchi et al 1993). Resistance has been attributed to a number of 
different molecular mechanisms through studies involving cell lines (Figure 1.8). 
However, the underlying mechanisms that lead to development of resistance in clinical 
tumours are poorly understood. 
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Figure 1.8: Postulated mechanisms of resistance to cisplatin: Resistance could result 
from decreased uptake or increased efflux of the drug, both leading to decreased drug 
accumulation; inactivation by cytoplasmic thiols such as glutathione, or through an 
enhanced capacity for repair of or tolerance to Pt-DNA adducts. Taken from Kartalou 
and Essigman 2001 
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1.4.1: Decreased Drug Accumulation 
 
Drug accumulation is critical for therapeutic efficacy and has been studied in many cell 
lines, including human ovarian, testicular, head and neck, lung and murine L1210 cells 
(Strandberg et al 1982 (a), Strandberg et al 1982 (b), Andrews et al 1987, Richon et al 
1987, Teicher et al 1987, Waud 1987, Eastman and Schutte 1988, Hospers et al 1988, 
Parker et al 1991 (a), Dabholkar et al 1992, Kelland et al 1992). The majority of cell 
lines that are selected for resistance display a decreased accumulation phenotype, and 
this is generally considered to be a result of decreased uptake into the cell as opposed to 
increased efflux.  
 
The exact mechanism of uptake of platinum drugs is poorly understood and passive 
diffusion appears to be the main route, with evidence of some active transport (Fuertes 
et al 2003). Cells which are resistant to cisplatin often display resistance to copper 
(Katano et al 2002), and reduced uptake of cisplatin has been shown in cells deficient in 
the copper transporter CTR1 (Ishida et al 2002, Lin et al 2002). Human CTR1 has been 
shown to be localised to both the plasma membrane, and also in intracellular vesicle 
perinuclear compartments (Klomp et al 2002). CTR1 deficient cells have also been 
linked with reduced uptake of carboplatin and oxaliplatin (Lin et al 2002) and there is 
growing evidence linking the expression and function of the human copper transporter 
CTR1 with uptake of platinum complexes (Lin et al 2002, Holzer et al 2004 (a), Holzer 
et al 2004 (b), Safaei et al 2004 (a), Safaei et al 2004 (b), Safaei and Howell 2005, 
Chen et al 2008, Larson et al 2009). In particular, strong evidence linking an increase in 
cisplatin and copper uptake with increased expression of CTR1 came from experiments 
with human ovarian cancer cells transfected to over-express CTR1 (Holzer et al 2004). 
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However, it is noteworthy that, the increased uptake was not accompanied by an 
increase in Pt-DNA adducts compared to cells transfected with empty vector. It remains 
unclear whether reduced accumulation of platinum could result from reduced 
expression of CTR1 or impaired function of CTR1, but it is possible that varying levels 
of CTR1 expression in different tumours might contribute to the variable responses 
observed to platinum complexes.  
 
Resistance to platinum complexes has also been associated with increased efflux both 
from cells (Mann 1990) and from the nucleus into the cytoplasm (Wang et al 2004). 
The copper exporter pumps ATP7A and ATP7B have been linked with efflux of 
platinum complexes (Katano et al 2003, Samimi et al 2003, Samimi et al 2004 (a), 
Samimi et al 2004 (b), Safaei et al 2008) and over-expression of ATP7B has been 
linked with poor outcome in both squamous cell head and neck (Miyashita et al 2003) 
and esophageal (Higashimoto et al 2003) cancers. The clinical significance of 
variations in uptake and efflux in solid tumours has yet to be fully addressed, with most 
information arising from studies in tissue culture monolayers. 
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1.4.2: Inactivation of Platinum Complexes 
 
Inactivation of platinum complexes through co-ordination to sulfur-containing 
molecules has been proposed as a potential mechanism of resistance. Thiol (-SH) 
containing molecules are implicated in inactivation of platinum complexes, of which 
the most abundant intracellular thiol is glutathione (GSH) (Meister 1983). There are 
many studies linking resistance to increased interaction of drug with GSH, and this is 
addressed in detail in section 1.7. The thiol-containing α-amino acid cysteine has also 
been implicated with co-ordination and inactivation of platinum complexes (Bose 1995, 
Bose et al 1997, Sadowitz et al 2002, Volckova et al 2002). Metallothioneins are 
cysteine-rich proteins involved in zinc homeostasis that have been associated with 
resistance to cisplatin (Andrews et al 1987, Endo et al 2004), although there is 
conflicting evidence (Masters et al 1996) and their contribution to resistance, if any, is 
unclear. Biomolecules containing thioethers (-C-S-C-), such as the amino-acid 
methionine, have also been investigated. There is limited evidence supporting a 
proposed role in forming a reservoir for platinum complexes that mediates the transfer 
of platinum to DNA (van Boom and Reedijk 1993, Barnham et al 1995). However, 
there is also evidence that they act in a similar manner to thiol-containing molecules 
and inactivate platinum complexes (Reedijk 1999, Reedijk and Teuben 1999).  
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1.4.3: DNA Repair 
 
Formation of adducts with DNA is considered to be a major part of the mechanism of 
platinum complexes, with increased tolerance and an improved ability to repair DNA 
seen as potentially important factors in the development of drug resistance. Tolerance 
to platinated DNA is a phenotype demonstrated in resistant cells from chemotherapy 
refractory patients (Johnson et al 1997), and also in cells selected for resistance in vitro 
(Johnson et al 1994 (a), Johnson et al 1994 (b)). Interstrand cross-links are believed to 
inhibit DNA replication as they block the unwinding of the DNA helix and strand 
separation. Intrastrand Pt-DNA adducts have been linked with stalling of DNA 
replication, although there is evidence that the replication mechanism can bypass the 
lesion by recruiting alternative DNA polymerases to the damaged site, and synthesising 
new DNA post-lesion (Reviewed by Prakash et al 2005).  
 
Following Pt-DNA adducts formation, repair systems intrinsic to cells are activated to 
recognize the damage and where possible to repair the DNA restoring normal structure 
and function. Several major repair processes have been implicated as determinants of 
cellular sensitivity to platinum-induced DNA modifications; nucleotide excision repair 
(NER), mismatch repair (MMR) and homologous recombination (HR)/ interstrand 
cross-link repair.  
 
The biochemical mechanism of nucleotide excision repair has been extensively studied, 
and is described in detail elsewhere (de Laat et al 1999, Costa et al 2003). NER is sub-
divided into two categories, global genome (GG-NER) and transcription coupled (TC-
NER), which are believed to recognise DNA damage through different mechanisms, 
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although the underlying repair mechanism is the same. GG-NER is believed to be 
initiated following recognition of DNA damage by the XPC-HR23B complex 
(Sugasawa et al 1998), although there is also evidence for involvement of the XPE 
protein (Kusumoto et al 2001). TC-NER initiation is believed to arise as a result of 
blockage of transcription elongation by RNA polymerase II when lesions are 
encountered (de Laat et al 1999). It is not known whether the stalled RNA polymerase 
II is displaced and/or dissociated from DNA to allow the NER machinery access to the 
damaged site. Cockayne Syndrome proteins A (CSA) and B (CSB) are believed to be 
involved, though their exact functions are not yet known. 
 
After initial recognition of DNA damage, TFIIH, XPA and RPA are the first set of 
NER proteins to assemble at the damaged site, followed by XPB and XPD helicases, 
which unwind the DNA helix allowing XPG and XPF-ERCC1 to bind to the unwound 
DNA. XPG makes an incision 3' to the damage (approximately 2-10 bases from the 
damage) and XPF-ERCC1 makes another incision 5' to the damage (approximately 15-
24 bases from the damage. The excised oligonucleotide containing the damaged section 
is released from the DNA leaving an exposed hydroxy (-OH) group at the 3' terminus 
of the gap, believed to act as a primer for DNA polymerases to synthesise the new 
DNA fragment. DNA polymerases delta and epsilon are implicated as the NER 
polymerases, with PCNA and RFC cofactors working as a complex to facilitate 
polymerase assembly. The last step in the process is the ligation of the newly 
synthesised DNA into the gap by DNA ligase I.  
 
There is strong evidence linking defects in NER with sensitivity to Pt-DNA damage, 
and NER-deficient cell lines have shown greater sensitivity to cisplatin than proficient 
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lines (Beck and Brubaker 1973, Drobnik and Horacek 1973, Markham and Brubaker 
1980, Brouwer et al 1981, Beck et al 1985, Fram et al 1985, Popoff et al 1987). Cells 
lacking specific components of the NER machinery have been shown to be 5- to 10-
fold more sensitive to cisplatin (Furuta et al 2002) and cells resistant to cisplatin have 
displayed greater than 2-fold increases in levels of proteins such as XPA, XPC and 
ERCC1 (Weaver et al 2005). Extracts of tissues from ovarian patients who have 
demonstrated resistance to cisplatin and carboplatin have also been shown to exhibit 
elevated levels of XPC and ERCC1 (Dabholkar et al 1994) and it has been suggested 
that the sensitivity of testicular tumours to cisplatin may be a direct result of decreased 
levels of NER proteins such as XPA, XPC and ERCC1 (Koberle et al 1997, Koberle et 
al 1999, Welsh et al 2004). 
 
The effect of NER on excision of individual cisplatin-DNA adducts however is poorly 
understood, with limited direct evidence of repair derived from studies investigating 
synthetic fragments of DNA in vitro (Szymkowski et al 1992, Huang et al 1994, 
Zamble et al 1996). Initial studies indicated that the 1,2-d(GpG) intrastrand cross-link 
was refractory to NER. Further studies however suggested that it is removed by NER, 
although at a lower efficiency than the 1,3-(GpXpG) intrastrand cross-link (Huang et al 
1994, Zamble et al 1996, Moggs et al 1997). No excision repair was identified for 
interstrand cross-links. (Zamble et al 1996). XPF and ERCC1, both components of the 
NER machinery, have previously been shown to have a potential role in the early stages 
of NER, possibly contributing to the excision of ICLs, but no further role in the repair 
process (de Silva et al 1999, de Silva et al 2000, McHugh et al 2000). However, it is 
important to note that the attribution of NER in the removal of Pt-DNA damage is 
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mainly inferred from studies of cellular sensitivity to platinum complexes, with very 
limited data on direct removal of Pt-DNA adducts.  
 
Defects in mismatch repair (MMR) have been shown to be associated with resistance to 
cisplatin. MMR is a post-replicative DNA repair system that corrects single base 
mismatches (Parsons et al 1993, Chu 1994). Proteins of the MMR system have been 
shown to recognise Pt-DNA cross-links (Duckett et al 1996, Yamada et al 1997), 
although MMR is not believed to directly repair such adducts. Studies using MMR 
defective cell lines have demonstrated that inactivation of MMR genes confer 
resistance to cisplatin (Aebi et al 1996, Anthoney et al 1996, Drummond et al 1996). 
Similarly, restoration of MMR function in yeast lacking the hMLH1 protein has been 
shown to restore sensitivity to cisplatin (Durant et al 1999). However, the underlying 
mechanism of cell death induction by MMR proteins remains unclear. There are two 
predominant hypotheses for MMR involvement in sensitivity to cisplatin. The first 
hypothesis is that proteins of the MMR system bind to damaged DNA and cell death is 
initiated by downstream pro-death molecules (Chu 1994, Fink et al 1996). The second 
is a repair-dependent hypothesis, where mismatches arise in the daughter strand of 
DNA as a result of translesion DNA synthesis. However, the damage remains on the 
parent strand and „futile‟ cycles of repair and re-synthesis of the daughter strand occur, 
believed to ultimately lead to double strand breaks (DSB) and induction of cell death 
(Karran and Bignami 1994, Mello et al 1996, Vaisman et al 1998). These hypotheses 
suggest that MMR defects confer resistance as a result of failure to recognise DNA 
damage and induce apoptosis, enabling resistant cells to acquire and tolerate damage 
that would otherwise be lethal. 
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Interstrand cross-links are not believed to be repaired by NER, but homologous 
recombination (HR) has been proposed to be involved. HR defective mammalian cells 
have shown greater sensitivity to cisplatin than wild type (Raaphorst et al 2005). HR is 
involved in repair of DSB and there is evidence of DSB occurring following incubation 
with cisplatin (Sorenson and Eastman 1988 (a)). However, there is conflicting evidence 
suggesting that cisplatin does not induce DSB (Frankenberg-Schwager et al 2005). It 
has been suggested that that HR may be important in repair of DSB caused as a result 
of interstrand cross-linking by cisplatin (Eastman and Schutte 1988), although it is 
important to distinguish that DSB result from cross-link repair as a specific mechanism 
from those that occur as a result of apoptotic degradation. 
 
1.4.4: Defective Apoptosis Response 
 
Cispaltin resistance has been linked with a decreased apoptotic response in ovarian 
carcinoma and lymphoma cells, and cisplatin-resistant ovarian cells have been shown to 
need higher levels of cisplatin to elicit a response (Fan et al 1994, Fajac et al 1996, 
Perego et al 1996). Alterations in expression of apoptotic regulators have also been 
linked to differences in sensitivity of cells to cisplatin. Decreased levels of Bax, an 
apoptosis promoter, have been shown in resistant ovarian cancer cells (Fajac et al 1996, 
Perego et al 1996, Sakakura et al 1997). Other reports have linked increased levels of 
Bax to the inherent increased sensitivity of testicular cancer cells to cisplatin and 
Lutzker and Levine 1996), although there is contradictory data to this (Burger et al 
1999). It is important to consider defects in apoptosis and drug resistance since, as 
described in the next section, apoptosis is involved in cell death following Pt-drug 
treatment.  
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1.5: Cell death induced by platinum complexes 
 
Apoptosis is the process of programmed cell death that normally occurs during 
development and aging as a homeostatic mechanism involved in maintaining the 
normal health and development of multicellular organisms. Apoptosis also occurs as a 
defence mechanism when cells are damaged by disease or noxious agents (Norbury and 
Hickson 2001).  Apoptosis is triggered by a variety of physiological signals and 
consists of a series of genetically programmed biochemical processes. Conversely 
necrosis refers to the disintegration of damaged cells, with the release of products of 
cellular degradation which have inflammatory effects in vivo. 
 
During the early stages of apoptosis, cells decrease in size making the cytoplasm denser 
and compacting organelles. Chromatin becomes irreversibly condensed in the nucleus 
(pyknosis), one of the most characteristic features of apoptosis (Kerr et al 1972, Wyllie 
et al 1980). On histologic examination the cell appears as a round/oval mass with a dark 
cytoplasm and dense chromatin fragments (see Elmore 2007). Extensive plasma 
membrane blebbing, nuclear fragmentation (karyorrhexis) and separation of cell 
fragments follows, forming apoptotic bodies which consist of a tightly packed 
cytoplasm, often with no visible signs of a nuclear compartment. Organelle integrity is 
retained as the plasma membrane remains intact. These apoptotic bodies are 
subsequently phagocytosed by macrophages. There is no inflammatory response 
involved with apoptosis, as unlike necrosis, no intracellular components are released 
into the surrounding tissues and the apoptotic bodies are quickly phagocytosed 
preventing secondary necrosis (Savill and Fadok 2000, Kurosaka et al 2003). 
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Studies using murine leukaemia L1210 and Chinese hamster ovarian cells provided the 
first details about the mechanism of cisplatin-induced cell death, with cells incubated 
with cisplatin shown to arrest in the G2 phase of the cell cycle. Cells incubated with low 
levels of cisplatin were able to recover from this arrested state, but cells incubated with 
increasing concentrations of cisplatin showed decreasing numbers of surviving cells 
(Sorenson and Eastman 1988 (a), Sorenson and Eastman 1988 (b)). The appearance of 
DSB in the DNA was the first detectable sign of cell death, and further investigation 
utilising gel electrophoresis studies identified these breaks as occurring in the 
nucleosome spacer region of the DNA. Cleavage of genomic DNA is a major part of 
the apoptotic process and is hallmarked by the appearance of nucleosome ladders of 
fragmented DNA in these studies. The appearance of nucleosome ladders has been 
shown after cisplatin treatment in murine leukaemia L1210 cells (Sorenson et al 1990), 
implicating apoptosis in the mechanism of cell death. The same study also showed a 
decrease in cell volume and the occurrence of surface blebbing, additional common 
hallmarks observed in cells undergoing apoptosis. These observations were also seen in 
Chinese hamster ovary cells (Barry et al 1990). However, it is not known to what extent 
apoptosis is essential for cytotoxicity, particularly in clinical tumours. Also, it is not 
understood how various types of DNA damage trigger apoptosis. 
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1.6: Adduct levels in clinical samples of cancer patients 
 
Platinum-based anticancer drugs are believed to exert their anti-tumour effect by 
reacting with DNA, and there have been many studies investigating adduct formation in 
vitro with purified DNA and human tumour cells (Roberts and Pascoe 1972, Johnson 
1982, Eastman 1983, Eastman 1985, Fichtinger-Schepman et al 1985, Johnson 1985, 
Eastman 1986, Fichtinger-Schepman et al 1987, Roberts and Friedlos 1987). However, 
it is inherently more complicated to study adduct formation in animals and in cancer 
patients because of the inability to repeatedly sample the tumour mass, the small 
sample sizes and numbers, and the low levels of Pt-DNA adducts requiring highly 
sensitive assays. Formation of Pt-DNA adducts in peripheral blood leukocytes (PBLs) 
has been correlated with clinical response and toxicity, suggesting that adduct 
formation in normal cells may be reflective of adduct formation in tumour tissue (Reed 
et al, 1988, Reed et al 1990, Parker et al 1991 (b), Schellens et al 1996). Correlations 
between adduct levels in PBLs of patients receiving cisplatin chemotherapy and adduct 
formation in PBLs from the same patients incubated with cisplatin in vitro have also 
been published (Fichtinger-Schepman et al 1990, Oshita et al 1995), but contradictory 
data has also been published (Bonetti et al 1996). Unfortunately pharmacokinetic 
parameters were not investigated. This means the data published may not reflect the 
effects on Pt-DNA adduct formation, but might be a result of differences in 
pharmacokinetics rather than differences in drug/DNA access. More recent studies have 
measured pharmacokinetics as well as Pt-DNA adducts formation in patients treated 
with cisplatin and carboplatin. Ghazal-Aswad et al showed that pharmacokinetic-based 
dosing of carboplatin accurately predicted the required dose to achieve a target AUC 
resulting in consistent patient exposure to active drug (Ghazal-Aswad et al 1999). The 
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same study also showed that Pt-DNA adduct levels in PBLs were positively related to 
carboplatin dose and AUC. However, similar studies that also investigated 
pharmacokinetics (Peng et al 1997, Veal et al 2001, Veal et al 2007) showed a poor 
correlation between the AUC of active drug and Pt-DNA adduct levels. The conclusion 
from these studies was that whilst pharmacokinetic monitoring is important to maintain 
a consistent AUC value in patients receiving cisplatin or carboplatin, variation in Pt-
DNA adduct formation cannot simply be attributed to the dose administered or drug 
exposure in patients. It is more likely therefore that differences in Pt-DNA adduct 
formation are attributable to host-specific characteristics such as variations in drug 
uptake in PBLs, differences in intracellular inactivation of the drugs or differences in 
factors in the blood that would affect drug availability (Veal et al 2001).  
 
The studies referred to above involved measurement of Pt-DNA adducts in normal 
blood cells. There are very limited data available on Pt-DNA adduct formation in 
tumour tissue from patients receiving cisplatin or carboplatin. Recently, Pt-DNA 
adducts in tumour biopsies from head and neck squamous cell carcinomas have been 
investigated (Hoebers et al 2006, Hoebers et al 2008). Normal tissue samples (WBCs 
and buccal cells) and tumour biopsies were investigated using a 
32
P post-labelling assay 
to quantify adduct levels. Although adduct levels were found to be higher in tumour 
biopsies than normal tissue samples, no correlation in Pt-DNA adducts levels was 
observed. As described more fully in chapter 6, one of the aims of the work described 
in this thesis was to measure the levels of Pt-DNA adducts formed in a small number of 
tumour biopsies removed from solid tumours during therapy. 
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1.7: Glutathione 
 
1.7.1: Intracellular chemistry and redox state of glutathione 
 
Glutathione (L-γ-glutamyl-L-cysteine-glycine) (GSH) is the most abundant non-protein 
thiol found in nearly all eukaryotic and prokaryotic cells at concentrations ranging 
between 0.5 and 10 mM (Meister 1983). GSH plays a major role in protecting cells 
from organic and inorganic xenobiotics by undergoing spontaneous or enzyme 
catalysed binding to form a conjugate with the toxic chemical species (Arrick and 
Nathan 1984). The resulting compounds are hydrophilic and readily excretable. GSH 
concentrations are highest in the liver, kidneys and spleen, probably due to the 
intrinsically high exposure of these organs to toxins. Many carcinogens and drug 
metabolites are excreted this way, although the pathway can also have the negative 
effect of inactivating reactive cytotoxic anticancer drugs before they reach DNA.  
 
O O
OH
NH2H
NHH
HS
H
N
OH
O
O
 
Figure 1.9: Structure of reduced GSH. Oxidised GSH comprises two molecules joined 
by an S-S bond 
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GSH is a tripeptide synthesised from three amino acid precursors (cysteine, glutamic 
acid and glycine) in a two step ATP-dependent manner (Meister 1983). The reactive 
sulfhydryl (-SH) group comes from the cysteine residue. Firstly, γ-glutamylcysteine is 
synthesised from L-glutamate and cysteine, catalysed by γ-glutamylcysteine synthetase.  
The enzyme γ-glutamylcysteine synthetase can be inhibited with D, L-buthionine-(S, 
R)-sulfoximine (BSO) and this has been widely used for investigating the role of GSH 
in cellular processes. The second step involves addition of glycine to the carboxyl 
group of the cysteine moiety via the enzyme GSH synthetase. In cells, GSH exists in 
the reduced form (GSH) and the oxidized or disulfide form (GSSG) (Arrick and Nathan 
1984). The overall cellular ratio of GSH:GSSG ranges from 30:1 to 100:1 (Bass 2004). 
In mammalian cells approximately 90% of the GSH is contained in the 
cytosolic/nuclear compartments, with approximately 10% in mitochondria and a very 
small amount in the endoplasmic reticulum (ER) (Meredith and Reid 1982, Hwang et al 
1992, Lu 1999). In the ER the ratio of GSH:GSSG differs to the normal cellular state in 
a range of 1:1 to 3:1, although it is not known how this oxidative state is maintained 
(Hwang et al 1992). Mitochondria are heavily dependent on GSH for prevention of 
oxidative damage as a result of aerobic respiration, although they cannot synthesise 
GSH de novo and require salvage from GSSG catalysed by GSH reductase and uptake 
of cytosolic GSH (Griffith and Meister 1985). GSH breakdown is initiated by γ-
glutamyl transpeptidase.  
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1.7.2: GSH and platinum drug resistance 
 
As discussed in section 1.3.2, intracellular cisplatin aquates, forming a species that is 
believed to be reactive with DNA. However, the intracellular environment is rich in 
thiols such as cysteine and GSH which are known to bind readily to cisplatin. 
Interestingly, there is evidence that, unlike DNA which reacts with cisplatin in its 
aquated from, GSH can directly attack and inactivate the dichloro form of the drug 
(Dedon et al 1987). This raises the interesting question of how cisplatin is able to react 
with DNA in the presence of the very high molar ratio of intracellular GSH to cisplatin 
(Reedijk, 1999). There have been studies that propose platinum-sulfur binding is 
kinetically less favourable than platinum-nitrogen, suggesting a possible reason why 
platinum drugs bind the nitrogen residues of DNA (Deubel 2004). However, the data 
come from theoretical modelling and have limited relevance to the intracellular 
pharmacology of platinum binding. It is interesting to note that the monoaqua and 
diaqua species of cisplatin were investigated. It is believed that the non-aquated form of 
cisplatin does not react with DNA, whereas it has been proposed that sulfur-containing 
molecules can attack the dichloro species of cisplatin.  
 
Many studies have investigated the role of GSH in resistance to cisplatin. Differences 
in GSH levels have been correlated with sensitivity to cisplatin with increased levels of 
GSH observed in cisplatin resistant cell lines (Behrens et al 1987, Wolf et al 1987, 
Godwin et al 1992). Studies in colon cancer cells have found a 3-fold increase in GSH 
in cisplatin-resistant cells (Fram et al 1990). Conversely, no increase in GSH was seen 
in ovarian carcinoma cells and human testicular nonseminomatous germ cells resistant 
to cisplatin compared to parental lines (Kelland et al 1992).  
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Covalent binding of cisplatin and GSH leads to formation of a complex which is 
believed to be inactive and is exported from cells by the ATP-dependent GSH C-
conjugate efflux pump (Dedon and Borch 1987, Ishikawa and Aliosman 1993). In 
addition, it has been proposed that GSH conjugated to monofunctionally platinated 
DNA inhibits the conversion to bifunctional cross-links, reducing the cytotoxic 
potential of the initial lesion (Eastman 1987). However, there is also the potential for 
conjugated cis-Pt(NH3)2(DNA)(GSH) cross-links to be cytotoxic as discussed below. 
 
1.7.3: Evidence for potential cis-Pt(NH3)2(DNA)(GSH) cross-links 
 
Current knowledge of Pt-DNA cross-links stems from the discovery of interstrand 
(Roberts and Pascoe 1972) and intrastrand (Fichtinger-Schepman et al 1985) cross-
links. In recent years evidence has been obtained that an additional class of DNA cross-
link can be formed in cells, potentially accounting for up to 25% of the total Pt-DNA 
products (Azim-Araghi 2003). These data arose from the novel combination of anion-
exchange chromatographic separation as described previously (Fichtinger-Schepman et 
al 1985), with the sensitive technique of inductively coupled plasma mass spectrometry 
(ICP-MS), to detect platinum in chromatographic fractions. ICP-MS is a technique 
principally developed for geochemical analyses and methodologies have been 
developed to allow detection limits of ~ 0.5 attomolar Pt levels, allowing for highly 
accurate and sensitive analysis of experimental samples at clinically relevant cross-link 
levels. This permitted the direct analysis of adducts present in DNA extracted from 
drug treated cells. As discussed in section 1.3.3, previous analyses relied on the use of 
antibodies or 
32
P post-labelling to increase detection sensitivity. Both methods are 
established and highly sensitive for specific adducts, but equally both could fail to 
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detect additional types of Pt-DNA cross-links that are formed in cells. The introduction 
of ICP-MS for detecting low levels of platinum has made possible new investigations. 
 
In the work referred to above (Azim-Araghi 2003) lung carcinoma cell lines were 
treated with cisplatin, DNA was extracted and enzymatically hydrolysed prior to 
analysis by anion exchange chromatography and ICP-MS. The results revealed the 
presence of additional products not detected when purified DNA was incubated with 
cisplatin (Figure 1.10). Comparison of calf thymus DNA incubated with cisplatin in the 
presence and absence of GSH confirmed these findings (Figure 1.11). Further analysis 
with increased nuclease concentrations confirmed these were not products of 
incomplete digestion of the DNA. Since these new cross-links had not been identified 
previously in purified DNA reacted with cisplatin (Fichtinger-Schepman et al 1985), or 
on single strand oligodeoxynucleotides (Meczes et al 2005), it was hypothesised that 
their formation was a result of platinum-mediated cross-linkage to a non-DNA 
molecule. The hypothesis underlying much of the work in this thesis is that this new 
type of cross-link is formed between GSH and Pt-DNA. 
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Figure 1.10: Mono-Q elution pattern for digested calf-thymus DNA (A) and Mor/P cell 
DNA (B) after incubation with cisplatin. DNA was enzymatically digested and eluted 
with increasing NaCl concentrations. Solid blue line: OD 260 nm () Platinum levels 
measured in collected fractions using ICP-MS. (1): Pt(NH3)2(R)(dGMP); (2): cis-
Pt(NH3)2d(ApG); (3): cis-Pt(NH3)2d(GpG); (4): cis-Pt(NH3)2(dGMP)2; (X): new 
product possibly involving thymine; (Y) new product possibly involving GSH. Adapted 
from Azim-Araghi 2003 
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Figure 1.11: Mono-Q elution pattern for digested calf-thymus DNA incubated with 
cisplatin in the presence and absence of GSH. (▲): Platinum after 2-hour incubation 
of DNA with 50 mM GSH (μmol/ml). (■): Platinum after 24 hour incubation of DNA 
with 50 mM GSH (μmol/ml). (▼): Platinum after 24 hour incubation of DNA in the 
absence of GSH (μmol/ml). (1): Pt(NH3)2(R)(dGMP); (2): cis-Pt(NH3)2d(ApG); (3): 
cis-Pt(NH3)2d(GpG); (4): cis-Pt(NH3)2(dGMP)2; (Y): new product possibly involving 
GSH. Adapted from Azim-Araghi 2003 
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Evidence for the cross-linking of GSH to purified DNA in the presence of cisplatin was 
first published by Eastman over twenty years ago (Eastman 1987). Eastman 
enzymatically digested salmon testes DNA incubated with cisplatin with and without 
GSH and chromatographically separated the resulting products. GSH was found to be 
able to react with monofunctionally platinated DNA, but was unable to form complexes 
with DNA that had no monofunctionally bound platinum. Eastman proposed therefore 
that GSH can block the conversion of monofunctional Pt-DNA lesions to the toxic 
bifunctional cross-links. The possibility that GSH could quench monofunctional Pt-
DNA adducts before rearrangement had been proposed previously (Micetich et al 
1983). Micetich et al presented kinetic data comparing mouse leukaemia L1210 cells 
resistant to cisplatin (L1210/PAM) with its parent cell line (L1210/NCL). The data 
showed an increased resistance to cisplatin in the L1210/PAM cells and proposed that it 
may be due to increased thiol content in the cell line blocking conversion to 
bifunctional cross-links. Suzukake et al had previously found the L1210/PAM cell line 
to have elevated levels of GSH compared to its parental line and concluded that this 
may be the reason for its resistance to L-phenylalanine mustard (Suzukake et al 1982, 
Suzukake et al 1983).  
 
Interestingly, the data described above made no suggestion that the formation of cross-
links with GSH could generate potentially cytotoxic lesions. The cross-linking of GSH 
to DNA was proposed to stop the conversion of monofunctional Pt-DNA lesions to 
toxic bifunctional Pt-DNA cross-links, and GSH binding to cisplatin was proposed to 
detoxify the drug. Two possible mechanisms were suggested for this. The first 
mechanism involved cisplatin binding to the sulphydryl residue in GSH, thereby 
blocking access of the drug to DNA (Eastman 1987). The second mechanism involved 
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binding to cisplatin monofunctionally bound to DNA, thereby detoxifying the lesion 
(Micetich et al 1983, Eastman 1987). Both mechanisms are plausible. Formation of 
monofunctional Pt-DNA lesions is believed to occur relatively rapidly, with conversion 
to bifunctional lesions occurring for up to 12 hours after drug removal (Zwelling et al 
1978, Eastman 1986). Even though the reaction of GSH with monofunctional Pt-DNA 
adducts is slow (Eastman 1987), the lengthy time to form bifunctional adducts suggests 
this is a possibility. Binding to and inactivating cisplatin in the cytoplasm may be a 
more efficient method of detoxification, especially considering the molar excess of 
GSH to drug, although the limited time between cisplatin uptake and reacting with 
DNA may limit the extent to which this occurs (Eastman 1987). It has also been 
suggested that reaction of cisplatin with intracellular sulfur ligands may form a 
reservoir from which the platinum complex is slowly released (van Boom and Reedijk 
1993) though this theory is not supported by more recent studies (Lau and Deubel 
2005). It is conceivable that both mechanisms may in turn contribute to the modulation 
of platinum drug toxicity. However, should cis-Pt(NH3)2(DNA)(GSH) cross-links 
contribute to platinum drug cytotoxicity it seems unlikely that this would involve initial 
binding to GSH, although neither possibility can be totally ruled out. 
 
Recent unpublished investigations at Newcastle have supported the possibility that 
GSH can cross-link to DNA in three ways. Firstly, in the presence of cisplatin, 
radioactively labelled GSH became bound to DNA. Secondly, the level of intrastrand 
1,2-d(GpG) cross-links as a proportion of total Pt-DNA adducts was reduced when the 
reaction between cisplatin and DNA took place in the presence of GSH. In this work 
total platinum was measured by AAS and intrastrand 1,2-d(GpG) cross-links by 
immunoassay with monoclonal antibody CP9/19. Thirdly, studies on two lung cancer 
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cell lines (Mor/P and H69), again using AAS for total platinum and immunoassay for 
cross-links, indicated that cross-links formed in Mor/P cells showed a smaller 
proportion of 1,2 cross-links than those formed in H69 cells (Tilby and Twentyman, 
unpublished). If the existence of such a new class of cross-links were to be proven, it 
would have a significant impact on our understanding of platinum drug pharmacology. 
  
1.7.4: Potential clinical implications of cis-Pt(NH3)2(DNA)(GSH)  cross-links 
 
It is well established that clinically active platinum complexes possess the cis-planar 
conformation and that trans-DDP, the structural isomer of cisplatin, is clinically 
ineffective (Roberts and Friedlos 1987). Investigations of the reactions of trans-DDP 
with DNA suggested that 85% of adducts formed are monofunctional, and the rate of 
conversion to bifunctional cross-links is very slow (Eastman 1987). Furthermore, it has 
been suggested that the lack of activity of trans-DDP may be attributable to its inability 
to form intrastrand 1,2- cross-links (Pinto and Lippard 1985).  
 
Early investigations with cis-DDP used thiourea to block monofunctional lesions 
rearranging to bifunctional cross-links (Micetich et al 1983, Eastman 1986). This 
approach was deployed by Eastman to study trans-DDP adducts formed in DNA 
(Eastman 1987). However, rather than “trapping” monofunctional lesions, thiourea 
displaced the drug from DNA. Eastman concluded that this was not surprising as ‘the 
strength of any ligand is markedly influenced by the ligand in a trans orientation’. 
Sulfur is a stronger ligand than nitrogen, and hence when thiourea was bound to DNA, 
the opposing Pt-N (guanine) bond was sufficiently labilised to remove the drug. 
Eastman further concluded that the major reaction of monofunctionally bound trans-
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DDP in cells would be with GSH (Eastman 1987). Andrews et al demonstrated that 
reducing GSH levels markedly enhanced toxicity to trans-DDP with little effect on 
cisplatin toxicity (Andrews et al 1985) supporting the possibility that GSH may act in a 
manner similar to that of thiourea in displacing trans-DDP from DNA. The trans-
labilising effect is particularly strong for the bond between Pt and the sulfur of GSH 
(Lau and Deubel 2005). The presence of GSH would cause the labilisation of one of the 
usually stable ammonia moieties in cisplatin, thus becoming a potential leaving group. 
The resulting adduct could then possibly undergo delayed reactions with other 
molecules, with possible implications on cell survival and drug efficacy. The same 
mechanism for trans-DDP would lead to the dissociation from DNA (Figure 1.12). 
 
Figure 1.12: Trans-labilisation of cis-DDP and trans-DDP by GSH and subsequent 
effect on binding of molecule to DNA. Red circles indicate active bond 
 
As described more fully in chapters 3 and 4, one of the aims of the work described in 
this thesis was to investigate whether or not cis-Pt(NH3)2(DNA)(GSH) cross-links can 
be formed in cells.  
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1.8: Sodium thiosulfate 
 
1.8.1: Sodium thiosulfate as a chemo-protective agent 
 
Cisplatin binds readily to sulfur-containing molecules. Thiourea is a sulfur-containing 
molecule that has previously been shown to reduce the toxicity and anti-tumoural 
activity of cisplatin (Burchenal et al 1978, Filipski et al 1979). It was proposed that 
sulfur-containing molecules may have a role in the selective protection from toxicity by 
reducing the amount of active drug in the circulation, although there was no data from 
animal or mouse studies at the time. 
 
 
Figure 1.13: The chemical structure of sodium thiosulfate 
 
Sodium thiosulfate (Na2S2O3) (STS) is a sulfur-containing molecule that is known to 
react with metals. It is used in the photographic industry as a fixative where it reacts 
with silver halides. It is also known to readily react with gold, and is often used in 
extraction as a replacement for cyanide. STS has also been used in patients as an 
antidote for cyanide poisoning. Howell et al proposed that like thiourea, STS could 
potentially have a role in modulating cisplatin toxicity (Howell and Taetle 1980). STS 
was shown to be toxic to CFU-C cells in vitro at concentrations above 10 mg/ml, 
whereas at 0.1 mg/ml STS significantly reduced the toxicity of cisplatin at 
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concentrations up to 10 µg/ml. The same study also showed STS to cause a dose-related 
decrease in nephrotoxicity in mice. Interestingly, simultaneous injection into mice 
reduced the antitumoural effect of cisplatin. STS has since been shown to bind and 
inactivate cisplatin and carboplatin in vitro (Abe et al 1986, Elferink et al 1986, Dedon 
et al 1988), and to reduce cisplatin-induced nephrotoxicity in animal models (Iwamoto 
et al 1984, Nagai et al 1995) and patients (Howell et al 1982, Pfeifle et al 1985). The 
exact mechanism by which STS protects against nephrotoxicity is unclear. There is 
evidence that STS binds and inactivates cisplatin in the kidneys, and high 
concentrations of thiosulfate have been found in urine during thiosulfate administration, 
suggesting that concentrations in kidney tissues are high (Shea and Howell 1984). At 
these high concentrations the reaction rate between cisplatin and STS is increased 
(Elferink et al 1986). Cisplatin nephrotoxicity is believed to be a result of cisplatin 
reacting with protein-bound thiol groups in the renal tubules (Weiner and Jacobs 1983), 
and this mechanism suggests that competition between the thiosulfate and thiol groups 
for binding cisplatin might explain the decreased nephrotoxicity. However, there is 
evidence that thiosulfate distribution remains extracellular (Gilman et al 1946), and that 
STS binds directly to inactive cisplatin in the systemic circulation, resulting in a 
decreased amount of cisplatin in the kidneys (Nagai et al 1995). This would suggest 
that the decrease in nephrotoxicity is attributable to cisplatin being inactivated before it 
reaches sites of potential toxicity. However, the exact mechanism through which STS 
protects against nephrotoxicity is still unknown. 
 
Platinum-induced hearing loss (ototoxicity) is progressive and irreversible in patients, 
and is associated in animal models with loss of the inner and outer hair cells of the 
inner ear (Neuwelt et al 1996). Ototoxicity is a particularly significant problem in 
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children receiving platinum-based chemotherapy, with ototoxicity noted by Parsons et 
al in 9/11 (82%) of children treated with carboplatin for neuroblastoma (Parsons et al 
1998). Hearing loss significantly affects quality of life and has been linked with 
delayed development of language and reading skills in children (Hindley 1997), and the 
development of depressive symptoms in elderly patients (Cacciatore et al 1999, Keller 
et al 1999).  
 
High frequency hearing loss is a major form of ototoxicity, and was a key negative 
finding in a study investigating the effects of carboplatin on human brain tumours, with 
blood brain barrier disruption to optimise drug delivery (Williams et al 1995). The 
positive reports of STS protecting against cisplatin-induced nephrotoxicity suggested 
that STS may have a role in protection against ototoxicity. Although the mechanism for 
protection against nephrotoxicity is unknown, the available evidence suggests a role for 
STS as a scavenger of free cisplatin in the kidneys. In protection against ototoxicity, 
STS is hypothesised therefore to accumulate in the cells of the inner ear, and bind and 
inactivate free drug (Neuwelt et al 1996). Neuwelt et al investigated the effects of STS 
in vitro and in vivo in protecting against carboplatin-induced ototoxicity, and found that 
STS protected against carboplatin toxicity in vitro when incubated for up to 8 hours 
after carboplatin was added, but no protection was seen at 24 hours (Neuwelt et al 
1996). In the same study, STS was found to be neurotoxic in vivo when administered 
immediately after blood brain barrier disruption, but no toxicity was seen at 30 minutes 
or 60 minutes after disruption, by which time the barrier is believed to have become re-
established (Neuwelt et al 1996). Further in vitro studies and investigations in animals 
and patients have confirmed the findings that delaying administration of STS can be 
used to reduce ototoxicity and have also indicated that this occurs without 
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compromising the anti-tumour effects of either cisplatin or carboplatin (Neuwelt et al 
1998, Muldoon et al 2000, Doolittle et al 2001, Harned et al 2008). STS is currently in 
a phase III clinical trial (SIOPEL 6) designed to investigate a potential role in reducing 
ototoxicity in paediatric patients receiving cisplatin for standard risk hepatoblastoma.  
 
The hypothesis for protection against nephrotoxicity and ototoxicity involves STS 
accumulating in the kidneys and inner ears respectively, and potentially binding and 
inactivating free drug. However, the mechanism through which this protection occurs is 
unknown. STS has previously been shown to remain extracellular (Gilman et al 1946) 
although this data is based on whole body distribution in dogs. It is therefore unclear to 
what extent STS is able to enter cells in humans. More recent studies have 
demonstrated that the human sulfate transporter SLC13A1 (NaS1, previously known as 
SUT-1) a member of the SLC13 sulfate transporter family found on the plasma 
membranes of mammalian cells and located on the apical membrane of the renal 
proximal tubule, is involved in the active transport of thiosulfate ions across the cell 
membrane (Busch et al 1994, Lee et al 2000, Pajor 2006). There is limited information 
available on another member of the SLC13 transporter family, SLC13A4 (NaS2), found 
predominantly in human placenta, although it is believed to have similar substrate 
specificity to SLC13A1 (Pajor 2006). This suggests a potential mechanism through 
which STS can enter cells, and we hypothesise that intracellular STS has the potential 
to interact with intracellular platinum drugs and even modify platinated DNA. Potential 
mechanisms by which this may occur include removal of pre-formed Pt-DNA adducts 
or removal of bound platinum, inactivation of cytoplasmic platinum drugs and/or 
quenching of monofunctionally bound Pt-DNA lesions. 
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1.9: Aims of this study 
 
The work described in this thesis addresses three topics related to the quantity and 
quality of DNA adducts formed by platinum drugs. 
 
1: To test the hypothesis that GSH can become cross-linked to DNA by platinum 
drugs 
 
Available evidence to support this hypothesis was described in section 1.7. If such 
adducts were to form in human tumour cells it would have broad implications in 
understanding the pharmacology of platinum-based anticancer drugs. 
 
This study was approached in two ways: 
1. To attempt to synthesise the putative cis-Pt(NH3)2(DNA)(GSH) cross-link using 
dGMP as a surrogate for DNA so as to identify its chromatographic behaviour 
2. To combine the methods of HPLC and ICP-MS for the analysis of DNA from a 
number of human tumour cell lines that had been exposed to platinum drugs to 
seek evidence of additional adducts to those previously identified 
 
2. To test the hypothesis that STS protects cancer cells by reduction of Pt-DNA 
interactions 
 
The effects of STS on modulating platinum drug toxicity were discussed in section 1.8. 
However, little is known about the mechanisms through which such protection occurs, 
or the effects of STS on Pt-DNA adduct formation. 
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This study was approached in two ways: 
1. To investigate the potential of STS to interact with platinated DNA using 
dGMPas a surrogate for DNA so as to identify its chromatographic behaviour 
and to identify any additional products in pure DNA 
2. To determine the effect of concurrent and delayed administration of STS on 
growth inhibition and total Pt-DNA adduct formation in human tumour cell 
lines exposed to cisplatin 
 
3. To assess the levels of Pt-DNA adducts achieved in human tumour biopsies 
compared to blood samples 
 
There is very limited data on the formation of Pt-DNA adducts in human tumours. The 
work described in the thesis aimed to establish the feasibility of analysing adducts in 
human tumour biopsies following treatment with carboplatin. 
 
This study aimed to measure adducts levels in solid tumour biopsies and peripheral 
blood mononuclear cells from patients treated with carboplatin for advanced ovarian 
cancer. This was approached in two ways: 
1. Determine the DNA adduct levels achieved in solid ovarian tumour tissue 
during therapy 
2. To compare these levels to adduct levels formed in peripheral blood 
mononuclear cells from the same patients 
3. To compare adducts levels to plasma pharmacokinetics for carboplatin 
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Chapter 2 
Materials and Methods 
 
2.1: Materials 
 
2.1.1: Reagents 
 
Unless otherwise stated all chemical reagents used were of analytical grade and 
purchased from Sigma-Aldrich Company ltd. (UK). 
 
Cisplatin was dissolved in sterile de-ionised water to a final concentration of 2 mM and 
stored at -20°C. Carboplatin (Johnson Mathey, UK) was dissolved in either full growth 
media or water immediately prior to use. Oxaliplatin was dissolved in sterile de-ionised 
water to a final concentration of 10 mM, then diluted in full growth medium 
immediately prior to use. Carboplatin and oxaliplatin were always prepared fresh for 
experiments. All handling of cytotoxic drugs for exposure to DNA was carried out in a 
BioMAT
2
 class II pharmaceutical safety cabinet (Medical Air Technology Ltd, UK) . 
All drugs were filter-sterilised immediately before use in tissue culture.  
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2.1.2: Solutions and Buffers 
 
Buffer C1 (QIAGEN) 1.28 M sucrose, 40 mM Tris-Cl, pH 7.5 
containing 20 mM magnesium chloride and 4% 
Triton X-100 
 
Buffer G2 (QIAGEN) 800 mM guanidine-HCl, 30 mM Tris-Cl, 30 mM 
disodium salt of ethylenediaminetetraacetate 
(EDTA), pH 8.0 containing 5% Tween-20 and 
0.5% Triton X-100 
 
Buffer QBT (QIAGEN) 750 mM sodium chloride, 50 mM 3-(N-
morpholino)propanesulfonic acid (MOPS), pH 7.0 
containing 15% isopropanol and 0.15% Triton X-
100 
 
Buffer QC (QIAGEN) 1 M sodium chloride, 50 mM MOPS, pH 7.0 
containing 15% isopropanol 
 
Buffer QF (QIAGEN) 1.25 M sodium chloride, 50 mM Tris-Cl, pH 8.5 
containing 15% isopropanol 
 
DNA buffer (DB) 50 mM sodium chloride, 50 mM sodium 
dihydrogen phosphate, 0.02% sodium azide, pH 
7.0  
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DNA digest buffer 10 mM Tris, pH 7.2 containing 0.1 mM EDTA. 
 
Freezing Solution 90% v/v foetal calf serum (FCS), 10% (v/v) 
dimethyl sulfoxide (DMSO) 
  
HA lysis buffer 80 mM potassium phosphate, 1% (v/v) Sarkosyl 
NL30 detergent, 10 mM EDTA, pH 6.8 
 
HPLC buffer A   12.5 mM Tris, pH 8.8 
 
HPLC buffer B   12.5 mM Tris, pH 8.8 with 1 M sodium chloride 
 
Kirby‟s Phenol 500 g phenol, 0.5 g 8-hydroxyquinoline, 55 ml 
de-ionised water, 70 ml m-cresol, pH 7.0. Prior to 
use Kirby‟s phenol was saturated with water by 
mixing with 80 mM KP buffer and centrifuged 
(150 x g, 5 minutes) 
 
Phosphate buffer (PB) 50 mM sodium phosphate, 0.02% sodium azide, 
pH 7.0 
 
10X PB 500 mM sodium phosphate, 0.02% sodium azide, 
pH 7.0 
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Phosphate Buffered Saline (PBS) 10 mM phosphate buffer, 2.7 mM potassium 
chloride, 137 mM sodium chloride, pH 7.4 
 
80 mM potassium phosphate (KP) 80 mM potassium phosphate, pH 6.8 
 
0.5 M KP    0.5 M potassium phosphate, pH 6.8 
 
Ribonuclease A (RNAase A) buffer 10 mg/ml RNAase A from bovine pancreas in 1.2 
g/l 10 mM Tris and 0.44 g/l 15 mM sodium 
chloride, pH 7.5.  
 
30 mM sodium acetate 172 µl glacial acetic acid in 100 ml water, 
adjusted to pH 5.3 with sodium hydroxide 
 
SRB stain    0.4% sulphorhodamine B in 1% acetic acid 
 
TE 10X Trypsin-EDTA (Gibco BRL) diluted 10-fold 
in warm PBS 
 
Tissue culture media Roswell Park Memorial Institute (RPMI-1640) 
tissue culture media with HEPES modification, 
supplemented with 10% (v/v) foetal calf serum 
(FCS) and 2 mM L-Glutamine, Penicillin (100 
units/ml) and Streptomycin (100 µg/ml) were also 
present in the media 
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10 mM Tris    10 mM Tris, no pH adjustment (pH ~ 9.6) 
 
5 M Urea, 80 mM KP   80 mM KP buffer containing 5 M Urea, pH 6.8 
 
6 M Urea, 80 mM KP   80 mM KP buffer containing 6 M Urea, pH 6.8 
 
2.1.3: Enzymes 
 
Ribonuclease A (RNAase A) was dissolved at 10 mg/ml in Ribonuclease 1 buffer and 
incubated in a boiling water bath for 15 minutes to inactive deoxyribonucleases. 
Aliquots were stored at -20°C. Deoxyribonuclease 1 (DNAase 1) was dissolved at 20 
Kunitz units/ml in DNA digest buffer immediately before use. Nuclease P1 was 
dissolved in 30 mM sodium acetate buffer at 200 units/ml and stored at -20°C. 
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2.2: Tissue Culture 
 
2.2.1: Equipment 
 
All tissue culture procedures were carried out in a BioMAT
2
 class II pharmaceutical 
safety cabinet (Medical Air Technology Ltd, UK). Cells were incubated in an MCO-
20AIC CO2 incubator (Sanyo Biomedical, Japan) maintained at 37°C, 5% CO2. A 
VacuSafe Comfort aspirator (Integra Biosciences, UK) was used to aspirate all culture 
media and drugs. All tissue culture plastic ware were obtained from Nunc (Fisher 
Scientific, UK). Routine centrifugation was carried out using a CR-4-22 refrigerated 
centrifuge (Jouan, UK), 
 
2.2.2: Cell lines 
 
Human testicular germ cell tumour cells (833K) and human colon adenocarcinoma cells 
(LoVo) were obtained from the American Type Culture Collection. Human ovarian 
carcinoma cells (A2780) were kindly donated by Dr Sally Coulthard, NICR. Cisplatin-
resistant human lung adenocarcinoma cells (Mor/CPR) were obtained from the 
European Collection of Cell Cultures (now HPA cultures). All cell lines were cultured 
in Roswell Park Memorial Institute (RPMI-1640) tissue culture media and maintained 
at 37°C, 5% CO2. 
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2.2.3: Maintenance of cell lines 
 
All cell lines were cultured as adherent mono-layers in tissue culture flasks and were 
sub-cultured frequently (less than 90% confluence) to maintain continuous growth. For 
routine sub-culture of all cell lines, media was removed through aspiration and cells 
washed with 10 ml warm PBS. Following aspiration, 2 ml warm TE was added to the 
flask and passed across the cells. Excess TE was aspirated after 30 seconds exposure 
and the flasks incubated at 37°C until all cells had detached. Cells were protected from 
TE through addition of 10 ml fresh culture media and cells counted. An appropriate 
volume of cell suspension was added to fresh culture media and transferred to a new 
flask. Mycoplasma testing was carried out every 3 months using a Mycoplasma 
Detection Kit (Roche Diagnostics, UK) and cells were negative for contamination 
throughout. 
 
2.2.4: Counting cells 
 
A haemocytometer comprises a glass slide containing chambers of a known depth with 
grids etched onto the surface. Each chamber is divided into 9 squares with surface areas 
of 1 mm
2
. When a glass cover slip is placed over the chambers and grid, the depth is 0.1 
mm and hence the volume of solution for each 1 mm
2
 is 10
-4 
ml. Cell samples were 
loaded into the counting chamber through capillary action. Cells were counted using a 
microscope and the density of cells per ml = average cell count per mm
2
 x 10
4
. To 
avoid overestimating the number of cells, any cells touching the upper and right hand 
perimeter lines were ignored. 
  
93 
 
2.2.5: Cryogenic storage and resuscitation of frozen cells 
 
Storage 
Cells were harvested using trypsin-EDTA as described in section 2.2.3 and collected by 
centrifugation (275 x g, 20°C for 5 minutes). Excess media was aspirated and cell 
pellets resuspended in freezing solution at a concentration of 10
6
 cells/ml. Cell 
suspensions (1 ml) was transferred into a cryovial, and then frozen for 24hr at -80°C in 
an expanded polystyrene box to achieve a slow freezing rate. Slow freezing and the 
presence of DMSO in the freezing solution help to minimise the formation of ice 
crystals which could potentially damage the cells. After initial freezing, cells were 
transferred to liquid nitrogen. 
 
Resuscitation 
Aliquots of frozen cells (1 ml), stored in liquid nitrogen, were thoroughly thawed to 
37°C and immediately added to 9 ml fresh tissue culture media. Cells were washed by 
centrifugation (275 x g, 20°C for 5 minutes) before being innoculated into tissue culture 
flasks. Cells were not used for experimentation for at least one week to ensure recovery 
from the effects of cryopreservation. 
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2.3: Exposure of cells to cytotoxic drugs 
 
Cell Lines – Incubations in flasks 
Cisplatin, carboplatin and oxaliplatin were prepared in medium at 5 to 10-fold higher 
initial concentrations and appropriate volumes added to cell cultures to achieve the 
desired final concentrations. For control experiments water without drug was added. 
Sterile sodium chloride was added to correct for osmotic changes as a result of adding 
water or aqueous drug solution. After exposure cells were washed three times with 
PBS, before harvesting by trypsinisation. Following centrifugation (275 x g, 20°C for 
10 minutes), pellets were stored at -20°C. 
 
Cell Lines – Incubations in 96 well plates 
Cisplatin, carboplatin and oxaliplatin were prepared in medium at 2-fold higher initial 
concentrations, and 100 µl/well added to cell cultures to achieve the desired final 
concentrations. For control experiments medium without drug was added. Cells were 
incubated at 37°C for varying times dependent on the experimental setup. 
 
Volunter Human Blood 
Blood was collected in sterile heparinised tubes, and then incubated in tissue culture 
flasks with 2 mM carboplatin (dissolved in saline) or saline alone for 60 minutes. 
Immediately after incubation, 10 ml blood samples were layered onto Lymphoprep 
(Axis Shield, Norway) and centrifuged (800 x g, 20°C for 15 minutes). Peripheral 
blood lymphocytes were collected and washed twice in sterile PBS, then pellets frozen 
at -20°C. Prior written consent was obtained for all volunteer samples. 
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2.4: Sulphorhodamine B colorimetric assay 
 
Principle 
Sulphorhodamine B (SRB) is an aminoxanthine dye with two sulphonic groups that 
binds electrostatically to basic amino acids of cell proteins under mildly acidic 
conditions. The intensity of staining is proportional to the amount of cellular protein 
and therefore cell number, assuming cell size is consistent. As described previously 
(Skehan et al 1990) the SRB colorimetric assay can be used as a rapid and sensitive 
means of determining cellular growth rate and growth inhibition. The SRB assay was 
carried out using 96-well microtitre plates. The number of cells plated was dependent 
on growth rate of the cells, the confluent cell density and the duration of the 
experiment. Cells were inoculated only in the inner 60 wells on the plate to avoid 
“edge-effect”, a phenomena that can cause abnormal growth in the outer wells (Dr 
Rony Nuydens, Jansenn Cilag ltd, Belgium - personal communication).  
 
Method: SRB Assay 
Cells were fixed by aspirating all media from the plates, followed by addition of 200 µl 
cold PBS and then 50 µl cold 50% trichloroacetic acid (TCA). After incubating at 4°C 
for 1hr, plates were washed with water and stored at 4°C ready for staining. To each 
well 100 µl SRB stain was added and incubated at room temperature for 30 minutes. 
Excess dye was removed by rinsing 5 times with 1% acetic acid (VWR). Rinsing was 
performed quickly but gently to avoid dislodging cells and prevent desorption of the 
protein-bound dye. Stained plates were air-dried overnight before addition of 100 µl 10 
mM Tris to each well to solubilise the dye. Staining intensity was then analysed at 490 
nm using a SpectraMAX 250 microplate reader (Molecular Devices). 
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2.5: DNA extraction 
 
2.5.1: DNA extraction using hydroxyapatite 
 
Principle 
DNA extraction using hydroxyapatite was described previously (Tilby et al 1991) for 
preparation of cellular DNA for measurement of melphalan-DNA adducts by 
immunoassay. Hydroxyapatite is a calcium phosphate mineral that is believed to 
interact with phosphate groups on DNA. By manipulating phosphate concentration (i.e. 
low phosphate concentration in solution) it is possible to bind DNA to hydroxyapatite, 
allowing retention of DNA whilst washing away any remaining cellular material. 
Increasing phosphate ion concentration causes DNA to elute from the hydroxyapatite. 
This method can reliably produce a good yield of DNA from a relatively small number 
of cells and produces low molecular weight DNA free of alcohol, RNA and protein. 
 
Method: DNA extraction 
Frozen cell pellets were lysed by addition of 2 ml HA lysis buffer and then sonicated 
for 2 minutes at full power in a 600 W Vibracell ultrasonic processor equipped with a 
water-filled cup-horn (Roth Scientific, UK). After sonication 20 µl RNAase A was 
added to each lysate to digest RNA and samples were incubated at 37°C for 15 minutes. 
Following incubation, an additional 3 ml HA lysis buffer was added along with 5 ml 
water saturated Kirby‟s phenol, and samples mixed by rotation at room temperature for 
20 minutes. Samples were centrifuged (700 x g, 4°C for 15 minutes) to separate the two 
phases. For each sample the aqueous upper phase (approximately 5ml) was collected 
and transferred to a fresh tube.  
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To each tube 25 ml of 6 M urea, containing 80mM KP buffer and 0.5 g DNA grade 
hydroxyapatite BioGel (BioRad, UK), was added to the DNA solution and mixed by 
rotation at room temperature for 20 minutes. The hydroxyapatite with DNA bound was 
collected above a filter in a spin column, which comprised a 10 ml syringe barrel 
(central Luer connection) with a piece of plastic gauze covering the bottom and a close-
fitted glass fibre filter paper disc. The syringes were suspended inside 50 ml tubes. 
Excess liquid was removed by centrifugation (50 x g, 20°C for 5 minutes) and washed 
twice with 10 ml 5 M Urea containing 80 mM KP buffer to remove traces of proteins, 
phenol and detergent, followed by three further washes with 10 mM KP buffer to 
remove urea. After each volume of wash buffer had been added the columns were 
centrifuged (50 x g, 20°C for 5 minutes) and the eluate discarded. DNA was finally 
eluted from the hydroxyapatite by addition of 2 ml 0.5 M KP buffer followed by 
centrifugation (50 x g, 4°C for 5 minutes). Eluates were stored at -80°C. 
 
Method: Removal of salt and concentration of DNA 
Desalting of the DNA solution was carried out using Centricon Ultracel YM-10 
centrifugal filter units (Millipore, UK). Initially the units were washed thoroughly with 
de-ionised water, then the DNA samples were added and centrifuged (5000 x g, 4°C) 
until the volume in the Centricon was approximately 60 µl. DNA was washed twice by 
addition of 1 ml DNA digest buffer and further centrifugation. 440 µl DNA digest 
buffer was added to the unit which was then left to stand at room temperature for one 
hour to allow DNA to dissociate from the filter. The resulting concentrated DNA 
solution was collected by placing a vial over the top of the Centricon, inverting, and 
centrifuging (500 x g, 4°C for 5 minutes). The DNA solution was stored at -80°C. 
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2.5.2: DNA extraction using QIAGEN Blood and Cell Culture DNA midi kit 
 
Principle 
The blood and cell culture DNA midi kit makes use of the QIAGEN „Genomic-tips‟, 
which use an anion exchange resin to retain DNA, without use of phenol or chloroform. 
In this procedure cells were lysed and digested with protease enzyme and the lysates 
then added to the column and allowed to pass through by gravity flow. The pH and low 
salt conditions of the buffer caused DNA to bind to the QIAGEN resin whilst other 
cellular constituents passed through. Purified DNA was eluted in a high salt buffer. The 
type of kit used was limited to processing cellular samples with a maximum cell count 
of 2 x 10
7
 (see section 1A) or tissue samples up to approximately 100 mg (see section 
1B). Section 2 was the same for both cellular and tissue preparations. 
 
Method 
Section 1A: Cell Pellets 
Frozen cell pellets were thawed fully, re-suspended in 1 ml PBS, and transferred to 15 
ml centrifuge tubes (Sarstedt, Germany). Ice cold buffer C1 (2 ml) was added and 
mixed and then 6 ml ice cold de-ionised water added. Samples were placed on ice for 
15 minutes, followed by centrifugation (1300 x g, 4°C for 15 minutes). Supernatants 
were discarded and pellets were each re-suspended in 1 ml ice cold buffer C1, mixed, 
and then 3 ml ice cold de-ionised water was added. They were again placed on ice for 
10 minutes, followed by centrifugation (1300 x g, 4°C for 15 minutes). Supernatants 
were discarded and pellets re-suspended in 1 ml buffer G2 and samples were sonicated 
for 2 minutes at full power in a 600 W Vibracell ultrasonic processor equipped with a 
water-filled cup-horn (Roth Scientific, UK). After sonication, buffer G2 (4 ml) and 
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RNAase A solution (10 µl) were added and incubated at 37°C for 20 minutes, followed 
by addition of QIAGEN protease (95 µl) and incubation at 50°C for 1hr.  
 
Section 1B: Human or Mouse Tissue Samples 
Tissue samples up to 100 mg were initially homogenised with 100 µl buffer G2 in a 1.5 
ml microtube using a plastic “pellet pestle” (Anachem, UK). A further 900 µl buffer G2 
was added and the sample transferred to a 15 ml centrifuge tube (Sarstedt, Germany). A 
further 1 ml buffer G2 was added and samples were sonicated for 2 minutes at full 
power in a 600 W Vibracell ultrasonic processor equipped with a water-filled cup-horn 
(Roth Scientific, UK). After sonication 7.5 ml buffer G2 and 19 µl RNAase A were 
added and samples incubated at room temperature for 15 minutes, followed by addition 
of 500 µl QIAGEN protease and incubation at 50°C for 2hr. 
 
Section 2: Genomic Tip DNA Extraction 
During the incubation steps columns were equilibrated with 4 ml buffer QBT. After 
incubation samples were added to the columns. At this point DNA became bound to the 
column, and was washed twice with 7.5 ml of buffer QC. DNA was eluted into 15 ml 
centrifuge tubes (Sarstedt, Germany) by addition of 5 ml of buffer QF. Isopropanol (3.5 
ml) was added to each DNA sample. The samples were centrifuged (5000 x g, 4°C for 
25 minutes). Supernatant was carefully poured off and 2 ml cold 70% ethanol was 
added, followed again by centrifugation (5000 x g, 4°C for 15 minutes). Supernatant 
was carefully poured off and samples were air-dried. DNA was dissolved in 500 µl de-
ionised water and stored at -80°C. 
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2.5.3: Measurement of DNA concentration 
 
The concentration of isolated DNA was quantified using either an NanoDrop ND-1000 
spectrophotometer (Thermo Finnigan, USA) or a Lambda 2 UV/Vis Spectrophotometer 
(Perkin Elmer, USA). DNA maximally absorbs light at a wavelength of 260 nm. A 
sample of pure DNA has a ratio of optical density (OD) 260/280 which is empirically 
determined to be 1.8. The overall absorbance of DNA is a combination of the 
absorbance peaks of the four DNA bases. Sample contamination, with proteins for 
example, can cause the OD 260/280 ratio to vary. Samples with an OD 260/280 of less than 
1.75 or greater than 1.90 were discarded. 
 
NanoDrop Spectrophotometer 
The NanoDrop is a rapid and simple method for measuring absorbance without the use 
of cuvettes. Samples (1 µl) are loaded onto a fibre optic cable (receiving fibre). 
Samples are maintained on the cable by surface tension. A second fibre optic cable 
(source fibre) is brought into contact with the sample, bridging the gap between the two 
fibres. The gap is controlled at 0.2 and 1 mm distances. A pulsed xenon flash lamp 
provides the light source, and a spectrophotometer with a linear CCD array used to 
analyse the light passing through the sample. The concentration of DNA is 
automatically calculated by the NanaDrop software, based on the principle that a 
sample of 50 µg/ml pure DNA has an absorbance of 1 AU at 260 nm in a 10 mm path 
length cuvette. This method was used for all samples of DNA isolated using Qiagen 
kits (section 2.5.2) and DNA concentrated from gel filtration (section 2.8) 
 
 
101 
 
Lambda 2 UV/Vis Spectrophotometer 
This method is much slower for determining DNA concentration, but possibly more 
reliable. The Lambda 2 uses double-beam optics for excellent long term stability, 
reference compensation and baseline correction, and can be used for measuring 
individual or multiple wavelengths, or for scanning wide wavelengths ranging from 
190-1100 nm, with scan speeds between 7.5-2880 nm/min. The Lambda 2 was used for 
measuring DNA isolated using hydroxyapatite (section 2.5.1) using a 1 mm path length 
cuvette and for measuring dissolved pure DNA (section 2.7.1) or DNA in gel filtration 
fractions (section 2.8) using a 10 mm path length cuvette.  
 
For DNA isolated by hydroxyapatite, approximately 500 µl samples were added. DNA 
digest buffer was initially measured at OD254nm to provide a blank reading. OD280nm was 
also measured to test sample purity. Between each sample the cuvette was rinsed 
thoroughly with acetone and air dried. DNA concentration was determined using the 
equation below: 
 
DNA concentration (µg/ml) = Absorbance 260nm * 50 * 10 
 
DNA in collected gel filtration fractions was measured at OD 254nm. Initially, OD 254nm 
of 50 mM sodium phosphate buffer was measured to provide a blank reading. The 
cuvette was not rinsed between samples. DNA concentration was not calculated as all 
gel filtration plots in this thesis used OD254nm as a vertical Y2 axis. 
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2.6: Enzymatic digestion of platinated DNA 
 
Principle 
Prior to chromatographic separation of Pt-DNA adducts DNA samples were 
enzymatically digested to form 5' mononucleotides and 5' dinucleotides, where adjacent 
nucleotides are joined by a Pt atom. DNAase1 was initially added to DNA samples and 
incubated. DNAase1 is a nuclease that cleaves DNA at phosphodiester linkages, 
preferentially adjacent to pyrimidine bases. This results in 5'-phosphate 
polynucleotides, with a free 3'-hydroxyl. Nuclease P1, which further cleaves DNA 
yielding 5'-monophosphate nucleotides, was added after incubation with DNAase1. 
Importantly, nuclease P1 cannot cleave dinucleotides linked by Pt, possibly due to 
steric hindrance. This allows for cleavage of Pt-DNA adducts from DNA with a 
terminal 5'-phosphate 
 
 
Figure 2.1 Enzymatic hydrolysis of platinated DNA to mono- and di-nucleotides, which 
were subsequently separated by anion exchange chromatography under varying salt 
concentrations 
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Method 
The volume of DNA solution required in each digest was calculated by dividing the 
required [DNA] from the measured [DNA], and multiplying this value by the total 
digest volume. The final concentration of DNA was 0.25 mg/ml, made up in a final 
volume of 200 µl. 20 Kunitz units of DNAase1, 4.8 µl 10 mM zinc sulfate and 3.2 µl 
250 mM magnesium chloride was added and incubated for an initial 2hr at 37°C. 
Nuclease P1 (200 units/ml) was added after the initial 2hr and incubated for a further 
16hr at 37°C. After the incubation period the digested DNA samples were added to a 
Microcon YM-10 ultrafiltration unit (Millipore, UK) (nominal 10 kDa MW cut-off) and 
centrifuged (14000 x g, 4°C for 1hr) to remove proteins prior to chromatography. 
Ultrafiltrates were stored at -80°C.  
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2.7: Reactions of cisplatin with nucleic acids 
 
2.7.1: Reaction of cisplatin with highly purified calf thymus DNA in the presence 
or absence of GSH or STS 
 
Highly purified calf thymus DNA (Merck, USA) was dissolved in 5 mM sodium 
chloride over several days at 4°C. DNA concentration was determined at OD260nm using 
a Lambda 2 UV/VIS spectrophotometer as described in section 2.5.3. Cisplatin was 
diluted in de-ionised water from a 2 mM stock stored at -20°C. The final required 
concentration was achieved by diluting cisplatin in water and 10X PB. GSH and STS 
were dissolved in PB immediately prior to use, and pH adjusted with 10 M and 1 M 
sodium hydroxide. 
 
Cisplatin was reacted with calf thymus DNA in the presence and absence of GSH or 
STS to give a final DNA concentration of 500 µg/ml. The DNA, GSH and STS 
solutions were prepared in PB. Cisplatin was added and the reaction vessels were 
immediately gassed with nitrogen to prevent oxidation. The mixture was then incubated 
at 37°C. Samples were stored at -80°C. Platinated DNA was separated by gel filtration 
chromatography as described in section 2.8. 
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2.7.2: Reaction of cisplatin with deoxyguanosine monophosphate (dGMP) in the 
presence or absence of GSH or STS 
 
dGMP was dissolved in de-ionised water to a concentration of 2 mM to match the 
concentration of cisplatin. Equal volumes of cisplatin and dGMP were mixed to achieve 
a final concentration of 1 mM, and incubated at 37°C. GSH and STS were dissolved in 
de-ionised water immediately prior to use, and pH adjusted with 10 M and 1 M sodium 
hydroxide. GSH and STS were added to the dGMP/cisplatin reaction mixture after 24hr 
incubation at 37°C. Reaction samples were stored at -80°C. 
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2.8: Gel filtration chromatography  
 
Principle 
Following reaction of calf thymus DNA with cisplatin in the presence or absence of 
GSH or STS, platinated DNA was separated from unreacted drug and other low 
molecular weight material by gel filtration chromatography. Gel filtration 
chromatography is a method that allows separation of molecules through a gel column 
on the basis of their molecular size. Molecules move through a bed of porous beads, 
diffusing into the beads based on size. Smaller molecules diffuse further and more often 
into the beads and therefore spend a greater proportion of time in the stationary phase 
compared to larger molecules, such as high molecular weight DNA, which are excluded 
from the pores of the stationary phase. Movement of solutes through the column is 
dependent on mobile phase flow rate and partitioning of molecules between the 
stationary and mobile phases based on molecular size. Molecules are eluted in the order 
of decreasing molecular size. 
 
Method – Gel Filtration 
PB was used as the mobile phase, and Sephadex G-75 as the stationary phase. 
Sephadex G-75 is a porous gel with a fractionation range of 3000 – 80000 MW, and 
was prepared by swelling the beads in de-ionised water overnight at room temperature, 
and then boiling for an hour to remove air. Two XK26 gel columns (Pharmacia, 
Sweden), each with an approximate bed volume of 400 ml, were used to contain the 
gel. The apparatus comprised two P1 peristaltic pumps (Pharmacia, Sweden), both 
routed through a 1.5 mm bore Omnifit rotary valve (Kinesis, UK) allowing 
simultaneous separation and flushing of alternate columns. Samples were introduced 
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through a Valve V7 mixer (Pharmacia) into a 10 ml sample loop (Pharmacia, Sweden) 
and collected using a Frac 200 collector (Pharmacia, Sweden). Fractions were collected 
over 5 minutes at a flow rate of 2.0 ml/min. DNA was detected in collected fractions by 
measuring OD254nm using a Lambda 2 UV/VIS spectrophotometer as described in 
section 2.5.3. Pt content determined by atomic absorption spectrometry as described in 
section 2.10, using nitric acid standards containing sodium phosphate to replicate the 
phosphate concentration of the diluted samples.  
 
Method – Concentration and Buffer Exchange of Solutions 
Fractions containing DNA were transferred to an Amicon stirred ultrafiltration cell 
model 8050 (Millipore, UK) with a 10000 kDA molecular weight cut off filter. DNA 
was concentrated under nitrogen gas pressure (~ 70 PSI). Phosphate buffer was 
replaced with DNA digest buffer through a series of washes under nitrogen gas 
pressure. DNA was collected from the cell in approximately 1 ml DNA digest buffer 
after the cell was stirred for 1hr with no nitrogen gas. This was necessary to allow the 
release of DNA from the membrane, thereby maximising DNA recovery. DNA 
concentration was determined by measuring OD260nm using a NanoDrop 
spectrophotometer as described in section 2.5.3. 
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2.9: Anion exchange chromatography 
 
Principle 
Ion exchange chromatography is a technique that allows separation of molecules based 
on their charge and can be sub-divided into cation and anion exchange chromatography. 
Cation exchange chromatography relies on positively charged molecules binding to 
negatively charged residues on the stationary phase of a column, whereas anion 
exchange chromatography relies on negatively charged molecules binding to positively 
charged residues on the stationary phase of the column. In the ion exchange 
chromatography method used here the ionic strength was increased over time by 
mixing together two buffers of different ionic composition. Samples were introduced in 
a starting buffer (low chloride ion concentration) and became bound to the column. The 
concentration of chloride ions was increased by steadily increasing the proportion of 
the second buffer (high chloride ion concentration). Molecules were selectively eluted 
based on their different binding affinity to the column at varying ionic strengths. 
 
Method 
DNA nucleotides (negatively charged) were separated using a MonoQ 5/50 GL anion 
exchange column (Amersham, UK) which carries –CH2-N
+
(CH3)3 as the charged 
group. Chromatography was carried out using a modified “FPLC system” with two P-
500 pumps (Pharmacia, Sweden) coupled to a mixer (Pharmacia, Sweden) and a Waters 
2487 dual λ absorbance detector (Waters, UK) with an inert taper split flow cell 
(Waters, UK). Samples were introduced through a Rheodyne 9725i manual injector 
port. Fractions of eluent were collected in a Frac 100 collector (Pharmacia, Sweden). 
The system was controlled through Clarity
®
 Chromatography data station software 
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(DataApex, UK). The pumps were controlled via a Clarity CB20 digital to frequency 
converter board and outputs from the UV monitor and injection valve were connected 
to a Clarity Int7 analogue to digital converter board.  
 
The chromatographic method for separating Pt-DNA adducts after enzymatic digestion 
was based on a method published previously (Fichtinger-Schepman et al 1985). Before 
sample injection the column was equilibrated with Cl
-
 ions by performing the salt 
gradient program as used for elution. This gradient was formed between HPLC buffers 
A and B by altering the proportion of each buffer entering the column by varying the 
pump rates (Table 2.1). The overall flow rate was 1 ml/min, with a typical pressure of 
between 3-3.5 MPa. During elution 500 µl fractions were collected every 30 seconds 
over a 25 minutes period. Fractions were stored at -20°C prior to further analysis.  
 
A mixture of dAMP, dCMP, TMP and dGMP (50 µg/ml final concentration) was 
analysed at the beginning and end of each set of chromatographic analyses of 
experimental samples to serve as a control to confirm satisfactory performance of the 
MonoQ column. 
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Table 2.1: Chromatographic gradient used for selective elution of mono- and di-
nucleotides from the MonoQ column 
Time (Minutes) HPLC Buffer B Salt Ion (M) 
0 – 1 Isocratic elution, 5% 0.05 
1 – 4 Linear Increase, 5% to 7.5% 0.05 to 0.075 
4 – 7.5 Isocratic elution, 7.5% 0.075 
7.5 – 10.5 Linear Increase, 7.5% to 10% 0.075 to 0.1 
10.5 – 25 Linear Increase, 10% to 25% 0.1 to 0.25 
25 – 26 Linear Increase, 25% to 100% 0.25 to 1 
26 – 30 Isocratic elution, 100% 1 
30 – 34 Wash, 0% 0 
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2.10: Graphite furnace Atomic Absorption Spectrometry (AAS) 
 
Principle 
Atomic absorption is a process that occurs when a ground state atom, usually a vapour, 
absorbs energy in the form of light of a specific wavelength and becomes elevated to an 
excited state. The amount of light energy absorbed at this wavelength increases as the 
number of atoms increases. Unknown concentrations of an element in a sample can be 
calculated by comparison to the amounts of light absorbed by a series of known 
standards. Graphite furnace AAS requires 1: a primary light source, e.g. a hollow 
cathode lamp; 2: an atom source, which is a sample in the form of a vapour generated 
in an electrically heated graphite cartridge; 3: a monochromator to isolate a specific 
wavelength of light; 4: a detector to measure light accurately; and 5: electronics to treat 
the signal and process the results. Samples are injected directly into a graphite tube and 
heated through a series of programmed steps to remove solvent and matrix components, 
before then finally atomising the remaining sample for analysis. 
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Method 
Analysis was performed using a flameless Perkin Elmer AAnalyst 600 graphite furnace 
AAS (Perkin Elmer, UK) using a method designed for analysis of Pt. The 
monochromator was set to a wavelength of 265.9 nm. The furnace program steps are 
shown in Table 2.2.  
 
A standard curve of known Pt concentrations ranging from 0-2000 ng/ml was prepared 
by diluting stock Pt standards 10-fold in 0.1 M nitric acid. These standards were used to 
determine Pt concentration in samples. Standards for analysis of gel filtration fractions 
contained 5 mM sodium phosphate to match the concentration of phosphate ions in the 
diluted samples. Samples were diluted 10-fold in 0.1 M nitric acid. Analysis of each 
sample was carried out in duplicate. 20 µl aliquots were injected into the graphite tube 
by an autosampler. 
 
Table 2.2: Furnace program used for determination of Pt concentration 
Step Temperature (°C) Ramp Time (secs) Hold Time (secs) 
1 110 1 60 
2 130 15 30 
3 1300 10 20 
4 2200 1 5 
5 2450 1 10 
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Figure 2.2: Typical standard curve used for determination of unknown Pt 
concentrations in samples by atomic absorption spectrometry 
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2.11: Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) 
 
Principle 
ICP-MS is an analytical technique used to determine the isotopic composition and 
concentration of elements present in samples. Samples are converted to atoms by high 
temperature and become ionised whereby they can be analysed by mass spectrometry. 
Sensitivity of detection varies between elements as a result of differences in: 1, ease of 
ionisation; 2, background levels of elements in the environment; 3, matrix effect and 4, 
interferences from combinations of atoms that form ions with the same mass/charge 
ratio as the element being detected. 
 
High temperature and ionisation is achieved by passing a volume of sample through an 
atomiser. This generates a fine mist which is then sprayed into an inductively couple 
plasma (ICP) torch. Argon gas flows inside the ICP torch, connected to a radio-
frequency (RF) generator connected to an RF load coil. As power is supplied to the 
load coil from the RF generator, oscillating electric and magnetic fields are generated at 
the tip of the ICP torch. When a spark is applied to argon flowing through the torch, 
electrons are stripped from the argon atom to form argon ions. These ions collide with 
other argon ions in the oscillating fields to form the argon plasma torch, maintained at 
approximately 10‟000°K by an induction coil supplied with an electric current. The 
Atomic Spectroscopy detection limit for Pt by ICP-MS is 0.002 µg/L. Samples are 
typically introduced in liquid state and nebulised before entry into the plasma torch, 
where in the high temperature of the plasma metals become ionised through electron 
loss and are extracted into the mass spectrometer. ICP-MS is a method suitable for 
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detecting low levels of Pt as sensitivity of detection is less than 0.1 parts per trillion 
(PPT). 
 
Two instruments were used in this thesis – A Sciex Elan 6000 Quadrupole ICP-MS 
(Perkin Elmer, UK) and a Finnigan Element2 Magnetic Sector Field ICP-MS (Thermo 
Electron, Germany). All ICP-MS analysis was carried out at the Northern Centre for 
Isotopic and Elemental Tracing at the Department of Earth Sciences, Durham 
University, Durham, UK. 
 
2.11.1: Sciex Elan 6000 Quadrupole ICP-MS 
 
Detection Principle 
Metals ions are extracted through a series of cones with decreasing sample holes (1 mm 
„sampler‟ cone and 0.4 mm „skimmer‟ cone) into the quadrupole mass spectrometer. 
The quadrupole consists of four parallel metal rods. Opposing rods are connected 
electrically, and a radio frequency applied between paired-rods. A direct current voltage 
is superimposed over the radio frequency voltage and ions are separated based on the 
stability of their trajectories in the oscillating electric fields that are applied to the 
quadrupole rods. Only ions of a certain mass/charge ratio can pass through the 
quadrupole to the detector. Pt ions hitting the detector were counted and the count rate 
was proportional to the concentration of Pt in the sample. The actual concentrations 
were calculated using a standard curve of known Pt concentrations. 
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Sample Preparation 
All samples were prepared in ultrapure nitric acid (UpA) (Romil, UK) with a Pt 
contamination of < 1 PPT diluted to 3.5% w/v in high purity water. For analysis of total 
Pt-DNA adducts on DNA, 20 µl samples were diluted in 980 µl UpA, then acid 
hydrolysed at 70°C overnight. For analysis of chromatographically separated individual 
adducts, 100 µl samples were diluted in 900 µl UpA. Maximum salt concentration in 
samples after dilution was 25 mM.  
 
Sample Analysis 
Samples were introduced by a peristaltic pump into a standard cross-flow nebuliser 
fitted to a Scott type double pass spray chamber. This ensured a fine mist entered the 
plasma torch, and removed large droplets of liquid that would hamper ionisation. 
Nebuliser gas flow rate was between 0.8-1.0 L/min, and this was optimised to maintain 
the production of cerium (Ce) oxide (CeO
+
) at less than 3% of the total Ce
+
 signal. Ce 
is prone to formation of oxides and is used as a measure of oxide formation for 
monitoring elemental interference. Maintaining low levels of interference ensures the 
detected signal originates from the element of interest. This is especially important for 
low level elemental analysis. RF power was generally 1150 W. 
 
Three isotopes of Pt were monitored: 
194
Pt (32.97% abundance), 
195
Pt (33.83% 
abundance) and 
196
Pt (25.24% abundance) allowing for evaluation of isotopic 
differences as a check for errors or interferences in the analysis. Concentrations 
calculated using each Pt isotope agreed within analytical error, indicating that other 
potential interferences are negligible. Hafnium (Hf) oxide species (
178
Hf
16
O and 
179
Hf
16
O) are the commonest potential isobaric interference when detecting Pt. The 
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very low levels of Hf in the DNA solutions meant that such interferences were 
insignificant to the analyses in this thesis and therefore no oxide corrections were 
required. Pt concentrations in samples were calculated from average values produced 
by the three isotopes. Previous studies at Newcastle had determined that procedural 
blanks of approximately 1 PPT, give limits of quantitation of close to 1.1 PPT in the 
final solution (Azim-Araghi 2001). Therefore, no blank corrections were made to the 
data. 
 
The samples analysed were low in dissolved solids and therefore could be analysed 
using instrument calibration based on standard Pt solutions. Pt standards of 0, 100, 500, 
1000 and 2000 PPT were made from a 1000 PPM Pt stock (Romil, UK). Most samples 
in the study gave signals within this range. The standard solutions were analysed at the 
beginning of the analytical session, and again at the end. The 500 PPT standard was 
checked routinely during each analysis. It was critical to monitor the standards before, 
during and after analysis for two reasons: 1, instrumental drift can occur as the number 
of analyses increases and 2, the mass spectrometer was set to detect Pt using a detection 
process called peak hopping. During peak hopping the spectrometer moves between 
pre-set peaks (values entered as integers) causing the mass spectrometer to detect the 
tops of the mass peaks. This requires knowledge of the composition of the element 
being analysed to ensure the tops of the mass peaks are correctly identified. The 
calibration was monitored routinely to ensure this. An alternative to peak hopping is 
mass focusing (see section 2.11.2). 
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Figure 2.3: Typical standard curve used for determination of unknown Pt 
concentrations in samples on the Sciex Elan 
 
2.11.2: Finnigan Element2 Magnetic Sector Field ICP-MS 
 
Detection Principle 
Magnetic sector field ICP-MS relies on a magnetic field to disperse metal ions 
according to their mass and energy, determining the trajectory by which they pass 
through the mass analyser. Faster moving (lighter) ions are deflected more than slower 
moving (heavier) ions and the mass analyser can be adjusted to deflect and thus detect a 
narrow range of ion masses, or to scan through a range of known ion mass/charge ratios 
to analyse specific ions.  
 
Sample Preparation  
All samples were prepared in UpA nitric acid (Romil, UK). This was diluted to 7% w/v 
in high purity water. The 7% UpA was spiked with a small volume of 3% UpA spiked 
with 50 PPB thallium (Tl) for analysis of instrumental drift and Pt sample correction 
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(see data analysis section below). This acid had a final composition of 7% UpA with 2 
PPB Tl. DNA samples (100 µg/ml) were prepared in ultra pure water and diluted with 
equal volumes of 7% UpA with 2 PPB Tl to achieve a final concentration of 50 µg/ml 
DNA in 3.5% UpA, 1PPB Tl. Samples were acid hydrolysed at 70°C overnight. 500 µl 
of sample was sufficient for analysis. 
 
A series of Pt standards were prepared for calibration of the ICP-MS. These standards 
were made fresh for each analysis. 7% UpA was diluted to 3.5% UpA with high purity 
water. The 3.5% UpA was spiked with a small volume of 3% UpA spiked with 50 PPB 
Tl to ensure the acid used in the standards was of the same final composition as the 
samples. This acid had a final composition of 3.5% UpA with 2 PPB Tl. A stock of 
1000 PPM Pt (Johnson Matthey, USA) was prepared in 3.5% UpA, 2PPB Tl was used 
to prepare standards. This was diluted to 1000 PPT Pt in 3.5% UpA, 2PPB Tl, and 
mixed at varying volumes with 3.5% UpA to achieve the desired final concentrations as 
shown in Table 2.3. 
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Table 2.3: Standards used for calibration of the Element2 ICP-MS. The 1000 PPT Pt 
stock was prepared in 3.5% UpA/2 PPB Tl 
Standard (PPT) Vol. 3.5% UpA (µl) Vol. 1000 PPT Stock (µl) 
0 10000 0 
1 9990 10 
2 9980 20 
5 9950 50 
10 9900 100 
50 9500 500 
100 9000 1000 
250 7500 2500 
500 5000 5000 
 
 
Sample Analysis 
Unlike the Sciex Elan which uses a peristalitic pump, samples are introduced into the 
Element2 by capillary action. This is a much slower method of sample introduction. 
Samples entered into a 100 µl/min microflow nebuliser fitted to a cyclone scott double 
pass spray chamber. This set up was similar to the Sciex Elan but sample flow was 
greatly reduced. Nebuliser gas flow rate was varied to maintain a CeO/Ce of less than 
3%. Typically, nebuliser gas flow was in the region of 0.95 L/min. RF power was 1300 
W. Plasma cool gas (Argon) flow rate was 16 L/min. Auxillary gas flow rate (Argon) 
was 1 L/min. Individual sample analysis time was 26 seconds. 
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Very low levels of Pt were expected to be detected in the samples analysed on the 
Element2 ICP-MS, so an increased number of elements were detected. As with the 
Sciex Elan, three isotopes of Pt were monitored: 
194
Pt (32.967% abundance), 
195
Pt 
(33.832% abundance) and 
196
Pt (25.242% abundance). As mentioned above, samples 
were spiked with Tl, and two isotopes of Tl were measure: 
203
Tl (29.524% abundance) 
and 
205
Tl (70.476% abundance). At the expected low levels of Pt, isotopic interference 
has a greater effect on accurately determining the actual element levels, so a number of 
elements were detected by the Element2 ICP-MS to confirm the detected Pt levels were 
correct. These are shown in Table 2.4. 
 
Table 2.4: Isotopes detected by the Element2 ICP-MS. Natural abundance values were 
obtained from Rosman and Taylor 1998 
Element Isotope Measured Natural Abundance 
Neodymium 
143
Nd 12.18% 
Dysprosium 
161
Dy 18.91% 
Hafnium 
178
Hf 27.28% 
 
179
Hf 13.62% 
Platinum 
194
Pt 32.967% 
 
195
Pt 33.832% 
 
196
Pt 25.242% 
Mercury 
200
Hg 23.10% 
Thallium 
203
Tl 29.524% 
 
205
Tl 70.476% 
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The standard solutions (Table 2.3) were analysed at the beginning of the analytical 
session, and again at the end. The 5 PPT standard was checked routinely during each 
analysis. The Element2 mass spectrometer detector uses a process of mass focusing to 
determine the levels of each isotope analysed. In this process a mass is programmed for 
each isotope, and around this a mass window is determined. In this mass window the 
mass spectrometer is focused to finding the nominal peak for each isotope through a 
number of scans inside the window, allowing a more accurate determination of the 
levels of each element. For this analysis a mass window of 60 was used (+/- 30). Three 
passes were made per isotope, and an average value per isotope calculated per run. Five 
runs were made in total, meaning the final value produced for elemental concentration 
was a result of 5 distinct averages.  
 
Data Analysis 
The measured levels of neodymium, dysprosium and hafnium were determined to be at 
satisfactorily low levels that they were having no interference on the levels of Pt being 
detected. As a result, they were excluded from further analysis of the data. Mercury is 
commonly detected in nitric acid (Dr Chris Ottley, personal communication) but does 
not interfere with the elements being detected and such was excluded also. 
 
Throughout analysis of samples, a blank UpA sample and the 5 PPT standard were 
analysed. An average value of all the blank UpA samples analysed for each of the three 
Pt and two Tl isotopes was calculated, and subtracted from all samples to subtract 
background element levels. The 5 PPT values were compared after the wash value had 
been subtracted to monitor instrument drift. No significant drift was detected in any 
analyses, and therefore no correction was applied. 
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To confirm all ICP-MS readings were reliable, the ratio of 
203
Tl:
205
Tl was calculated. 
The natural abundances are 29.524% 
203
Tl and 70.476% 
205
Tl so a ratio of 1:2.3 was 
expected. An average ratio of 1:2.95 (+/- 0.1) was achieved, though this was constant 
throughout all analyses. To normalise the detected Pt values throughout, the individual 
counts per second (CPS) was divided by the CPS for the 
205
Tl isotope. This was applied 
to all standards to produce a standard curve of Pt (PPT) against CPS Pt/CPS 
205
Tl. A 
typical standard curve is shown in Figure 2.4. The concentration of Pt (PPT) in each 
sample was calculated in Prism4 (GraphPad Software). This value was converted to 
moles/ml by multiplying the value (PPT) by 5.13e
-15
. An average value for the three Pt 
isotopes was determined, and subsequently divided by the concentration of DNA in the 
sample (5.0e
-5
 g/ml) to determine an overall Pt-DNA adduct level in nmol Pt g
-1
 DNA. 
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Figure 2.4: Typical standard curve used for determination of unknown Pt 
concentrations in samples analysed on the Element2 ICP-MS. () 194Pt, () 195Pt and 
() 196Pt  
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2.12: Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass 
Spectrometry (MALDI-TOF) 
 
MALDI-TOF mass spectrometry is a widely used technique for biomolecule analysis. 
Samples are mixed with a molar excess of ultraviolet absorbing matrix and dried on 
MALDI plates. MALDI is a “soft” ionisation technique in which samples become 
ionized by laser pulses through proton transfer: 
 
Matrix-H
+
 + Sample → Matrix + Sample-H+ 
 
Ions of varying sizes are formed in pulses and extracted through a drift tube to a 
detector, with smaller ions reaching the detector more rapidly. The “Time-of-Flight” 
(TOF) mass analyser measures the time taken for ions to reach the detector (drift time). 
The mass/charge ratio of the ions is proportional to the square of the drift time, and is 
calculated using the following equation: 
 
m/z = 2t
2
 x K / L
2
 
 
m mass 
z number of charges on ion 
t drift time 
K kinetic energy of ion 
L drift length 
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MALDI-TOF mass spectrometry was performed at the Institute for Cell and Molecular 
Biosciences Pinnacle laboratory for Proteomics and Biological Mass Spectrometry, 
Newcastle University by Dr Joe Gray and Mr Robert Liddell. MALDI-TOF mass 
spectrometry was carried out using a Voyager-DE STR Biospectrometry workstation 
(Applied Biosystems, UK).  
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2.13: Nuclear Magnetic Resonance Spectrometry (NMR) 
 
NMR is a powerful spectroscopic method based on absorption of energy in the 
radiofrequency region of the electromagnetic spectrum by nuclei (hydrogen) of 
elements that have spin angular momentum and a magnetic moment. Elements whose 
nuclei possess spin angular momentum and a magnetic moment are assigned half-
integral or integral numbers, which determine the number of orientations in space that 
can be adopted by the spinning nuclei when an external magnetic field is applied. 
Electrons also possess a spin angular momentum, which generates a magnetic moment 
that affects the magnitude of the external field experienced by the nuclei.  
 
Nuclei of a particular element that occur in different chemical environments generally 
experience slightly different magnetic field strengths due to shielding and deshielding 
by nearby electrons, and thus their resonant frequencies differ in a way that is defined 
as a chemical shift value. The spin states of one nucleus can affect the magnetic field 
experienced by nearby elements and groups through intervening bonds causing the 
absorption peaks to split into multiple components. This effect provides information 
that permits interpretation of spectra to determine specific locations of nuclei in 
compounds. NMR spectrometers comprise a superconducting solenoid or 
electromagnet to generate a stable magnetic field, a transmitter to generate the required 
radiofrequencies, and a receiver coil to monitor the detector signal. 
 
Two NMR methods were applied in this thesis – proton NMR (1H-NMR) and two-
dimensional correlation NMR (COSY-NMR). NMR spectra are often too complex to 
interpret due to signal overlap. Two dimensional NMR (such as COSY-NMR) allows 
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determination of molecular connectivity based on spin-spin interactions. In two-
dimensional NMR both the X and Y axes plot chemical shifts and 2D spectra can be 
plotted like a grid.  
 
Samples for NMR were prepared in ultrapure water. dGMP and GSH were dissolved at 
10 mM, and cisplatin at 5 mM. For NMR analyses of dGMP and GSH alone, samples 
were freeze dried then re-dissolved in D2O. This was done twice. For NMR analyses of 
platinated dGMP and GSH, samples were incubated with cisplatin (2:1 molar ratio) for 
72hr, then freeze-dried and re-dissolved in D2O. This was done once. All samples for 
NMR were dissolved in 0.7 ml D2O. 
 
NMR was performed at the School of Chemistry by Professor William McFarlane 
using a Jeol Eclipse 11.7 Tesla (
1
H at 500 MHz) spectrophotometer with Delta 
software.  
  
128 
 
2.14: Statistical analysis 
 
Statistical analyses were carried out using GraphPad prism software version 4.0. Unless 
otherwise indicated, unpaired t-tests were used for analysing significance.  
 
For the curve fitting to data (SRB data) the following logistic equation was used: 
 
Y = M*X^S / (X^S+K^S) 
 
Where 
 
M = Maximum value of Y 
S = Slope 
K = Value of X at which Y = 0.5*M 
 
So: 
 
Y = OD as % of control and M is fixed at 100%, X = drug concentration 
K therefore is the drug concentration at which Y = 50% (GI50 value)
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Chapter 3 
In vitro characterisation of potential new Pt-DNA adducts 
formed in the presence of glutathione 
 
3.1: Introduction 
 
The early works of Roberts et al (1972) and Fichtinger-Schepman et al (1985) 
described in detail in chapter one provided the foundation for the understanding of the 
cytotoxic properties mechanisms of Pt-based anticancer drugs (Roberts and Pascoe 
1972, Fichtinger-Schepman et al 1985). Their findings provided evidence that 
formation of lesions across DNA was a major part of the mechanism attributed to such 
drugs, and although the exact mechanisms of cytotoxicity are still unclear, it is accepted 
that DNA is the major target. 
 
A major limitation in many early studies however was the lack of sensitivity in 
detection. AAS was often used to determine the levels of Pt in DNA hydrolysates or 
chromatographically separated DNA which had been enzymatically digested to mono- 
and dinucleotides. AAS was used with pure DNA that had been reacted with high 
concentrations of cisplatin, but unfortunately it was not possible to extend such 
techniques to the study of DNA from drug-treated cells. The development of sensitive 
immunochemical methods (Tilby et al 1991, Meczes et al  2005, Liedert et al 2006) and 
32
P post-labelling assays (Blommaert and Saris 1995, Welters et al 1997, Pluim et al 
1999) as described in chapter 1, enabled investigation of more clinically relevant levels 
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of Pt and investigation of DNA from drug treated cells. However, there are inherent 
limitations with both approaches. Immunochemical studies involve antibodies raised 
against specific lesions, and thus are limited to detection of those specific adducts. 
Postlabelling assays are highly sensitive for the 1,2-intrastrand cis-Pt(NH3)2d(GpG) 
adduct, and to a lesser extent the cis-Pt(NH3)2d(ApG) adduct. Indeed, neither method is 
appropriate for the study of all types of adducts that might be present in DNA in cells. 
 
The limitation of AAS for detecting Pt in DNA from drug-treated cells has more 
recently been overcome through the development of assays involving the highly 
sensitive method of ICP-MS. Although originally a geochemical technique developed 
for studying low level elements, ICP-MS has been used in studying the interactions of 
Pt with cytoplasmic molecules (Esteban-Fernandez et al 2007, Esteban-Fernandez et al 
2008) and Pt-DNA adducts (Sar et al 2008, Harrington et al 2010). In more recent 
years, through the application of ICP-MS, evidence has been obtained suggesting that 
an additional class of novel Pt-DNA adducts is formed in drug-treated cells, accounting 
for up to 25% of the total Pt-DNA products (Azim-Araghi 2003). These data arose from 
the novel combination of anion exchange chromatographic separation of enzymatically 
digested DNA from drug treated cells as described previously (Fichtinger-Schepman et 
al 1985, Azim-Araghi 2003) with ICP-MS to detect Pt in chromatographic fractions. In 
this work, DNA from two lung carcinoma cell lines (H69/p and Mor/p) incubated with 
cisplatin was enzymatically digested and separated as described above. Analysis by 
ICP-MS revealed the presence of additional products not detected when purified DNA 
was incubated with cisplatin. From these data it was hypothesised that the newly 
detected product was a result of a Pt-mediated cross-link to a non-DNA molecule with 
this molecule proposed to be glutathione (GSH). 
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The first evidence that GSH is able to cross-link to DNA via Pt was published over 
twenty years ago (Eastman 1987). Eastman provided evidence that GSH was able to 
form lesions with monofunctionally bound Pt and proposed that this form of binding 
stopped the conversion of monofunctional to bifunctional cross-links, believed to be 
responsible for cytotoxicity. These data fitted with previous findings that GSH could 
quench monofunctional adducts (Micetich et al 1983). No indication was presented 
however to support the role that such adducts could contribute to the cytotoxic 
mechanism of Pt-based drugs. 
 
Previous work at Newcastle (Azim-Araghi 2003) has indicated that GSH is able to 
cross-link to DNA via cisplatin, forming a novel adduct in cells. However, there is 
limited information on the chromatographic properties of such a product. The 
experiments presented in this chapter investigated the in vitro formation of putative cis-
Pt(NH3)2(DNA)(GSH) adducts. The aim of the experiments was to synthesise putative 
products using 5'-deoxyguanosine monophosphate (dGMP) as a surrogate for DNA 
products. This would allow characterisation of the chromatographic properties of GSH-
containing adducts, thereby facilitating their identification in DNA hydrolysates. The 
use of dGMP permitted investigations at high concentrations of cisplatin so that Pt-
containing products formed in the reactions with cisplatin in the presence and absence 
of GSH could be readily detected by AAS.  
 
Following characterisation of the chromatographic system to be used, initial 
experiments were aimed at generating dGMP-Pt-Cl, whereby dGMP is bound to one of 
the arms of cisplatin, mimicking the formation of monofunctional Pt-DNA adducts. 
These products would then be further reacted with GSH with the aim of generating cis-
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Pt(NH3)2(dGMP)(GSH) products. It was anticipated that this approach would also 
provide sufficient quantities of product to allow for structural analysis. The findings in 
this chapter would therefore provide important information for investigating novel Pt-
DNA adducts formed in cells incubated with Pt drugs. 
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3.2: Chromatographic system 
 
Experiments in this study investigating the formation of Pt-DNA adducts used an anion 
exchange chromatographic system with a MonoQ column (section 2.9) to detect 
potential products by UV absorbance, and either AAS (dGMP) or ICP-MS (DNA) to 
detect Pt in collected fractions. Anion exchange was chosen for the separation 
procedure for three reasons: (1) a similar setup had previously been used for the 
identification of Pt-DNA adducts formed in pure DNA (Fichtinger-Schepman et al 
1985); (2) the combination of the MonoQ system with ICP-MS had provided the initial 
evidence of additional types of DNA adducts formed in cells to those characterised in 
purified DNA (Azim-Araghi 2003) and (3) anion exchange analysis allowed for the 
study of nucleotides. Eastman had previously used a reverse-phase chromatographic 
system to study nucleosides (Eastman 1983), but this involved additional enzymatic 
digestion of DNA incubation with alkaline phosphatase. As the nature and stability of 
the putative cis-Pt(NH3)2(DNA)(GSH) products was unclear, limiting the processing 
steps prior to analysis was favourable. The actual MonoQ chromatographic setup and 
method is described in section 2.9. 
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3.3: Results 
3.3.1: Characterisation of the chromatographic system using mononucleotides  
 
Four mononucleotides of dAMP, dCMP, dGMP and TMP were analysed individually 
using the MonoQ system to determine their retention times for future reference. 
Mixtures containing the four mononucleotides were analysed to assess the effectiveness 
of the MonoQ column in separating multiple components. Solutions (100 µl at 50 
µg/ml) were injected onto the column and the optical densities of the eluents were 
measured at 254nm and 230nm. Typical results are shown in order of increasing 
retention time for dCMP, dAMP, TMP and dGMP (Figure 3.1), with elution patterns 
for a mixture containing 50 µg/ml or 100 µg/ml of the four mononucleotides shown in 
Figure 3.2. Typical retention times compared to previous analyses (Fichtinger-
Schepman et al 1985, Azim-Araghi 2003) are shown in Table 3.1. 
 
Absorbance at 254 nm was higher for dAMP, dGMP and TMP than at 230 nm. 
Conversely, absorbance was higher at 230 nm for dCMP. This is in agreement with 
data obtained for each solution (50 µg/ml) analysed for absorbance in the UV 
wavelength region of 210-320 nm, using the scanning function of the Lamdba 2 
UV/Vis spectrophotometer (typically used for measuring DNA concentration (section 
2.5.3)) (Figure 3.3) and data published previously (Cavaluzzi and Borer 2004). 
 
Separation of the four nucleotides confirmed that the MonoQ system gave reproducible 
results and the separations were consistent with previous work (Fichtinger-Schepman et 
al 1985, Azim-Araghi 2003).  
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Figure 3.1:  Typical MonoQ elution profiles for individual mononucleotides. Solutions 
(100 µl at 50 µg/ml) of dCMP (A), dAMP (B), TMP (C) and dGMP (D) were injected 
onto the MonoQ column and eluted at 1 ml/min with increasing NaCl concentrations. 
(▲, dotted black line): NaCl concentration gradient; solid red line: OD 254 nm; solid 
blue line: OD 230 nm 
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Figure 3.2: Typical MonoQ elution profile for a mixture of the four mononucleotides. 
Solutions (100 µl at 50 µg/ml (A) or 100 µg/ml (B)) of the mononucleotide mixture 
were injected onto the MonoQ column and eluted at 1 ml/min with increasing NaCl 
concentrations. (▲, dotted black line): NaCl concentration gradient; solid red line: 
OD 254 nm; solid blue line: OD 230 nm 
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Figure 3.3: Analysis of absorbance of dAMP (black), dCMP (red), dGMP (blue) and 
TMP(green) in the UV region 210-320 nm using scanning function of the Lambda 2 
UV/Vis spectrophotometer. Solutions (50 µg/ml) were placed inside a 10 mm path 
length cuvette and UV absorbance measured. 
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Table 3.1: Average retention times on MonoQ column for the four mononucleotides 
compared with previous observations by Azim-Araghi (2003) and Fichtinger-Schepman 
et al (1985). Standard deviation for this study is shown in brackets. 
 
 
Retention Time (min) 
Current Study 
Retention Time (min) 
Azim-Araghi 
Retention Time (min) 
Fichtinger-Schepman 
dCMP 5.2 (0.1) 4.6 5.0 
dAMP 6.0 (0.2) 5.6 5.8 
TMP 6.7 (0.2) 6.1 6.4 
dGMP 12.5 (0.1) 11.8 12.0 
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3.3.2: Anion exchange separation of enzymatically digested calf thymus DNA 
 
Before analysing Pt-DNA adducts in DNA from drug-treated cells, it was important to 
confirm that the MonoQ chromatographic system used here yielded the same pattern of 
Pt-DNA adducts previously identified on purified DNA (Fichtinger-Schepman et al 
1985).  
 
Calf thymus DNA (500 µg/ml) was incubated with or without cisplatin (15 µM) for 2 
hours at 37°C, then DNA was separated from unreacted drug by gel filtration on a G-75 
Sephadex column (section 2.8). DNA (0.25 mg/ml) was enzymatically digested to 
mono and dinucleotides (section 2.6), then nucleotides were separated using the 
MonoQ anion exchange column (section 2.9). Pt species in collected fractions were 
detected using ICP-MS (section 2.11). 
  
A typical MonoQ elution profile for enzymatically digested calf thymus DNA not 
exposed to cisplatin is shown in Figure 3.4 (graph A). The four mononucleotides eluted 
in a similar manner to that seen with a mixture of deoxynucleotides (Figure 3.2). As 
expected Pt levels were at instrument background, showing no major Pt contamination 
during sample preparation. 
 
Calf thymus DNA incubated with 15 µM cisplatin (Figure 3.4, graph B) showed the 
presence of four Pt-containing products with similar retention times to previous studies 
(Fichtinger-Schepman et al 1985, Azim-Araghi 2003). Retention times for these 
products and the percentage of total Pt eluted in each adduct is shown in Table 3.2. A 
comparison of these data with the above mentioned studies is also given in Table 3.2.  
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The similarity between the present data and those of Fichtinger-Schepman et al (1985) 
and Azim-Araghi (2003), regarding retention times and distribution of Pt across the 
four peaks, suggests that the nature of the four detected products in this study is the 
same as the products characterised by DEAE-Sephacel and NMR previously 
(Fichtinger-Schepman et al 1985). The four peaks therefore were attributed to: A: 
Pt(NH3)2(R)(dGMP); B: cis-Pt(NH3)2d(ApG); C: cis-Pt(NH3)2d(GpG) and D: cis-
Pt(NH3)2(dGMP)2 (Figure 3.4). 
 
The percentage of Pt eluted for each individual product is similar between this study 
and previous studies, although a difference was seen in the total percentage of eluted Pt 
in the cis-Pt(NH3)2d(GpG) between this study (64.4%) and Azim-Araghi 2003 (66.6%), 
when compared to the percentage reported by Fichtinger-Schepman et al 1985 (47%). 
The quantity of the four eluted adducts expressed as a percentage of total eluted Pt was 
similar in this study (94.7%) to that of Azim-Araghi (95.2%). Total Pt recovery was 
always greater than 90% of the total amount of Pt injected. 
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Figure 3.4: Typical MonoQ elution profile for enzymatically digested calf thymus DNA 
(A) and calf thymus DNA incubated with 15 µM cisplatin (B). Solutions (100 µl) were 
injected onto the MonoQ column and eluted at 1 ml/min with increasing NaCl 
concentrations. Pt concentration in collected fractions was determined by ICP-MS. (●) 
Pt concentration; dotted line: OD 254 nm. Peaks A: Pt(NH3)2(R)(dGMP); B: cis-
Pt(NH3)2d(ApG); C: cis-Pt(NH3)2d(GpG) and D: cis-Pt(NH3)2(dGMP)2 
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Table 3.2: Chromatographic separation of enzymatically digested pure DNA reacted with cisplatin. Retention times (RT) of 8 substances eluted 
from the MonoQ column and quantity of adducts expressed as a percentage of the total Pt recovered. Data from three separate digestions in this 
current study, compared to Azim-Araghi 2003 and Fichtinger-Schepman 1985. SD is shown in brackets  
Peak Substance This Study Azim-Araghi 2003 Fichtinger-Schepman 1985 
  RT (min) % Pt Eluted RT (min) % Pt Eluted RT (min) % Pt Eluted 
 dCMP 5.2 (0.1)  4.6  5.0  
 dAMP 6.0 (0.2)  5.6  5.8  
 TMP 6.7 (0.2)  6.1  6.4  
 dGMP 12.5 (0.1)  11.8  12.0  
A Pt(NH3)2(R)(dGMP) 1.5 (1.0) 2.9 (0.8) 1.0 1.4 1.7 3 
B cis-Pt(NH3)2d(ApG) 4.0 (1.0) 20.5 (3.5) 2.5 20.7 3.5 23 
C cis-Pt(NH3)2d(GpG) 7.5 (1.5) 64.4 (3.1) 8.0 66.6 7.8 47 
D cis-Pt(NH3)2(dGMP)2 9.5 (2.0) 6.9 (1.8) 11.5 6.5 9.7 8 
TOTAL (% of Pt in adducts) 94.7 (3.7)  95.2  81 
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3.3.3: Identification of products formed in the reaction of cisplatin with 
deoxyguanosine monophosphate 
 
The key aim of this particular section of the study was to determine appropriate 
incubation conditions for the reaction between cisplatin and dGMP to maximise 
formation of the monofunctionally bound cisplatin-dGMP species. Three incubation 
conditions were considered: cisplatin and dGMP in an equimolar ratio, cisplatin in 
excess of dGMP in a 2:1 molar ratio or dGMP in excess of cisplatin in a 2:1 molar 
ratio. Cisplatin in excess of dGMP would be advantageous as it would favour the 
formation of monofunctionally bound dGMP products, although this condition was 
eliminated due to concerns of excess cisplatin interacting with other molecules during 
further reactions. An excess of dGMP was also excluded as this condition would favour 
the formation of bifunctionally bound species, which are considered to be non-reactive. 
An equimolar ratio was chosen for the reaction conditions to maximise the formation of 
monofunctionally bound products, accepting that there would be some bifunctional 
products also formed. 
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3.3.3.1: Preliminary Identification of products formed between cisplatin and 
dGMP 
 
Reaction of equimolar cisplatin and dGMP was predicted to yield four products. Three 
of these products were predicted to be monofunctionally bound cisplatin-dGMP with 
the chemical composition cis-Pt(NH3)2(R)(dGMP), where R could be either an aqua 
(OH2), hydroxy (OH) or chlorine (Cl) ligand. The fourth product was predicted to have 
dGMP bifunctionally bound to cisplatin (cis-Pt(NH3)2(dGMP)2). The retention time for 
the four products was unknown, but cis-Pt(NH3)2(OH2)(dGMP) was predicted to elute 
first due to a net electropositive charge across the molecule.  
 
As the equimolar incubation of cisplatin with dGMP was predicted to leave residual 
unreacted cisplatin in the reaction mixture, it was necessary to initially identify the 
chromatographic nature of cisplatin alone. A typical MonoQ elution profile for 1 mM 
cisplatin is shown in Figure 3.5. Analysis of Pt content in collected fractions (by AAS) 
showed that cisplatin typically eluted very rapidly from the column (less than 2 minutes 
retention). 
 
Equimolar cisplatin and dGMP were incubated for 24 hours, with aliquots removed at 
2hr, 4hr, 8hr and 24hr and analysed by MonoQ anion exchange chromatography 
(Figure 3.6). Incubation times of 2hr and 4hr were insufficient for the reaction, with 
detectable levels of unreacted dGMP observed in the UV traces (Figure 3.6, graphs A 
and B). When incubated for 8hr (Figure 3.6, graph C) and 24hr (Figure 3.6, graph D) 
there was no detectable unreacted dGMP. AAS analysis of collected fractions eluted 
from the MonoQ column indicated five Pt-containing species (Figure 3.7). The first 
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eluting species (approximately 1.5 minutes, label cis) had previously been determined 
to be unreacted cisplatin in the reaction mixture. The remaining four species were 
believed to represent the predicted three monofunctionally bound cis-
Pt(NH3)2(R)(dGMP) species and one bifunctionally bound cis-Pt(NH3)2(dGMP)2 
species, although at this stage the order of elution was unknown. 
 
The average retention time for peak 4 (later identified as the cis-Pt(NH3)2(GMP)2 
species) was 10 minutes, although the range of retention varied between 9-12 minutes 
in different experiments. As the analyses were performed on different days it is most 
likely that this difference arose from subtle variations in the salt concentration and 
overall pH of buffer B (12.5 mM tris, 1 M NaCl, pH 8.8). The elution of products is 
based on varying concentrations of ions, so it is most probable that when the product 
eluted at later times, it was a result of slightly lower salt concentrations. However, as 
the overall effect of this would be reflected in the elution of all products (larger 
variations seen as the salt concentrations increases) this was not deemed to be 
detrimental to the analyses. 
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Figure 3.5: Typical MonoQ elution profile for 1mM cisplatin. Solutions (100 µl) were 
injected onto the MonoQ column and eluted at 1 ml/min with increasing NaCl 
concentrations. Pt concentration in collected fractions was determined by AAS. (●) Pt 
concentration; dotted line: OD 254 nm. Pt recovery was always greater than 90% of 
the total Pt loaded. 
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Figure 3.6: Typical MonoQ elution profile for 1mM cisplatin incubated with 1 mM 
dGMP. Solutions (100 µl) of cisplatin and dGMP incubated for 2 hours (A), 4 hours 
(B), 8 hours (C) and 24 hours (D) were injected onto the MonoQ column and eluted at 
1 ml/min with increasing NaCl concentrations. (▲, dotted black line): NaCl 
concentration gradient; solid red line: OD 254 nm; solid blue line: OD 230 nm 
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Figure 3.7: Typical MonoQ elution profile for 1mM cisplatin incubated with 1 mM 
dGMP for 24hr. Solutions (100 µl) were injected onto the MonoQ column and eluted at 
1 ml/min with increasing NaCl concentrations. Pt concentration in collected fractions 
was determined by AAS. (●) Pt concentration; dotted line: OD 254 nm. Peak cis 
represents unreacted cisplatin as identified previously. Peaks 1-4 are unknown species. 
Total Pt recovery was always greater than 90% of total Pt loaded. 
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3.3.3.2: Determination of the chemical nature of the products formed between 
cisplatin and dGMP 
 
Four cisplatin-dGMP products were identified by MonoQ anion exchange 
chromatography coupled with Pt species detection by AAS (Figure 3.7). These were 
predicted to be three monofunctionally bound cis-Pt(NH3)2(R)(dGMP) and one 
bifunctionally bound cis-Pt(NH3)2(dGMP)2 species. A series of experiments were 
conducted to determine the identities of the four Pt-containing species, in which 
cisplatin and dGMP were incubated initially for 24 hours, followed by a further 24 
hours in the presence of 1 mM and 2.5 mM dGMP, NaCl and NaOH. The rationale for 
incubating further with dGMP was to favour the conversion of monofunctionally bound 
to the bifunctionally bound cis-Pt(NH3)2(dGMP)2 species. Further incubation with 
NaCl and NaOH was designed to favour the formation and/or conversion to the 
monofunctionally bound cis-Pt(NH3)2(Cl)(dGMP) and cis-Pt(NH3)2(OH)(dGMP) 
species respectively. The remaining Pt-containing species was predicted therefore to be 
the cis-Pt(NH3)2(OH2)(dGMP) species, expected to elute first of the four based on its 
net electropositive charge. 
 
Further incubation with 1 mM and 2.5 mM dGMP favoured the formation of peak 4 
(Figure 3.7), with increases in ratio of peak area of 1:1.6 and 1:2.3 for 1 mM (Figure 
3.8, graph A) and 2.5 mM (Figure 3.8, graph B) respectively, when compared to the 
initial identified peak (Figure 3.7). Incubation with 1 mM and 2.5 mM NaCl favoured 
the formation of peak 3 (Figure 3.7), with increases in ratio of peak area of 1:1.3 and 
1:1.8 for 1 mM (Figure 3.9, graph A) and 2.5 mM (Figure 3.9, graph B) respectively, 
when compared to the initial identified peak (Figure 3.7). Incubation with 1 mM and 
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2.5 mM NaOH favoured the formation of peak 2 (Figure 3.7), with increases in ratio of 
peak area of 1:1.1 and 1:2.1 for 1 mM (Figure 3.10, graph A) and 2.5 mM (Figure 3.10, 
graph B) respectively, when compared to the initial identified peak (Figure 3.7). The 
remaining unidentified peak (Figure 3.7, peak 1) therefore was assigned to be the cis-
Pt(NH3)2(OH2)(dGMP) species, eluting first of the four species as predicted. The order 
of elution for the four species was cis-Pt(NH3)2(OH2)(dGMP), cis-
Pt(NH3)2(OH)(dGMP), cis-Pt(NH3)2(Cl)(dGMP) and finally cis-Pt(NH3)2(dGMP) 2. 
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Figure 3.8: Typical MonoQ elution profile for cisplatin-dGMP incubated with dGMP. 
Solutions (100 µl) of cisplatin-GMP reacted with 1 mM dGMP (A) and 2.5 mM dGMP 
(B) were injected onto the MonoQ column and eluted at 1 ml/min with increasing NaCl 
concentrations. (▲, dotted black line): NaCl concentration gradient; solid red line: 
OD 254 nm; solid blue line: OD 230 nm. Proposed nature of the peaks is 1: cis-
Pt(NH3)2(OH2)(dGMP), 2: cis-Pt(NH3)2(OH)(dGMP), 3: cis-Pt(NH3)2(Cl)(dGMP), and 
4: cis-Pt(NH3)2(dGMP)2). 
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Figure 3.9: Typical MonoQ elution profile for cisplatin-dGMP incubated with NaCl. 
Solutions (100 µl) of cisplatin-dGMP reacted with 1 mM NaCl (A) and 2.5mM NaCl 
(B) were injected onto the MonoQ column and eluted with increasing NaCl 
concentrations. (▲, dotted black line): NaCl concentration gradient; solid red line: 
OD 254 nm; solid blue line: OD 230 nm. Proposed nature of the peaks is 1: cis-
Pt(NH3)2(OH2)(dGMP), 2: cis-Pt(NH3)2(OH)(dGMP), 3: cis-Pt(NH3)2(Cl)(dGMP), and 
4: cis-Pt(NH3)2(dGMP)2). 
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Figure 3.10: Typical MonoQ elution profile for cisplatin-dGMP incubated with NaOH. 
Solutions (100 µl) of cisplatin-dGMP reacted with 1 mM NaOH (A) and 2.5mM NaOH 
(B) were injected onto the MonoQ column and eluted with increasing NaCl 
concentrations. (▲, dotted black line): NaCl concentration gradient; solid red line: 
OD 254 nm; solid blue line: OD 230 nm. Proposed nature of the peaks is 1: cis-
Pt(NH3)2(OH2)(dGMP), 2: cis-Pt(NH3)2(OH)(dGMP), 3: cis-Pt(NH3)2(Cl)(dGMP), and 
4: cis-Pt(NH3)2(dGMP)2). 
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3.3.3.3: Timecourse of the formation of products between cisplatin and dGMP  
 
The reaction of cisplatin with dGMP was performed on three separate occasions. 
Aliquots were taken at 2, 4, 8 and 24hr (Figure 3.6) and analysed using the MonoQ 
system. Using Clarity 4.0 software (DataApex, UK), peak area for the detected peaks as 
a percentage of total peak area was determined. Analysis of the loss of free dGMP over 
time is shown in Figure 3.11. Analysis of the formation of the four products is shown in 
Figure 3.12. 
 
Using Prism 4 software (GraphPad), a one-phase exponential decay was fitted to the 
data for the loss of the free dGMP in the reaction with cisplatin (Figure 3.11). From this 
a half-life of 1.5hr was determined. After 8 and 24hr reactions, the total amount of free 
GMP accounted for less than 1% of the total products detected. 
 
Peaks 2 and 4, attributed to cis-Pt(NH3)2(OH)(dGMP) and cis-Pt(NH3)2(dGMP)2 
respectively, increased over the 24hr incubation period (Figure 3.12).  Peak 1, 
attributed to cis-Pt(NH3)2(OH2) reached its maximum amount after 8hr, then decreased 
at 24hr. Peak 3, attributed to cis-Pt(NH3)2(Cl)(dGMP), reached its maximum amount 
after 2hr, and then levels decreased up to 8hr and remained constant through 24hr.  
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Figure 3.11: Timecourse of the decrease in free dGMP in the reaction of equimolar (1 
mM) cisplatin and dGMP. Peak area was determined using Clarity 4.0 software and is 
expressed as a percentage of total area. A one-phase exponential decay line was fitted 
in Prism 4 software. Each point represents the mean of 3 different experiments and 
error bars reflect standard deviation. Where not shown, error bars lie within the points. 
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Figure 3.12: Timecourse of the formation of four products during the reaction of 
equimolar (1 mM) cisplatin and dGMP. Peak area was determined using Clarity 4.0 
software and is expressed as a percentage of total area. (): Peak 1, (): Peak 2, 
(): peak 3, and (): Peak 4.  One-phase exponential association line fitted in Prism 
4 software for peaks 2 and 4 (r
2
 of 0.98 and 0.97 respectively). Peak identities are 
proposed to be 1: cis-Pt(NH3)2(OH2)(dGMP), 2: cis-Pt(NH3)2(OH)(dGMP), 3: cis-
Pt(NH3)2(Cl)(dGMP) and 4: cis-Pt(NH3)2(dGMP)2.  
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3.3.3.4: MALDI-TOF mass spectrometric analysis of products formed in the 
reaction of cisplatin and dGMP 
 
Equimolar (1 mM) cisplatin and dGMP were incubated at 37°C for 24hr, and then 
stored at -20°C. Prior to storage, aliquots of the reaction mixture were removed and 
analysed by MALDI-TOF mass spectrometry. Mass spectrometry of reaction mixtures 
was either performed by Mr Robert Liddell or Dr Joe Gray in the Pinnacle Lab in the 
Institute for Cell and Molecular Biosciences at Newcastle University. 
 
Monofunctionally bound cisplatin-dGMP could be in the form of 3 individual products 
of the species cis-Pt(NH3)2(R)(dGMP) where R was either OH2, OH or Cl. Based on 
computer analysis of such species using ChemOffice software, products with masses of 
594.38, 593.37 and 611.81 were predicted to be detected by mass spectrometry, based 
on the 
195
Pt isotope. The cis-Pt(NH3)2(dGMP)2 species was predicted to have a mass of 
923.58. Typical MALDI-TOF mass spectrometric analyses are shown in Figure 3.13 
and Figure 3.14. 
 
Three major peaks with masses of 921.1, 922.1 and 923.1 were detected, and these 
were attributed to the cis-Pt(NH3)2(dGMP)2 species, with the three masses representing 
the 
194
Pt, 
195
Pt and 
196
Pt isotopes of cisplatin (Figure 3.13). Masses in the region of 904-
906 m/z were also detected, and these were attributed to the loss of one NH3 ligand to 
form the species [cis-Pt(NH3)(dGMP)2]
+
. Further species with masses in the region of 
887-889 were also detected, and these were attributed to the loss of the both NH3 
ligands, possibly during ionisation, forming [cis-Pt(dGMP)2]
2+
. 
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Three major peaks of 610.0 m/z, 611.0 m/z and 612.0 m/z were detected, and these 
were attributed to the 
194
Pt, 
195
Pt and 
196
Pt isotopes of cisplatin in the species cis-
Pt(NH3)2(Cl)(dGMP) (Figure 3.14). 
 
A series of peaks were detected in the region of 592-597 m/z, and in these peaks were 
the two remaining monofunctional species (cis-Pt(NH3)2(OH2)(dGMP) and cis-
Pt(NH3)2(OH)(dGMP)) (Figure 3.14). The group of products detected with masses in 
the region 574-576 m/z were predicted to be isotopic variants of the [cis-
Pt(NH3)2(dGMP)]
+
 species (Figure 3.14). 
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Figure 3.13: Typical MALDI-TOF mass spectrometry analysis of products formed in the reaction of equimolar (1mM) cisplatin and dGMP after 
a 24hr incubation. Products with masses in the range of 250-1500 m/z were scanned, and a typical 800-1000 m/z region is shown. MALDI-TOF 
mass spectrometry data were acquired by either Mr Robert Liddell or Dr Joe Gray (Newcastle University)  
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Figure 3.14: Typical MALDI-TOF mass spectrometry analysis of products formed in the reaction of equimolar (1mM) cisplatin and dGMP after 
a 24hr incubation. Products with masses in the range of 250-1500 m/z were scanned, and a typical 550-800 m/z region is shown. MALDI-TOF 
mass spectrometry data were acquired by either Mr Robert Liddell or Dr Joe Gray (Newcastle University) 
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Summary of the evidence presented to support the proposed peak identities 
Peak Identification Evidence 
Peak 1 
Retention Time ~ 2.5mins 
 
Mono-Aqua 
 
 Decreases after further incubation with dGMP 
 Decreases when NaCl added - Not mono-chloro 
 Decreases when NaOH added - Not mono-hydroxy 
 Net positive charge - should interact least with the MonoQ column 
 MALDI-TOF data showing product with correct mass 
Peak 2 
Retention Time ~ 4.5mins 
 
Mono-Hydroxy 
 
 Decreases after further incubation with dGMP 
 Decreases when NaCl added - Not mono-chloro 
 Increases when NaOH added - Favours mono-hydroxy 
 MALDI-TOF data showing product with correct mass 
Peak 3 
Retention Time ~ 5.5mins 
 
Mono-Chloro  
 Decreases after further incubation with dGMP 
 Increases when NaCl added - Favours mono-chloro 
 Decreases when NaOH added - Not mono-hydroxy 
 MALDI-TOF data showing product with correct mass 
 
Peak 4 
Retention Time ~ 9.5mins 
 
di-GMP 
 
 Increases after addition of dGMP 
 Peaks 1-3 all decrease after addition of dGMP, whereas peak 4 
increases 
 MALDI-TOF data showing product with correct mass 
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3.3.4: Identification of products formed in the reaction of platinated dGMP with 
GSH 
 
Having identified three monofunctional products with reactive potential, the next step 
was to incubate further with various concentrations of GSH. As carried out the 
reactions described earlier, equimolar (1 mM) cisplatin and dGMP were initially 
incubated for 24hr. At 24hr, varying concentrations of GSH were added and further 
incubated for 24hr. GSH was added after the initial incubation of cisplatin and dGMP 
because cisplatin rapidly reacts with glutathione and under such incubation conditions 
the amounts of product formed are markedly lower. As described earlier, the reaction 
conditions chosen meant that there was unreacted cisplatin remaining in the mixture. It 
was therefore also important to investigate the reaction of cisplatin and GSH alone. 
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3.3.4.1: Incubation of cisplatin with GSH 
 
Immediately before incubation with cisplatin, GSH was dissolved in water (4 mM) and 
pH adjusted to 7.0. It was important to dissolve GSH before each reaction to limit the 
amount of the oxidised GSSG product in the mixture. Cisplatin was incubated with 
GSH in a 1:2 molar ratio to ensure that no unreacted drug would be present in the 
mixture. Immediately after addition of cisplatin, reaction mixtures were gassed with 
nitrogen to limit the oxidation of GSH to GSSG. Reaction mixtures were analysed 
using the MonoQ system. Pt content in collected fractions was measured by AAS. A 
typical MonoQ elution for the reaction of cisplatin with GSH is shown in Figure 3.15. 
 
Cisplatin had been identified as having a very short elution time on the MonoQ column 
(Figure 3.5).However; it was unclear where cisplatin-GSH conjugates would elute. Two 
peaks were detected by UV with elution times of approximately 7 minutes and 27 
minutes (Figure 3.15). The latter peak was the only detected species associated with Pt, 
and this was therefore determined to be Pt-GSH conjugate (Figure 3.15). The Pt-GSH 
conjugate eluted during the phase of the chromatographic program in which the salt 
concentration was at 1 M. The earlier peak was unreacted GSH in the mixture. This had 
previously been determined by injecting GSH alone into the chromatographic system.   
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Figure 3.15: Typical MonoQ elution profile for 1 mM cisplatin incubated with 2 mM 
GSH for 24hr. Solutions (100 µl) were injected onto the MonoQ column and eluted at 
1ml/min with increasing NaCl concentrations. Pt concentration in collected fractions 
was determined by AAS. (●) Pt concentration; dotted red line: OD 254 nm; dotted blue 
line: OD 230 nm. Total Pt recovery was always greater than 90% of total Pt loaded. 
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3.3.4.2: Identification of products formed in the reaction of cisplatin-dGMP with 
GSH 
 
Equimolar (1 mM) cisplatin and dGMP were incubated at 37°C for 24hr. Aliquots were 
removed and analysed using the standard MonoQ system. The remaining mixture was 
split and further incubated with GSH (1 mM, 2.5 mM and 5 mM) for 24hr. These 
reaction mixtures were again analysed using the standard MonoQ system, with Pt 
content in collected fractions determined by AAS. Typical MonoQ elution profiles are 
shown in Figure 3.16. 
 
Analysis of the aliquots removed prior to addition of GSH showed similar elution 
profiles and UV absorbing peaks with similar chromatographic properties as those 
observed previously (Figure 3.16, graph A). Following further incubation with GSH, a 
number of additional UV absorbing peaks were detected (Figure 3.16, graph B-D). 
These products typically eluted at 14, 17 and 21 minutes. AAS analysis of fractions 
eluted from the MonoQ column confirmed that all three species contained Pt (Figure 
3.17). An additional product was also seen in the incubations with 2.5 mM and 5 mM 
GSH that eluted at approximately 25.5mins (Figure 3.16, graphs C and D), but no Pt 
was associated with this species. 
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Figure 3.16: Typical MonoQ elution profile for 1mM cisplatin incubated for 24hr with 
1 mM dGMP (A), then incubated for a further 24hr with 1 mM GSH (B), 2.5 mM GSH 
(C) and 5 mM GSH (D). Solutions (100 µl) were injected onto the MonoQ column and 
eluted at 1 ml/min with increasing NaCl concentrations. (▲, dotted black line): NaCl 
concentration gradient; solid red line: OD 254 nm; solid blue line: OD 230 nm. The 
identities of peaks A-C are unknown 
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Figure 3.17: Typical MonoQ elution profile for cisplatin-dGMP incubated with 2.5 mM 
GSH for 24hr. Solutions (100 µl) were injected onto the MonoQ column and eluted at 1 
ml/min with increasing NaCl concentrations. Pt concentration in collected fractions 
was determined by AAS. (●) Pt concentration; dotted line: OD 254 nm. The identities of 
peaks A-C are unknown. Total Pt recovery was always greater than 90% of total Pt 
loaded. 
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3.3.4.3: Analysis of the three peaks identified in the reaction of GSH with 
platinated dGMP 
 
Three new Pt-containing products were identified in the reaction of cisplatin-dGMP 
with GSH. It was unclear at this point which, if any, were the proposed cis-
Pt(NH3)2(dGMP)(GSH) cross-links. Total peak areas for each of the three peaks with 
varying concentrations of GSH were therefore calculated to provide further evidence. 
Total peak areas were calculated using Clarity software. To ensure only the peaks of 
interest were analysed, integrations were applied between two timepoints: 0-7 minutes 
and 10-25 minutes. By applying such limitations the peak areas of unreacted GSH and 
of Pt-GSH were excluded from the calculations, as the increase of these peaks could in 
theory affect changes in the amount of each product. Analysis of the three 
monofunctional and cis-Pt(NH3)2d(GMP2) products is shown in Figure 3.18. Analysis 
of the three products identified following further incubation with GSH is shown in 
Figure 3.19. 
 
As would be expected, the net pattern is a loss of detection of the three monofunctional 
products as the concentration of GSH in the reaction mixture increases, with the 
exception of cis-Pt(NH3)2(Cl)(dGMP) in the incubation with 1 mM GSH which 
appeared to increase (Figure 3.18). This rise however is most probably due to the loss 
of the other peaks and the overall effect of this on total peak area, as opposed to an 
increase in the amount of this product. When the specific peak areas were calculated in 
Clarity, total areas of 5168 mV/min (+/- 847 SD) and 4497 mV/min (+/- 983 SD) were 
calculated at 0 mM GSH and 1 mM GSH respectively for the cis-Pt(NH3)2(Cl)(dGMP) 
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product, showing the increase in peak area wasn‟t reflective of increases in product 
amount. Levels of the cis-Pt(NH3)2(dGMP)2 product remained constant. 
 
Three potential cis-Pt(NH3)2(dGMP)(GSH) candidates were identified by UV 
absorbance and AAS after the reaction of cisplatin-dGMP with GSH. Of the three 
peaks identified, only levels of peak C, which typically eluted at 21 minutes, increased 
as the concentration of GSH in the reaction mixture increased. Although it is not 
possible to exclude peaks A and B from being potential GSH containing cross-links, the 
most probable candidate of the three newly identified products is peak C. 
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Figure 3.18: Analysis of the changes in peak area for the four products identified in the 
reaction of equimolar (1 mM) cisplatin with dGMP (24hr) prior to further incubation 
with GSH. Peak areas were determined using Clarity 4.0 software and are expressed as 
a percentage of total area. (): cis-Pt(NH3)2(OH2)(dGMP), (): cis-
Pt(NH3)2(OH)(dGMP),(): cis-Pt(NH3)2(Cl)(dGMP), and (): cis-Pt(NH3)2d(GMP2). 
One-phase exponential decay line fitted to data for cis-Pt(NH3)2(OH2)(dGMP) and cis-
Pt(NH3)2(OH)(dGMP) peak in Prism 4 software. Each point represents the mean of 3 
different experiments and error bars reflect standard deviation. Where not shown, 
error bars lie within the points. 
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Figure 3.19: Analysis of the changes in peak area for the three products identified in 
the reaction of equimolar (1 mM) cisplatin with dGMP (24hr) followed by further 
incubation with GSH. Peak area was determined using Clarity 4.0 software and is 
expressed as a percentage of total area. (): Peak 1, (): Peak 2 (): Peak 3. Each 
point represents the mean of 3 different experiments and error bars reflect standard 
deviation. Where not shown, error bars lie within the points. 
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3.3.5: Structural analysis of products formed in the reaction of platinated dGMP 
with GSH 
 
Seven regions of dGMP were predicted to be detected by NMR. These include the 
C(8)-H proton of guanine, five C-H protons on the deoxyribose sugar ring, and the C-
H2 protons between the sugar ring and phosphate. The locations of these protons are 
shown in the appendix. NMR analyses of dGMP alone showed the presence of seven 
protons. Analyses of platinated dGMP showed seven detectable protons, comparable to 
those of dGMP alone. 
 
Six regions of GSH were predicted to be detected by NMR. These included a C-H and 
two C-H2 protons on the glutamate chain, C-H and C-H2 protons on the cysteine chain, 
and C-H2 protons on the glycine chain. The locations of these protons are shown in the 
appendix. NMR analyses of GSH alone showed the presence of six protons. NMR 
analysis of platinated GSH failed to give interpretable data.  
 
Analyses of the putative cis-Pt(NH3)2(dGMP)(GSH) products described in chapter 3 
failed to give interpretable data. Possible reasons for this are discussed in chapter 7. 
Typical NMR data are presented in the appendix of this thesis. 
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3.4: Discussion 
 
The main aim of the experiments described in this chapter was to produce and 
characterise cis-Pt(NH3)2(dGMP)(GSH) cross-links that would help in the analysis of 
putative cis-Pt(NH3)2(DNA)(GSH) cross-links formed in DNA from drug-treated cells. 
Azim-Araghi (2003) had provided evidence for the formation of such adducts, but very 
little information on their chromatographic behaviour was available. A secondary aim 
of this chapter was to attempt to confirm the structural nature of such products. 
 
Initial experiments were carried out to re-establish the MonoQ chromatographic system 
Azim-Araghi had used in the analyses of DNA from drug-treated cells. Having re-
established the MonoQ setup, analyses were carried out on calf thymus DNA incubated 
in the presence and absence of cisplatin. Calf thymus DNA incubated with 15 µM 
cisplatin showed the presence of four Pt-containing products. The similarity between 
the present data and that of Fichtinger-Schepman et al (1985) and Azim-Araghi (2003) 
regarding retention times and distribution of Pt across the four peaks suggests that the 
four products detected in this study are the same as the products characterised by 
DEAE-Sephacel and NMR previously (Fichtinger-Schepman et al 1985). 
 
Determining the chromatographic nature of putative cis-Pt(NH3)2(dGMP)(GSH) cross-
links was the main aim for this chapter. This was approached using a two-step 
methodology. In the initial step, cisplatin and dGMP were reacted at equimolar (1 mM) 
concentrations. The second step in the approach was then to add GSH and carry out 
additional incubations, with the products of these reactions analysed during each step 
using the MonoQ system re-established as described above. 
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In the reaction of equimolar cisplatin and dGMP, four products were detected by UV 
absorbance. Confirmation that these products contained Pt was achieved using AAS. 
Further experiments showed that three of the products involved dGMP bound to one 
arm of cisplatin forming the species cis-Pt(NH3)2(R)(dGMP) in which R could be either 
a Cl, OH or OH2 ligand. MALDI-TOF mass spectrometry of the reaction mixture 
confirmed products of the expected masses were produced. The fourth product 
identified was cis-Pt(NH3)2(dGMP)2. Again, MALDI-TOF mass spectrometry of the 
reaction mixture confirmed this product was of the expected mass. 
 
The second step in the approach was to incubate GSH with the products of the 
cisplatin-dGMP reaction. The production of monofunctionally bound dGMP products 
in the first step was key to this reaction, to allow further formation of the species cis-
Pt(NH3)2(dGMP)(GSH). The chromatographic nature of this species would be 
important in analysing the Pt-DNA adducts formed in drug-treated cells. After reacting 
GSH with platinated dGMP, three products were detected by UV, all containing Pt 
(determined by AAS). Of these, the extent of formation of a product with an elution 
times of 21 minutes, increased as the concentration of GSH in the reaction mixture was 
increased. However, the other two products couldn‟t be eliminated as cis-
Pt(NH3)2(dGMP)(GSH) cross-links. Attempts were made to purify these products for 
structural analysis but these were unsuccessful. 
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Chapter 4 
Analysis of Pt-DNA adducts formed in cells 
 
4.1: Introduction 
 
Whilst investigating Pt-DNA adducts formed in human lung cancer cell lines (H69/p 
and Mor/p) (Azim-Araghi 2003), a novel Pt-containing product was detected that had 
different chromatographic properties to the known Pt-DNA adducts previously 
characterised (Fichtinger-Schepman et al 1985). As described in chapter 3, this product 
was proposed to be the result of GSH becoming cross-linked to DNA via Pt. 
 
Prior to the work by Azim-Araghi, evidence had been published suggesting that GSH 
can cross-link to monofunctionally bound Pt-DNA (Eastman 1987). Binding of 
radioactively labelled GSH to DNA in the presence of cisplatin had also been observed 
(Tilby, unpublished data). The novel Pt-DNA product observed in DNA extracted from 
drug-treated cells by Azim-Araghi was detected using a combination of MonoQ anion 
exchange chromatography with ICP-MS. When this setup was applied by Azim-Araghi 
to studying pure calf thymus DNA incubated with GSH in the presence of cisplatin, the 
same novel product seen in cellular DNA hydrolysates was detected. It is therefore 
hypothesised that the novel product detected previously is cis-Pt(NH3)2(DNA)(GSH). 
The implications of such a product for the cellular pharmacology of Pt-drugs are 
unknown. These observations need to be confirmed and extended to other Pt-containing 
drugs and other cell lines. 
176 
 
Four human tumour cell lines were chosen for investigation. 833K, A2780 and LoVo 
cells were derived from testicular, ovarian and colorectal cancer respectively, and were 
chosen as these types of cancers are often treated with the platinum-based drugs used in 
this study. The cisplatin-resistant Mor/CPR cells were chosen for two reasons: firstly, 
the parental line Mor/P was used by Ali Azim-Araghi (Azim-Araghi 2003). 
Unfortunately the parental line wasn‟t available for this study. Secondly, in order to 
include a drug-resistant cell line in the investigation. 
 
Initially the sensitivity of the four chosen cell lines to the growth inhibitory effects of 
the drugs was defined in order to ensure that the drug concentration/DNA adducts 
levels being studied were biologically relevant. Also, as a body of data was to be 
accumulated this sensitivity data would permit comparisons between adducts levels and 
growth inhibitory effects. 
 
By analysing the products of reactions with cisplatin with dGMP and GSH (see chapter 
3), a putative cis-Pt(NH3)2(dGMP)(GSH) species has been synthesised and purified by 
anion exchange chromatography. The aim of the work described in this chapter was to 
investigate the potential formation of GSH-containing Pt-DNA adducts in the DNA of 
human tumour cells incubated with cisplatin. This was approached as follows: 
 
1. Analyse the chromatographic behaviour of all adducts formed in cells by 
cisplatin to compare with adducts formed on pure DNA and, hopefully, identify 
the additional products observed previously. 
2. Extension of these analyses to the other clinically used platinum-based drugs 
carboplatin and oxaliplatin  
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4.2: Results 
4.2.1: Sensitivity of human tumour cells to Pt-drugs 
4.2.1.1: Determination of optimal seeding density 
 
The optimal incubation period of cell cultures before and after drug treatments varies 
between individual cell lines. Therefore, initial experiments were carried out to 
determine the optimal growth conditions for each of the four cell lines. Appropriate 
inoculation densities could then be chosen that would ensure cells remained in active 
phase throughout the whole period of incubation with Pt-drugs. Cells were seeded at a 
number of increasing densities into 96 well plates, and incubated at 37°C for 24hr 
initially to allow cells to settle and attach. Cells were then fixed at 0hr, 24hr, 48hr and 
72hr. Cell density was determined using the SRB assay. 
 
Typical growth curves are shown in Figure 4.1. The four cell lines were subsequently 
innoculated at 8000 cells/well. 
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Figure 4.1: Typical analysis of growth of 833K (A), A2780 (B), LoVo (C) and MorCPR 
(D) cells. Cells from each cell line were seeded in 96 well plates at (): 1000 
cells/well, (): 2000 cells/well, (): 4000 cells/well, (): 6000 cells/well, (): 8000 
cells/well, (): 10000 cells/well, (): 20000 cells/well and (): 40000 cells/well. Cell 
density was measured by the SRB assay at 24, 48 and 72 hours. Absorbance was 
measured at 490nm. Error bars represent the mean +/- standard deviation. Where not 
shown, error bars lie within the data point. 
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4.2.1.2: Determination of sensitivity to Pt drugs 
 
Cells were inoculated at the chosen density (8000 cells/well) and after 24hr; cisplatin, 
carboplatin or oxaliplatin was added at a range of concentrations. Medium in the wells 
was replaced with drug-free medium after 2, 6 or 24hr and cells were fixed at 72hr after 
addition of drugs. 
 
Initial experiments to establish appropriate ranges of drug concentrations were 
performed in triplicate. From these experiments, the final ranges of drug concentrations 
for each of the three drugs for the four cell lines were chosen. Results for triplicate 
experiments in the chosen drug concentrations are shown in Figure 4.2 - Figure 4.4. 
Calculated GI50 values are presented in Table 4.1. 
 
Comparison of GI50 values in each cell line with time 
GI50 values following exposure times of 2hr and 6hr were compared to GI50 values after 
24hr exposure. Data is shown in Table 4. 2. 24hr incubation gave the lowest GI50 values 
as expected, whereas for cisplatin shorter incubations gave GI50 values up to 9-fold 
higher. For carboplatin and oxaliplatin, the length of incubation time generally had a 
larger effect on survival with GI50 values up to 23-fold higher  
 
Analysis of sensitivity to carboplatin and oxaliplatin compared to cisplatin 
GI50 values for carboplatin and oxaliplatin were compared to cisplatin. Data is shown in 
Table 4. 3. Carboplatin was 7-52-times less toxic than cisplatin, depending on cell line 
and exposure time. Oxaliplatin showed comparable GI50 values to cisplatin, except in 
Mor/CPR cells where it was about 10-fold less toxic.  
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Analysis of variation in cell line sensitivity 
GI50 values for A2780, LoVo and Mor/CPR cells were compared to 833K cells. Data is 
presented in Table 4. 4. A2780 cells were 1.4-2.2 times less sensitive to cisplatin and 
1.9-2.6 times less sensitive to carboplatin. A2780 cells were however more sensitive to 
oxaliplatin than cisplatin. LoVo cells were 1.8-2.3, 2.7-5.5 and 1.3-1.5 times less 
sensitive to cisplatin, carboplatin and oxaliplatin respectively. Mor/CPR cells were 
markedly the least sensitive of all the cell lines. 
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Figure 4.2: The effect of cisplatin on growth inhibition in human tumour 833K (A), 
A2780 (B), LoVo (C) and Mor/CPR (D) cells. Cell were incubated with various 
concentrations of drug for 2hr (), 6hr () and 24 hr (). Growth inhibition was 
measured using the SRB assay. Each data point represents the mean of three individual 
experiments +/- standard deviation. Where not shown, error bars lie within the data 
point. 
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Figure 4.3: The effect of carboplatin on growth inhibition in human tumour 833K (A), 
A2780 (B), LoVo (C) and Mor/CPR (D) cells. Cell were incubated with various 
concentrations of drug for 2hr (), 6hr () and 24 hr (). Growth inhibition was 
measured using the SRB assay. Each data point represents the mean of three individual 
experiments +/- standard deviation. Where not shown, error bars lie within the data 
point. 
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Figure 4.4: The effect of oxaliplatin on growth inhibition in human tumour 833K (A), 
A2780 (B), LoVo (C) and Mor/CPR (D) cells. Cell were incubated with various 
concentrations of drug for 2hr (), 6hr () and 24 hr (). Growth inhibition was 
measured using the SRB assay. Each data point represents the mean of three individual 
experiments +/- standard deviation. Where not shown, error bars lie within the data 
point. 
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Table 4.1: GI50 values for 833K, A2780, LoVo and Mor/CPR human tumour cells exposed to cisplatin, carboplatin and oxaliplatin for 2hr, 6hr 
and 24hr at 37°C. Growth Inhibition was measured at 72hr by the SRB assay. Each value represents the mean readings from 3 individual 
experiments. Standard deviation is shown in brackets. 
Cell Line Incubation Time GI50: Cisplatin (µM) GI50: Carboplatin (µM) GI50: Oxaliplatin (µM) 
833K 2hr 4.1 (0.1) 77.6 (1.2) 13.4 (0.2) 
6hr 1.6 (0.02) 24.9 (0.4) 3.3 (0.1) 
24hr 0.6 (0.01) 4.3 (0.1) 0.6 (0.01) 
A2780 2hr 6.8 (0.1) 159.5 (2.6) 8.6 (0.2) 
6hr 2.2 (0.04) 47.0 (1.0) 2.5 (0.1) 
24hr 1.3 (0.02) 11.2 (0.3) 0.4 (0.01) 
LoVo 2hr 9.3 (0.3) 207.2 (5.7) 18.0 (0.3) 
6hr 3.2 (0.1) 77.6 (1.7) 5.0 (0.1) 
24hr 1.1 (0.04) 23.5 (0.6) 0.8 (0.02) 
Mor/CPR 2hr 68.0 (1.9) 2049 (33) 986.2 (52.5) 
6hr 28.2 (1.1) 1479 (18.2) 251.5 (11.4) 
24hr 7.7 (0.2) 116.8 (1.6) 77.8 (3.7) 
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Table 4. 2: GI50 ratios for 833K, A2780, LoVo and Mor/CPR cells incubated with 
cisplatin, carboplatin or oxaliplatin. Each ratio is calculated compared to the 24hr 
incubation value (2hr/24hr or 6hr/24hr). 
Cell Line Inc. Time Cisplatin Carboplatin Oxaliplatin 
833K 2hr 6.8 18.0 22.3 
 6hr 2.7 5.8 5.5 
 24hr 1 1 1 
A2780 2hr 5.2 14.2 21.5 
 6hr 1.7 4.2 6.3 
 24hr 1 1 1 
LoVo 2hr 8.5 8.8 22.5 
 6hr 2.9 3.3 6.3 
 24hr 1 1 1 
Mor/CPR 2hr 8.8 17.5 12.7 
 6hr 3.7 12.7 3.2 
 24hr 1 1 1 
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Table 4. 3: GI50 ratios for 833K, A2780, LoVo and Mor/CPR cells incubated with 
carboplatin or oxaliplatin compared to cisplatin. Each ratio is calculated compared to 
cisplatin. 
Cell Line Inc. Time Cisplatin Carboplatin Oxaliplatin 
833K 2hr 1 18.9 3.3 
 6hr 1 15.6 2.1 
 24hr 1 7.2 1 
A2780 2hr 1 23.5 1.3 
 6hr 1 21.4 1.1 
 24hr 1 8.6 0.3 
LoVo 2hr 1 22.3 1.9 
 6hr 1 24.3 1.6 
 24hr 1 21.4 0.7 
Mor/CPR 2hr 1 30.1 14.5 
 6hr 1 52.4 8.9 
 24hr 1 15.2 10.1 
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Table 4. 4: Ratio of GI50 values for A2780, LoVo and Mor/CPR cells to 833K GI50 
values. All 833K values are considered to be 1 (not shown in table). 
Cell Line Inc. Time Cisplatin Carboplatin Oxaliplatin 
A2780 2hr 1.7 2.1 0.6 
 6hr 1.4 1.9 0.8 
 24hr 2.2 2.6 0.7 
LoVo 2hr 2.3 2.7 1.3 
 6hr 2.0 3.1 1.5 
 24hr 1.8 5.5 1.3 
Mor/CPR 2hr 16.6 26.4 73.6 
 6hr 17.6 59.4 76.2 
 24hr 12.8 27.2 129.7 
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4.2.1.3: Total Pt-DNA adducts formed in cells 
 
833K, A2780, LoVo and Mor/CPR cells were incubated in medium containing 
cisplatin, carboplatin or oxaliplatin at a range of concentrations for 2hr and 24hr. The 
concentration ranges were chosen from previous preliminary experiments. Cells were 
harvested immediately after drug exposure and cell pellets were stored at -20°C prior to 
DNA extraction. Pt levels in DNA hydrolysates were determined by ICP-MS. 
 
Mean levels of Pt-DNA adducts determined from triplicate experiments are shown in 
Figure 4.5 - Figure 4.7. Values for total Pt-DNA adducts (+/- SD) for all four cell lines 
and all three drugs are given in Table 4.5 - Table 4.7. 
 
There were clear linear relationships between drug concentration and Pt-DNA adducts 
levels at both incubation times. For both incubation schedules the total amount of Pt-
DNA adducts was highest in the A2780 cells, followed by LoVo and 833K cells, except 
after 2hr incubation with carboplatin, where the total Pt-DNA adducts level was highest 
in the 833K cells. For both incubation schedules, the total Pt-DNA adducts levels were 
lowest in the Mor/CPR cells.  
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Figure 4.5: Total Pt-DNA adducts levels formed in human tumour 833K (), A2780 
(), LoVo () and Mor/CPR () cells following incubation with various 
concentrations of cisplatin for 2hr (A) and 24hr (B). Pt levels were measured by ICP-
MS. Linear regression lines fitted by Prism 4 software. Each data point represents the 
mean of three individual experiments +/- standard deviation. Where not shown, error 
bars lie within the data point. 
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Figure 4.6: Total Pt-DNA adducts levels formed in human tumour 833K (), A2780 
(), LoVo () and Mor/CPR () cells following incubation with various 
concentrations of carboplatin for 2hr (A) and 24hr (B). Pt levels were measured by 
ICP-MS. Linear regression lines fitted by Prism 4 software. Each data point represents 
the mean of three individual experiments +/- standard deviation. Where not shown, 
error bars lie within the data point. 
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Figure 4.7: Total Pt-DNA adducts levels formed in human tumour 833K (), A2780 
(), LoVo () and Mor/CPR () cells following incubation with various 
concentrations of oxaliplatin for 2hr (A) and 24hr (B). Pt levels were measured by ICP-
MS. Linear regression lines fitted by Prism 4 software. Each data point represents the 
mean of three individual experiments +/- standard deviation. Where not shown, error 
bars lie within the data point. 
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Table 4.5: Pt-DNA adduct levels in human tumour 833K, A2780, LoVo and Mor/CPR cells following incubation with various concentrations of 
cisplatin for 2hr and 24hr. Standard deviation is shown in brackets. 
  Total Pt-DNA Adduct Level (nmol Pt g
-1
 DNA) 
Cisplatin (µM) 0 10 30 60 0 1 3 6 
833K 2hr 6.5 (0.7) 22.7 (1.45) 40.5 (3.6) 68.8 (4.2)     
24hr     8.2 (1.6) 10.3 (0.7) 23.8 (0.5) 42.9 (0.7) 
A2780 2hr 5.6 (1.2) 36.2 (1.4) 90.3 (2.7) 159.8 (9.3)     
24hr     4.7 (0.1) 21.9 (2.2) 66.6 (2.0) 148.2 (3.3) 
LoVo 2hr 6.4 (1.3) 22.5 (1.7) 63.9 (0.5) 134.5 (3.1)     
24hr     4.6 (2.0) 11.6 (0.7) 31.7 (1.6) 60.1 (1.0) 
Mor/CPR 2hr 4.0 (0.8) 8.6 (0.1) 17.0 (1.4) 45.1 (1.5)     
24hr     4.3 (0.8) 9.0 (0.4) 16.8 (1.5) 28.1 (2.4) 
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Table 4.6: Pt-DNA adduct levels in human tumour 833K, A2780, LoVo and Mor/CPR cells following incubation with various concentrations of 
carboplatin for 2hr and 24hr. Standard deviation is shown in brackets. 
  Total Pt-DNA Adduct Level (nmol Pt g
-1
 DNA) 
Carboplatin (µM) 0 250 750 1500 0 25 75 150 
833K 2hr 7.6 (0.2) 17.6 (1.6) 35.0 (3.8) 66.4 (0.7)     
24hr     8.2 (1.0) 21.9 (2.2) 47.6 (4.2) 77.4 (5.3 
A2780 2hr 7.8 (0.7) 12.5 (1.8) 26.6 (1.7) 36.1 (3.2)     
24hr     8.0 (1.1) 31. 0 (2.1) 91.3 (1.2) 194.1 (5.7) 
LoVo 2hr 6.8 (1.7) 11.1 (1.9) 17.1 (1.9) 28.5 (1.5)     
24hr     6.3 (1.2) 20.5 (1.2) 52.5 (1.2) 104.0 (9.0) 
Mor/CPR 2hr 2.0 (0.3) 6.9 (0.2) 11.9 (0.3) 16.9 (1.4)     
24hr     4.6 (0.7) 8.8 (0.4) 19.2 (1.2) 34.1 (0.6) 
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Table 4.7: Pt-DNA adduct levels in human tumour 833K, A2780, LoVo and Mor/CPR cells following incubation with various concentrations of 
oxaliplatin for 2hr and 24hr. Standard deviation is shown in brackets. 
  Total Pt-DNA Adduct Level (nmol Pt g
-1
 DNA) 
Oxaliplatin (µM) 0 10 30 60 0 1 3 6 
833K 2hr 3.1 (1.1) 11.5 (1.8) 20.7 (3.3) 35.2 (2.9)     
24hr     0.8 (0.2) 7.5 (3.0) 14.7 (0.9) 26.7 (2.7) 
A2780 2hr 1.4 (0.5) 9.1 (1.8) 30.2 (2.6) 57.1 (1.4)     
24hr     1.7 (0.7) 8.8 (2.2) 28.9 (3.9) 50.5 (1.0) 
LoVo 2hr 1.6 (0.8) 12.5 (1.3) 26.4 (1.2) 48.5 (2.8)     
24hr     1.5 (0.3) 7.0 (5.8) 17.4 (2.0) 37.3 (1.0) 
Mor/CPR 2hr 1.9 (0.4) 7.0 (0.4) 10.2 (0.7) 14.1 (0.7)     
24hr     0.4 (0.1) 5.8 (0.5) 11.8 (0.7) 25.7 (1.9) 
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4.2.2: Chromatographic Analysis of Pt-DNA adducts formed in cells 
 
As discussed in detail previously (see chapters 1 and 3) the combination of ICP-MS 
with chromatographic separation of Pt-DNA adducts permits the detection of all the 
types of adducts even at low levels. This permits the direct analysis of adducts formed 
in cells without relying on their ability to be detected by a suitable antibody or a 
specialised post-labelling assay. It was of particular interest to survey adducts formed in 
a number of cell lines because of previous results which indicated the formation, in 
cells, of a new type of adduct, hypothesised to involve GSH. 
 
Cells were incubated for 24hr with either 6 µM cisplatin or oxaliplatin, or 150 µM 
carboplatin. 24hr incubation was initially chosen for all four cell lines as previous work 
had shown monofunctional platinum products to form quickly, but closure to 
bifunctional products and/or binding of GSH to take many hours (Eastman 1987). DNA 
was extracted from cells and enzymatically digested as described in section 2.6. 
Previous work by Azim-Araghi (Azim-Araghi 2003) had confirmed that the levels of 
enzymes used in the initial digest were more than sufficient to achieve total digestion of 
the DNA. DNA ultrafiltrates were collected by centrifugation at 13000 x g, 4°C for 60 
minutes using a Microcon YM-10 ultrafiltration unit (Millipore, UK) to remove 
proteins that would increase contamination of the MonoQ column. Solutions (100 µl) 
of the digested mixture were injected into the MonoQ system and eluted at 1 ml/min in 
increasing NaCl concentrations. UV absorbance was monitored at 254 nm and fractions 
collected as described in section 2.9. Pt levels were then measured by ICP-MS.  
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4.2.2.1: DNA adducts formed in cells exposed to cisplatin for 24hr 
 
Measurements before and after ultrafiltration of enzymatic hydrolysates of DNA 
confirmed that less than 5% of the total Pt was retained by the ultrafilter. Typical 
MonoQ elution profiles for hydrolysates of DNA from 833K, A2780, LoVo and 
Mor/CPR cells incubated for 24hr with 6 µM cisplatin are shown in Figure 4.8 (graphs 
A-D respectively). Mean retention times of the four mononucleotides (detected by UV) 
and four Pt-containing species are shown in Table 4.8. This also shows that the 
recovery of Pt from the column exceeded 92%. 
 
Analyses of Pt content in collected chromatographic fractions showed the presence of 
four Pt-containing products. These products had similar retention times and relative Pt 
levels of adducts formed by the reaction of cisplatin with pure DNA analysed using a 
similar method (Meczes et al 2005). Therefore, these products are suggested to be of 
the same nature as the major Pt-DNA products characterised previously (Fichtinger-
Schepman et al 1985). The chemical nature of the four peaks in order of elution 
therefore was designated as: 1: Pt(NH3)2(R)(dGMP), 2: cis-Pt(NH3)2d(ApG), 3: cis-
Pt(NH3)2d(GpG) and 4: cis-Pt(NH3)2(dGMP)2. Four products that were detected by UV 
eluted at similar times to the previously characterised mononucleotides described in 
chapter 3, and therefore were assigned in order of elution as dCMP, dAMP, TMP and 
dGMP. 
 
The mean yields of each adduct type as a percent of total Pt recovered was calculated 
from three analyses of separate DNA preparations. The results (Table 4.11) show that 
peak 3, attributed to cis-Pt(NH3)2d(GpG) was the major Pt-containing product detected, 
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contributing approximately 60% of the total Pt detected. Peak 2, attribute to cis-
Pt(NH3)2d(ApG) was the second major Pt-containing product detected, contributing 
approximately 20% of the total Pt detected. An approximate ratio of 1: 2.5 was 
observed for the ApG: GpG adducts which is similar to previous analyses (Azim-
Araghi 2003). Levels of peak 1 (attributed to Pt(NH3)2(R)(dGMP)) ranged from 2.6-
7.3%, and levels of peak 4 (attributed to cis-Pt(NH3)2(dGMP)2) ranged from 7.1-13.3%. 
 
However, no additional Pt-containing products were detected in any of the four cell 
lines investigated and no evidence for the putative cis-Pt(NH3)2(DNA)(GSH) cross-link 
was observed. 
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Figure 4.8: Typical MonoQ elution pattern for 833K (A), A2780 (B), LoVo (C) and 
Mor/CPR (D) cells incubated with 6 µM cisplatin for 24hr. Solutions (100 µl) of DNA 
were injected into the MonoQ column and eluted at 1 ml/min. Fractions were collected 
with increasing NaCl concentration and Pt levels in each fraction measured by ICP-
MS. (), Pt concentration; dotted line: OD 254 nm. Peaks 1: Pt(NH3)2(R)(dGMP); 2: 
cis-Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4:cis-Pt(NH3)2(dGMP)2 
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Table 4.8: Mean retention times for the products detected by UV absorbance and ICP-MS in DNA extracted from cisplatin-treated cells. Mean 
values from three individual analyses are shown. Ranges in retention time are shown in brackets except for total Pt recovered in which SD is 
shown. 
Peak Identity 833K A2780 LoVo Mor/CPR 
 dCMP 5.3 (0.1) 5.4 (0.1) 5.6 (0.2) 5.4 (0.1) 
 dAMP 5.8 (0.1) 6.1 (0.2) 6.2 (0.2) 5.9 (0.2) 
 TMP 6.7 (0.2) 7.1 (0.2) 7.3 (0.1) 6.9 (0.1) 
 dGMP 12.5 (0.2) 13.0 (0.3) 13.2 (0.2) 12.4 (0.1) 
1 Pt(NH3)2(R)(dGMP) 2.5 (0.5) 3.0 (0.5) 2.5 (0.5) 2.0 (0.5) 
2 cis-Pt(NH3)2d(ApG) 4.5 (0.5) 5.5 (1.0) 4.5 (0.5) 4.5 (0.5) 
3 cis-Pt(NH3)2d(GpG) 8.5 (1.0) 9.0 (1.0) 9.0 (1.0) 9.5 (1.0) 
4 cis-Pt(NH3)2(dGMP)2 10.5 (1.0) 11.5 (1.0) 11.0 (0.5) 10.5 (0.5) 
Total Pt Recovery (%) 103.5 (6.7) 92.3 (4.4) 91.7 (5.6) 98.3 (3.3) 
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4.2.2.2: DNA adducts formed in cells exposed to carboplatin for 24hr 
 
Typical MonoQ elution profiles for hydrolysates of DNA from 833K, A2780 and LoVo 
cells incubated for 24hr with 150 µM carboplatin are shown in Figure 4.9 (graphs A-C 
respectively). Mean retention times of the four mononucleotides (detected by UV) and 
four Pt-containing species are shown in Table 4.9. This also confirms that recovery of 
Pt from the column exceeded 92%. 
 
Analyses of Pt content in collected chromatographic fractions showed the presence of 
four Pt-containing products. These products had similar retention times and relative Pt 
levels of adducts to those seen in the incubation with cisplatin and therefore are 
suggested to be of the same nature. 
 
The mean yields of each adduct type as a percent of total Pt recovered was calculated 
from three analyses of separate DNA preparations. The results (Table 4.11) show that 
the relative proportions of the peaks were very similar to those values for cisplatin and, 
like cisplatin, did not vary markedly between cell lines. 
 
Similarly to cisplatin, no additional Pt-containing products were detected in any of the 
three cell lines. No evidence has previously been presented for potential carboplatin-
DNA cross-links with GSH although, as adducts formed are believed to be the same as 
those for cisplatin, their formation was plausible. However, the data in this section 
provides no evidence to support their formation. 
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Figure 4.9: Typical MonoQ elution pattern for 833K (A), A2780 (B) and LoVo (C) cells 
incubated with 150 µM carboplatin for 24hr. Solutions (100 µl) of DNA were injected 
into the MonoQ column and eluted at 1 ml/min. Fractions were collected with 
increasing NaCl concentration and Pt levels in each fraction measured by ICP-MS. 
(), Pt concentration; dotted line: OD 254 nm. Peaks 1: Pt(NH3)2(R)(dGMP); 2: cis-
Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4:cis- Pt(NH3)2(dGMP)2 
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Table 4.9: Mean retention times for the products detected by UV absorbance and ICP-MS in DNA extracted from carboplatin-treated cells. 
Mean values from three individual analyses are shown. Ranges in retention time are shown in brackets except for total Pt recovered in which SD 
is shown. 
Peak Identity 833K A2780 LoVo 
 dCMP 5.4 (0.1) 5.5 (01.) 5.6 (0.1) 
 dAMP 6.0 (0.1) 6.0 (0.1) 6.1 (0.1) 
 TMP 7.0 (0.2) 7.1 (0.1) 7.0 (0.1) 
 dGMP 13.1 (0.1) 13.1 (0.2) 13.1 (0.2) 
1 Pt(NH3)2(R)(dGMP) 2.0 (0.5) 3.0 (1.0) 2.5 (0.5) 
2 cis-Pt(NH3)2d(ApG) 5.5 (1.0) 5.5 (0.5) 5.0 (0.5) 
3 cis-Pt(NH3)2d(GpG) 9.5 (1.0) 9.5 (1.0) 9.5 (1.0) 
4 cis-Pt(NH3)2(dGMP)2 12.0 (1.0) 12.0 (1.0) 11.5 (1.0) 
Total Pt Recovery (%) 92.3 (6.7) 104.5 (7.8) 101.3 (8.6) 
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4.2.2.3: DNA adducts formed in cells exposed to oxaliplatin for 24hr 
 
Typical MonoQ elution profiles for hydrolysates of DNA from 833K, A2780 and LoVo 
cells incubated for 24hr with 6 µM oxaliplatin are shown in Figure 4.10 (graphs A-C 
respectively). Mean retention times of the four mononucleotides (detected by UV) and 
four Pt-containing species are shown in Table 4.10. Recovery of Pt from the column 
exceeded 95%. 
 
Oxaliplatin is believed to form similar Pt-DNA cross-links as cisplatin (Jennerwein et 
al 1989, Saris et al 1996) with the major difference being the DACH ligand in place of 
the two NH3 ligands of cisplatin. Analyses of Pt content in collected chromatographic 
fractions showed the presence of four Pt-containing products. These products had 
similar retention times and relative Pt levels of adducts to those seen in the incubation 
with cisplatin and therefore are suggested to be of a similar nature. 
 
The mean yields of each adduct type as a percent of total Pt recovered was calculated 
from three analyses of separate DNA preparations. The results (Table 4.11) show that 
the relative proportions of the peaks were very similar to those values for cisplatin and, 
like cisplatin, did not vary markedly between cell lines. 
 
Similarly to cisplatin, no additional Pt-containing products were detected in any of the 
three cell lines. No evidence has previously been presented for potential oxaliplatin-
DNA cross-links with GSH although, as adducts formed are believed to be similar to 
those for cisplatin, their formation was plausible. However, the data in this section 
provides no evidence to support their formation. 
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Figure 4.10: Typical MonoQ elution pattern for 833K (A), A2780 (B) and LoVo (C) 
cells incubated with 6 µM oxaliplatin for 24hr. Solutions (100 µl) of DNA were injected 
into the MonoQ column and eluted at 1 ml/min. Fractions were collected with 
increasing NaCl concentration and Pt levels in each fraction measured by ICP-MS. 
(), Pt concentration; dotted line: OD 254 nm. Peaks are proposed to be 1: 
Pt(DACH)(R)(dGMP); 2: cis-Pt(DACH)d(ApG); 3: cis-Pt(DACH)d(GpG) and 4:cis-
Pt(DACH)(dGMP)2 
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Table 4.10: Mean retention times for the products detected by UV absorbance and ICP-MS in DNA extracted from oxaliplatin-treated cells. 
Mean values from three individual analyses are shown. Ranges in retention time are shown in brackets except for total Pt recovered in which SD 
is shown. 
Peak Identity 833K A2780 LoVo 
 dCMP 5.6 (0.1) 5.6 (0.1) 5.4 (0.1) 
 dAMP 6.1 (0.1) 6.1 (0.1) 6.0 (0.1) 
 TMP 7.4 (0.2) 7.1 (0.2) 7.2 (0.2) 
 dGMP 13.0 (0.1) 12.9 (0.2) 13.0 (0.2) 
1 Pt(DACH)(R))dGMP) 2.5 (0.5) 2.5 (0.5) 2.0 (1.0) 
2 cis-Pt(DACH)d(ApG) 5.5 (0.5) 5.0 (0.5) 4.5 (0.5) 
3 cis-Pt(DACH)d(GpG) 9.5 (1.0) 9.5 (0.5) 9.5 (1.0) 
4 cis-Pt(DACH)(dGMP)2 11.0 (0.5) 11.0 (1.0) 12.5 (1.5) 
Total Pt Recovery (%) 95.3 (3.3) 103.2 (4.7) 101.2 (5.5) 
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Table 4.11: Pt content of each of the four main peaks of Pt-containing material recovered from anion exchange chromatographic analysis of 
enzymatic hydrolysates of DNA extracted from drug-treated cells. Pt content is expressed as a percentage of Pt contained in the four identified 
peaks in relation to the total Pt recovered. Each value represents the mean of three individual analyses. Standard deviation is shown in brackets. 
Drug (conc. used) Peak Identity 833K A2780 LoVo MorCPR 
Cisplatin 1 7.1 (0.5) 2.6 (0.2) 5.2 (0.2) 7.3 (0.1) 
(60 µM) 2 21.2 (1.5) 26.5 (1.9) 26.1 (1.2) 23.6 (0.4) 
 3 58.3 (0.8) 63.8 (4.6) 56.3 (2.5) 61.0 (1.0) 
 4 13.3 (0.7) 7.1 (0.5) 12.4 (0.5) 8.1 (0.1) 
Carboplatin 1 4.7 (0.4) 3.7 (0.1) 1.9 (0.2)  
(150 µM) 2 24.7 (1.9) 29.6 (0.7) 31.7 (2.4)  
 3 61.5 (4.8) 60.3 (1.3) 60.1 (4.5)  
 4 9.2 (0.7) 6.3 (0.1) 6.3 (0.5)  
Oxaliplatin 1 5.0 (0.2) 4.6 (0.2) 3.7 (0.1)  
60 (µM) 2 24.9 (1.2) 29.3 (1.2) 25.8 (1.0)  
 3 59.5 (2.8) 59.7 (2.4) 61.7 (2.4)  
 4 10.7 (0.5) 6.4 (0.3) 8.8 (0.3)  
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4.2.2.4:  DNA adducts formed in LoVo cells exposed to drugs for 2hr 
 
Since the previous described experiments failed to provide evidence for the formation 
of additional DNA adducts in cells, the possibility was considered that the hypothesised 
adducts were short-lived because either 1, the putative cis-Pt(NH3)2(DNA)(GSH) cross-
links were unstable and/or 2, the putative cross-links were more readily repaired by 
cells than the established classes of adducts. To investigate such possibilities, LoVo 
cells were incubated for 2hr with either 60 µM cisplatin or oxaliplatin or 1500 µM 
carboplatin. Typical MonoQ elution results for DNA hydrolysates analysed using the 
standard MonoQ system are shown in Figure 4.11. 
 
Table 4.12 shows results for three separate experiments for each drug where the 
quantity of Pt in each peak is expressed as a percentage of the total recovered platinum. 
For the LoVo cells incubated with cisplatin and carboplatin, similar proportions of the 
peaks 2 and 3 (proposed to be cis-Pt(NH3)2d(ApG) and cis-Pt(NH3)2d(GpG) 
respectively) were detected between the two incubation times. As would be expected 
with these incubation periods, proportions of the peak 1 (proposed to be 
Pt(NH3)2(R)(dGMP)) decreased between 2hr and 24hr incubations, and proportions of 
peak 4 (proposed to be cis-Pt(NH3)2(dGMP)2) increased. These changes in yield were 
of comparable proportions (- 3.7 and + 5.1 for cisplatin and - 4.2 and + 3.3 for 
carboplatin).  
 
Similarly to cisplatin and carboplatin, for oxaliplatin the proportion of Pt in peak 1 
(proposed to be Pt(DACH)(R)(dGMP)) decreased between 2hr and 24hr. However, 
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unlike cisplatin and carboplatin, this was accompanied with a more marked increase in 
peak 3 (proposed to be cis-Pt(DACH)d(GpG). 
 
Overall, no additional Pt-containing products were detected following the 2hr 
incubations with cisplatin, carboplatin or oxaliplatin. This indicates a lack of any 
evidence for formation of the proposed cis-Pt(NH3)2(DNA)(GSH) cross-links, as was 
the case for the samples from cells exposed to drugs for 24hr. 
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Figure 4.11: Typical MonoQ elution pattern for LoVo cells incubated with 60 µM 
cisplatin (A), 1500 µM carboplatin (B) and 60 µM oxaliplatin (C) for 2hr. 100 µg/ml 
DNA was applied to the column. Fractions were collected with increasing NaCl 
concentration and Pt levels in each fraction measured by ICP-MS. (), Pt 
concentration; dotted line: OD 254 nm. Peaks for cisplatin and carboplatin are  1: 
Pt(NH3)2(R)(dGMP); 2: cis-Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4: cis-
Pt(NH3)2(dGMP)2. Peaks for oxaliplatin are proposed to be 1: Pt(DACH)(R)(dGMP); 
2: cis- Pt(DACH)d(ApG); 3: cis-Pt(DACH)d(GpG) and 4: cis-Pt(DACH)(dGMP)2. 
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Table 4.12: Pt content of each of the four main peaks of Pt-containing material recovered from anion exchange chromatographic analysis of 
enzymatic hydrolysates of DNA extracted from drug-treated LoVo cells. Pt content is expressed as a percentage of Pt contained in the four 
identified peaks in relation to the total Pt recovered. Each value represents the mean of three individual analyses. Standard deviation is shown 
in brackets. 
 Peak Identity % Pt (2hr) % Pt (24hr) Difference (2hr-24hr) 
Cisplatin 1 8.9 (0.2) 5.2 (0.2) - 3.7 
 2 25.9 (0.7) 26.1 (1.2) + 0.2 
 3 57.9 (1.5) 56.3 (2.5) - 1.6 
 4 7.3 (0.2) 12.4 (0.5) + 5.1 
Carboplatin 1 6.1 (0.3) 1.9 (0.2) - 4.2 
 2 31.9 (1.4) 31.7 (2.4) - 0.2 
 3 59.0 (2.6) 60.1 (4.5) + 1.1 
 4 3.0 (0.1) 6.3 (0.5) + 3.3 
Oxaliplatin 1 10.1 (0.5) 3.7 (0.1) - 6.4 
 2 28.6 (1.5) 25.8 (1.0) - 2.8 
 3 54.2 (2.9) 61.7 (2.4) + 7.5 
 4 7.1 (0.4) 8.8 (0.3) + 1.7 
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4.2.3: Pt-DNA adducts formed on purified DNA in the presence of GSH 
 
The main aim of studying adducts formed in cells by cisplatin was to confirm the 
previous findings that an additional major class of Pt-containing DNA adducts could be 
detected when DNA extracted from cisplatin-treated cells was analysed by anion 
exchange chromatography and ICP-MS. As discussed in chapter 1, such adducts had 
been detected previously (Azim-Araghi 2003) and were thought to contain GSH cross-
linked to DNA. However, the data described in this section so far for four cell lines 
incubated with cisplatin has shown no evidence to support this hypothesis. 
 
In the previous work (Azim-Araghi 2003) a novel Pt-containing product with similar 
chromatographic properties to the product seen in cells had been identified in pure 
DNA incubated with cisplatin. As discussed in chapter 1, this finding was consistent 
with a number of other preliminary observations and, if correct, could have significant 
implications for the cellular pharmacology of Pt-based drugs. Therefore, attempts were 
made to reproduce the putative formation of cis-Pt(NH3)2(DNA)(GSH) cross-links of 
purified DNA to determine the plausibility of such products occurring in cells. 
 
Initial experiments were aimed at defining the conditions for reacting cisplatin with 
DNA in the presence of GSH so as to generate suitable quantities of adducts for 
subsequent analysis. Then, the main aim was to test the hypothesis that the additional 
adducts could be detected on such DNA when analysed by anion exchange 
chromatography/ICP-MS compared to adducts formed in the absence of GSH. 
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Pure calf thymus DNA (500 µg/ml) was mixed with 0, 10, 25, 50 and 100 mM GSH 
before addition of 15 µM cisplatin. The mixtures were incubated for 2hr and 24hr at 
37°C under anoxic conditions (see section 2.7.1) and then stored at -80°C. DNA was 
then separated from low molecular weight products such as unreacted drug and 
products of the reaction of cisplatin with GSH by gel filtration on a G-75 Sephadex 
column as described in section 2.8. Collected fractions were analysed for DNA 
concentration by measuring O.D. at 254nm. All fractions containing DNA were pooled 
together and concentrated by ultrafiltration. Pt-DNA adduct levels were determined by 
ICP-MS.  
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4.2.3.1: Gel Filtration separation of platinated DNA 
 
Typical gel filtration chromatographic separations for reaction mixtures in the absence 
(A) and presence (B) of GSH are shown in Figure 4.12. These results showed that DNA 
passed through the column rapidly; typically eluting between 40 and 60 minutes post 
injection (Figure 4.12, peak 1). This is consistent with its exclusion from the G-75 
Sephadex beads because of its high molecular weight. Unbound Pt eluted typically 
between 110 and 150 minutes (Figure 4.12, peak 2). Following 2hr incubation, 32% of 
the total Pt eluted was associated with the DNA (Figure 4.12, graph A peak 1). 
 
The presence of 10 mM GSH in the incubation caused a decrease from 32% to 9% of 
the total Pt associated with DNA (Figure 4.12, graph B peak 1). An additional optical 
density peaked was observed between 110 and 140 minutes that eluted slightly earlier 
than unbound platinum (Figure 4.12– Graph B peak 3). This product is likely to be a 
conjugate between cisplatin and GSH. Typical Pt recovery was greater than 90% of the 
total Pt loaded for all separations. 
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Figure 4.12: Typical Sephadex G-75 gel elution profiles of calf thymus DNA (500 
µg/ml) incubated for 2hr with cisplatin (15 µM) alone (A) and with 10 mM GSH (B). 
(), Optical density was measured at OD 254 nm. (), Platinum concentrations 
determined by AAS. Peaks are: 1, DNA; 2, low molecular weight products such as 
unreacted cisplatin or GSH; 3, possible cisplatin-GSH conjugate 
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4.2.3.2: Effect of GSH on total Pt-DNA adduct level 
 
Pt-DNA adducts levels for calf thymus DNA (500 µg/ml) reacted with cisplatin (15 
µM) in the presence of increasing concentrations of GSH for 2hr and 24hr are shown in 
Table 4.13. Total adduct levels expressed as a percentage of control for 2hr (A) and 
24hr (B) are shown in Figure 4.13. 
 
When no GSH was added, a total adduct level of 3.9 (+/- 0.1 SD) µmol Pt g
-1
 DNA was 
observed after a 2hr incubation with cisplatin. This increased to 13.5 (+/- 0.4 SD) µmol 
Pt g
-1
 DNA when incubated for 24 hours. Incubation with 10 mM GSH decreased the 
total adduct level to 0.7 (+/- 0.03 SD) and 1.2 (+/- 0.1 SD) µmol Pt g
-1
 DNA (18.7% 
and 8.5% of control) for the 2hr and 24hr incubations respectively. Data interpolated 
from the graph (first order exponential decay line fitted in Prism) suggests 
concentrations of values of 3.9 mM and 2.7 mM GSH are required to achieve a 50% 
decrease in total Pt-DNA adducts levels for 2hr and 24hr respectively.  
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Table 4.13: Pt-DNA adduct levels expressed as µmoles Pt/g DNA and as a percentage of the control for calf thymus DNA mixed with increasing 
concentration of GSH, then incubated with 15 µM cisplatin for 2 and 24 hours. Each value represents the mean of 3 individual experiments. 
Standard deviation is shown in brackets. 
 Concentration of GSH (mM) 
Control (0) 10 25 50 100 
2 hours µmol Pt g
-1
 DNA 3.9 (0.1) 0.7 (0.03) 0.3 (0.01) 0.1 (0.01) 0.02 (0.01) 
% Control  18.5 (0.7) 6.4 (0.3) 2.0 (0.1) 0.5 (0.1) 
24 hours µmol Pt g
-1
 DNA 13.5 (0.4) 1.2 (0.1) 0.3 (0.01) 0.1 (0.01) 0.03 (0.01) 
% Control  8.7 (0.1) 2.2 (0.01) 0.7 (0.03) 0.2 (0.02) 
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Figure 4.13: Effect of increasing GSH concentration on total adducts formation of 
cisplatin-DNA adducts. Calf thymus DNA (500 μg/ml) was reacted with 15 µM cisplatin 
for 2 hours (A) and 24 hours (B) with increasing concentrations of GSH. () Total 
platinum levels determined by ICP-MS. Solid line indicates one phase exponential 
decay curve fitted by Prism software. Each point represents the mean of 3 different 
experiments and error bars reflect standard deviation. Where not shown, error bars lie 
within the points. 
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4.2.3.3: Effect of GSH on the formation of specific types of Pt-DNA adducts 
 
Typical MonoQ elution profiles for calf thymus DNA (500 µg/ml) incubated with 15 
µM cisplatin for 2hr is shown in Figure 4.14 and with 10 mM GSH and 15 µM cisplatin 
for 2hr and 24hr in Figure 4.15. Analyses of Pt content in collected chromatographic 
fractions showed that there were four major Pt-containing products detected with 
similar retention times seen in the previous analyses with cisplatin (section 4.2.2.1). 
The four peaks were therefore assigned the same chemical nature as those observed in 
the cisplatin analyses. 
 
Mean retention times of the four mononucleotides (detected by UV) and four Pt-
containing species are shown in Table 4.14. The percentage of Pt contained in the 
products detected by ICP-MS is shown in Table 4.15. No difference in retention times 
or relative Pt contained in the peaks was observed in the presence of absence of GSH. 
Levels of Pt were lower in the reactions containing GSH but were still readily 
detectable. 
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Figure 4.14: Typical MonoQ elution pattern for calf thymus DNA (500 µg/ml)  
incubated with 15 µM cisplatin for 2hr. Solutions (100 µl) of DNA were applied to the 
column and eluted at 1 ml/min. Fractions were collected with increasing NaCl 
concentration and Pt levels in each fraction measured by ICP-MS. (), Pt 
concentration; dotted line: OD 254 nm. Peaks 1: Pt(NH3)2(R)(dGMP)]; 2: cis-
Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4: cis-Pt(NH3)2(dGMP)2 
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Figure 4.15: Typical MonoQ elution pattern for calf thymus DNA (500 µg/ml)  
incubated with 15 µM cisplatin and 10 mM GSH for 2hr (A) and 24hr (B). Solutions 
(100 µl) of DNA were applied to the column and eluted at 1 ml/min. Fractions were 
collected with increasing NaCl concentration and Pt levels in each fraction measured 
by ICP-MS. (), Pt concentration; dotted line: OD 254 nm. Peaks 1: 
Pt(NH3)2(R)(DGMP); 2: cis-Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4:cis-
Pt(NH3)2(dGMP)2 
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Table 4.14: Mean retention times for the products detected by UV absorbance and ICP-MS in purified DNA exposed to 15 µM cisplatin in the 
presence and absence of 10 mM GSH. Mean values from individual analyses of three separate DNA preparation are shown. Ranges in retention 
time are shown in brackets except for total Pt recovered in which SD is shown. 
Peak Identity Cisplatin Alone 10 mM GSH 2hr 10 mM GSH 24hr 
 dCMP 5.4 (0.1) 5.4 (0.1) 5.3 (0.2) 
 dAMP 5.9 (0.1) 6.0 (0.1) 6.0 (0.1) 
 TMP 7.2 (0.1) 7.2 (0.1) 7.2 (0.1) 
 dGMP 13.1 (0.2) 13.0 (0.1) 13.1 (0.2) 
1 Pt(NH3)2(R)(dGMP) 2.0 (0.5) 2.0 (0.5) 2.5 (0.5) 
2 cis-Pt(NH3)2d(ApG) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5) 
3 cis-Pt(NH3)2d(GpG) 9.5 (0.5) 9.5 (1.0) 9.0 (1.0) 
4 cis-Pt(NH3)2(dGMP)2 12.0 (1.0) 12.0 (0.5) 11.5 (0.5) 
Total Pt Recovery (%) 97.3 (2.1) 103.4 (4.2) 106.5 (7.2) 
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Table 4.15: Percentage of the Pt in peaks formed in calf thymus DNA (500 µg/ml) 
incubated with 15 µM cisplatin +/- 10 mM GSH for 2hr and 24hr. The percentage of 
total Pt is expressed as a percentage of Pt contained in the four identified peaks in 
relation to the total Pt in the four peaks combined. Each value represents the mean of 
three individual analyses. Standard deviation is shown in brackets. 
 
Peak CT-DNA 10 mM GSH 2hr 10 mM GSH 24hr 
1 12.6 (0.4) 11.8 (0.2) 6.3 (0.1) 
2 20.2 (0.6) 22.1 (0.4) 22.7 (0.4) 
3 59.3 (1.7) 56.6 (0.9) 56.6 (1.1) 
4 7.9 (0.2) 9.4 (0.2) 14.5 (0.3) 
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It seemed possible that the formation of the cis-Pt(NH3)2(DNA)(GSH) cross-links was 
not detected because of factors such as steric hindrance resulting in a very low 
probability that GSH would react with Pt monofunctionally bound to DNA before the 
latter had undergone second arm reaction with DNA. When cisplatin was initially 
reacted with dGMP, and then further incubated with GSH (see chapter 3), there was 
evidence of GSH cross-linking to Pt-dGMP. Therefore an attempt was made to detect 
the proposed adduct in samples in which DNA was allowed to react with cisplatin 
before addition of GSH. This approach was not physiologically relevant, but previous 
published data had shown the initial reaction of cisplatin with DNA to form 
monofunctional Pt-DNA products was rapid (Eastman 1987). The strategy for these 
experiments therefore was to initially incubate with cisplatin for 1hr, and then add GSH 
to the incubation mixture and incubate further. 
 
Pure calf thymus DNA (500 µg/ml) was incubated with 15 µM cisplatin for 1hr, 
followed by addition of 10 mM GSH and further incubation for 2hr or 24hr  at 37°C 
under anoxic conditions (see section 2.7.1) and then stored at -80°C. DNA was then 
separated from low molecular weight products such as unreacted drug and products of 
the reaction of cisplatin with GSH by gel filtration on a G-75 Sephadex column as 
described in section 2.8. Collected fractions were analysed for DNA concentration by 
measuring O.D. at 254nm. All fractions containing DNA were pooled together and 
concentrated by ultrafiltration. Pt-DNA adduct levels were determined by ICP-MS.  
 
A Typical MonoQ elution profile for calf thymus DNA (500 µg/ml) incubated with 15 
µM cisplatin for 1hr is shown in Figure 4.16. Mean retention times of the four 
mononucleotides (detected by UV) and four Pt-containing species are shown in Table 
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4.16. The percentage of Pt contained in the products detected by ICP-MS is shown in 
Table 4.17.  
 
The data confirms the expected pattern of Pt containing products similar to the data for 
purified DNA incubated with cisplatin for 2hr. The main difference was the increase in 
peak 1 (attributed to cis-Pt(NH3)2(R)(dGMP)) which was expected be higher in this 
incubation due to the rapid formation of monofunctional products and slower closure to 
bifunctional. Levels of the monofunctional product would most likely have been higher 
at the time of GSH addition to the data presented here because second-arm reactions 
would have continued during the gel filtration procedure (200 minutes). Similar to 
previous analyses however, no evidence was found of the putative cis-
Pt(NH3)2(DNA)(GSH) cross-link after further incubation in the presence of 10 mM 
GSH (Figure 4.17) 
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Figure 4.16: Typical MonoQ elution pattern for calf thymus DNA (500 µg/ml)  
incubated with 15 µM cisplatin for 1hr. Solutions (100 µl) of DNA were applied to the 
column and eluted at 1 ml/min. Fractions were collected with increasing NaCl 
concentration and Pt levels in each fraction measured by ICP-MS. (), Pt 
concentration; dotted line: OD 254 nm. Peaks 1: Pt(NH3)2(R)(dGMP); 2: cis-
Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4:cis-Pt(NH3)2(dGMP)2 
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Figure 4.17: Typical MonoQ elution pattern for calf thymus DNA (500 µg/ml)  
incubated with 15 µM cisplatin for 1hr, followed by further incubation with 10 mM 
GSH for 2hr (A) and 24hr (B). Solutions (100 µl) of DNA were applied to the column 
and eluted at 1 ml/min. Fractions were collected with increasing NaCl concentration 
and Pt levels in each fraction measured by ICP-MS. (), Pt concentration; dotted line: 
OD 254 nm. Peaks 1: Pt(NH3)2(R)(dGMP); 2: cis-Pt(NH3)2d(ApG); 3: cis-
Pt(NH3)2d(GpG) and 4:cis-Pt(NH3)2(dGMP)2 
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Table 4.16: Mean retention times for the products detected by UV absorbance and ICP-MS in purified DNA exposed to 15 µM cisplatin in the 
delayed presence and absence of 10 mM GSH. Mean values from individual analyses of three separate DNA preparation are shown. Ranges in 
retention time are shown in brackets except for total Pt recovered in which SD is shown. 
Peak Identity Cisplatin Alone 10 mM GSH 2hr 10 mM GSH 24hr 
 dCMP 5.4 (0.1) 5.5 (0.1) 5.4 (0.1) 
 dAMP 5.9 (0.1) 6.2 (0.1) 6.1 (0.1) 
 TMP 7.1 (0.1) 7.1 (0.1) 7.1 (0.2) 
 dGMP 13.1 (0.1) 13.1 (0.2) 12.9 (0.2) 
1 Pt(NH3)2(R)(dGMP) 2.5 (0.5) 2.5 (0.5) 2.5 (0.5) 
2 cis-Pt(NH3)2d(ApG) 5.5 (1.0) 4.5 (0.5) 5.0 (1.0) 
3 cis-Pt(NH3)2d(GpG) 9.5 (0.5) 9.0 (1.0) 9.0 (1.0) 
4 cis-Pt(NH3)2(dGMP)2 11.5 (0.5) 11.5 (1.0) 11.5 (1.0) 
Total Pt Recovery (%) 92.4 (2.3) 94.3 (1.7) 91.3 (3.4) 
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Table 4.17: Percentage of the Pt in peaks formed in calf thymus DNA (500 µg/ml) 
incubated with 15 µM cisplatin for 1hr, followed by further incubation with 10 mM 
GSH for 2hr and 24hr. The percentage of total Pt is expressed as a percentage of Pt 
contained in the four identified peaks in relation to the total Pt in the four peaks 
combined. Each value represents the mean of three individual analyses. Standard 
deviation is shown in brackets. 
Peak CT-DNA 10 mM GSH 2hr 10 mM GSH 24hr 
1 23.0 (0.4) 8.7 (0.3) 3.2 (0.1) 
2 21.9 (0.2) 28.1 (0.9) 29.2 (1.4) 
3 52.6 (0.9) 57.5 (1.9) 55.4 (2.6) 
4 2.5 (0.1) 5.6 (0.2) 12.2 (0.6) 
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4.3: Discussion 
 
Analysis of Pt-DNA adducts formed in cells by cisplatin 
 
Previous analyses of Pt-DNA adducts had described the nature of four major Pt-
containing products formed in purified DNA. However, these studies had been limited 
to using purified DNA due to the need to work with large quantities of cisplatin-DNA 
adducts because of the limitations of using AAS to detect Pt. Advances in studying Pt-
DNA adducts were made with the development of highly sensitive immunoassays and 
32
P post-labelling assays which allowed the study of adducts at clinically relevant drug 
concentrations and analyses of Pt-DNA adducts formed in cells. These methods 
however were inherently limited to the study of specific Pt-DNA adducts, specifically 
the 1,2-intrastrand cis-Pt(NH3)2d(ApG) and cis-Pt(NH3)2d(GpG) adducts. 
 
Azim-Araghi (2003) applied ICP-MS to the previously described method of separating 
enzymatically digested DNA by anion exchange chromatography (Fichtinger-
Schepman et al 1985), and provided evidence for the formation of novel Pt-DNA 
adducts in cells incubated with cisplatin. Further analysis with purified calf thymus 
DNA provided evidence that such adducts potentially contained GSH. 
 
Evidence that GSH is able to cross-link to monofunctionally bound Pt-DNA adducts 
was published over twenty years ago (Micetich et al 1983, Eastman 1987).  More 
recently a number of strands of unpublished evidence had accumulated in studies at 
Newcastle which supported the possibility that such adducts can form. Furthermore, it 
seemed possible that they could have interesting biologically relevant properties.  
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In the present work, similar methodology to that used by Azim-Araghi was applied to 
study, in greater depth, the adducts formed by cisplatin using four human tumour cell 
lines (833K, A2780, LoVo and Mor/CPR) following incubations with cisplatin. The 
results confirmed the presence of the four major previously identified Pt-DNA adducts. 
The percentage contribution of the two major Pt-DNA products is similar to previous 
studies (Fichtinger-Schepman et al 1985, Eastman 1986). These products were also 
identified in purified calf thymus DNA incubated with cisplatin at a similar ratio. 
 
The additional Pt-containing peak identified in the analyses of Azim-Araghi however 
was not observed in any of the four cell lines investigated in this study. Azim-Araghi 
used H69/p and Mor/p cell lines. Although the H69/p cell line was not used in this 
study, both investigations used the Mor cell line. Azim-Araghi used the parental Mor/p 
cell line, whereas this study used the cisplatin-resistant Mor/CPR sub-line because the 
original cells had become contaminated and could not be procured from elsewhere. The 
Mor/CPR cell line had been derived from the Mor/P line by selection for drug 
resistance (Twentyman et al 1991). It is possible that the resistance mechanisms 
resulted in altered types of DNA adducts being formed in the Mor/CPR line compared 
to the cells used by Azim-Araghi, but it seems unlikely that a major class of adducts 
would be completely lost, especially since the extra peak could not be detected in 
analyses of DNA from three other cell lines. 
 
The evidence for the putative cis-Pt(NH3)2(DNA)(GSH) cross-link observed by Azim-
Araghi in cellular DNA was previously supported by data from incubations of cisplatin 
with calf thymus DNA in the presence of GSH. In these analyses, a product with the 
same chromatographic properties was observed to the product identified in cellular 
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DNA. No evidence for such products in purified DNA was observed in this study using 
the same incubation conditions or when GSH addition was delayed to allow initial 
binding of cisplatin to DNA. Possible reasons for the discrepancy between the previous 
results and the present data will be discussed in chapter 7. 
 
Analysis of Pt-DNA adducts formed in cells by carboplatin and oxaliplatin 
Although the main aim was to confirm the presence of additional adducts formed by 
cisplatin in cells, the study has also investigated adducts formed by carboplatin and 
oxaliplatin using the same methods, which, as described above, permit, for the first 
time, the analysis of essentially all of the Pt-containing adducts present in DNA from 
drug-treated cells. This type of analysis has never been reported before for carboplatin 
or oxaliplatin. 
 
ICP-MS analysis of Pt content in collected fractions of DNA hydrolysates from drug 
treated cells separated using the standard MonoQ system showed the presence of four 
Pt-containing products for both carboplatin and oxaliplatin. In both cases, these 
products had similar retention times and relative Pt levels of adducts to those seen in 
the incubation with cisplatin and therefore are suggested to be of a similar nature 
(except for the non-leaving groups of NH3 for carboplatin and the DACH ligand for 
oxaliplatin). The relative proportions of the four products were very similar to those 
values for cisplatin and, like cisplatin, did not vary markedly between cell lines. 
 
No additional Pt-containing products were detected following either 2hr of 24hr 
incubations with carboplatin or oxaliplatin. This indicates a lack of any evidence for 
formation of additional adducts species such as cis-Pt(NH3)2(DNA)(GSH) cross-links. 
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However, the formation of such adducts cannot be excluded. It is possible that they are 
being formed, but at levels which fall below the limit of detection of MonoQ/ICP-MS 
detection method. The lack of detection in this work does fit with the general belief that 
the effect of GSH is to inactivate intracellular cisplatin. 
 
Relationship between adduct levels and sensitivity to growth inhibition 
Factors that affect the sensitivity of cells to Pt drugs can be grouped into three classes: 
1, factors that affect access of drug to DNA, such as differences in uptake or 
intracellular thiols; 2, the properties of the adducts formed; and 3, factors that affect 
how the cell responds to the damage, such as repair or replication by-pass mechanisms. 
The latter factors are very dependent upon the nature of adducts formed. 
 
All of these factors contribute towards the GI50 values. However, if the level of adducts 
required to achieve a 50% growth inhibition (AL50) is determined, this data is 
independent of the first set of factors and so reflects the nature of adducts and how cells 
respond to them. Since the relationship between adduct levels and drug concentrations 
were linear, these values were straightforward to calculate by combining GI50 values 
and adduct dose responses. These values are shown in Table 4.18. 
 
The GI50 values for all cell lines and drugs showed a marked decrease when the 
exposure time was increased from 2hr to 24hr, as would be expected. The ratio of GI50 
for 2hr exposure was 5-22 times larger than the equivalent 24hr values (mean ratio = 
14). A similar analysis of the AL50 values shows that exposure time affected these to a 
much smaller degree, with ratios of AL50 (2hr) to AL50 (24hr) showing an average of 
1.3 across all the cell lines and drugs investigated. These data are shown in Table 4.19. 
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These findings are consistent with the decrease in GI50 with increased exposure being 
due to increased access of drug to intracellular targets. 
 
If two drugs form the same types of adducts then they should exhibit similar AL50 
values in the same cell lines. It is not clear from the literature if DNA adducts formed 
by cisplatin and carboplatin differ and, if so, to what extent and in what manner. 
Chemically they are expected to form the same adducts because the non-leaving groups 
on Pt are the same. However, data from Fichtinger-Schepman et al (1995 a) indicated 
that carboplatin forms a larger proportion of the 1,2-intrastrand cis-Pt(NH3)2d(ApG) 
adducts. Analysis of the AL50 data in Table 4.18 shows that for the 833K cells the AL50 
values of cisplatin and carboplatin are similar. However for the other cells the values 
for carboplatin are about half of the values for cisplatin, except for LoVo cells exposed 
for 24hr. This suggests that adducts formed by carboplatin can be slightly more toxic 
than those formed by cisplatin. However, the chromatographic analysis of DNA 
adducts formed in cells by cisplatin and carboplatin (Table 4.11) showed no detectable 
differences.  
 
AL50 values for oxaliplatin are generally similar to those of cisplatin and carboplatin 
after 2hr exposure and lower after 24hr, except for Mor/CPR cells where the AL50 
values are markedly higher. These data suggest that Mor/CPR cells are able to tolerate 
much larger amounts of oxaliplatin-DNA adducts than the other cell lines investigated 
in this study. This contrasts with previous findings that showed that oxaliplatin forms 
fewer Pt-DNA adducts at equitoxic concentrations. However, these were in other cell 
lines and using less sensitive or less direct methods to measure Pt-DNA adduct levels 
(Saris et al 1996, Woynarowski et al 1998, Woynarowski et al 2000).  
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Table 4.18: Units of adduct levels (AL50) values for 833K, A2780, LoVo and Mor/CPR 
cells exposed to cisplatin, carboplatin or oxaliplatin. Values were calculated in Prism 
4.0 and are expressed in µM. 
Drug Inc. Time 833K A2780 LoVo Mor/CPR 
Cisplatin 2hr 13.7 26.5 23.0 48.1 
 24hr 9.8 31.4 13.9 35.0 
Carboplatin 2hr 10.3 11.7 9.9 22.9 
 24hr 12.0 16.8 20.3 27.4 
Oxaliplatin 2hr 11.6 9.0 17.0 187.3 
 24hr 4.5 5.1 5.7 319.0 
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Table 4.19: Ratios of 2hr and 24hr GI50 and AL50 values for 833K, A2780, LoVo and 
Mor/CPR cells exposed to cisplatin, carboplatin or oxaliplatin. 
Cell Line Cisplatin Carboplatin Oxaliplatin 
Ratio GI50 AL50 GI50 AL50 GI50 AL50 
833K 6.8 1.4 18.0 0.9 22.3 2.6 
A2780 5.2 0.8 14.2 0.7 21.5 1.8 
LoVo 8.5 1.7 8.8 0.5 22.5 3.0 
Mor/CPR 8.8 1.4 17.5 0.8 12.7 0.6 
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Chapter 5 
Characterisation of cisplatin-DNA adducts formed in the 
presence of sodium thiosulfate 
 
5.1: Introduction 
 
Platinum-based anticancer complexes are often associated with severe toxicities that 
can limit their clinical usage. Endogenous sulfur-containing compounds such as 
glutathione and thiourea have been shown to bind to and inactivate platinum complexes 
(Burchenal et al 1978, Filipski et al 1979, Micetich et al 1983, Eastman 1987). As 
described in chapter 1, exogenous sulfur-containing compounds have been proposed as 
potential protective agents to limit normal tissue toxicity, and have shown promising 
protection against chemotherapy drugs both in experimental studies and clinical trials. 
These have been recently reviewed (Wang et al 2007).  
 
Sodium thiosulfate (STS) is an exogenous compound that has been proposed as a 
protective agent for patients receiving cisplatin or carboplatin-based chemotherapy. As 
described in chapter 1, STS has been recently used in oncology to reduce 
nephrotoxicity associated with cisplatin treatment. The mechanism through which this 
occurs is unclear, but is proposed to be a result of STS reducing delivery of cisplatin, 
and by reducing cisplatin accumulation (Weiner and Jacobs 1983, Shea and Howell 
1984, Elferink et al 1986). Based on the positive data accumulated for STS in 
protection against nephrotoxicity, it was proposed that STS may have a protective role 
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against cisplatin-induced ototoxicity. Neuwelt et al investigated the effects of STS in 
vitro and in vivo in protecting against carboplatin-induced ototoxicity (Neuwelt et al 
1996). They showed that STS protected against carboplatin toxicity in vitro when 
incubated for up to 8 hours after carboplatin was added, but no protection was seen 
when STS was added 24hr post-carbopaltin (Neuwelt et al 1996). Further in vitro 
studies and investigations in animals and patients have confirmed the findings that 
delayed administration of STS can reduce ototoxicity and also have indicated that this 
occurs without compromising the anti-tumour effects of either cisplatin or carboplatin 
(Neuwelt et al 1998, Muldoon et al 2000, Doolittle et al 2001, Harned 2008). 
 
STS is currently in a phase III clinical trial (SIOPEL 6) to investigate its potential 
application as a protective against ototoxicity in paediatric patients receiving cisplatin 
for standard risk hepatoblastoma. This trial is built on positive data from experiments in 
animals that led to the hypothesis that delayed administration of STS in patients can 
protect against ototoxicity without reducing antitumour efficacy. This is based on the 
assumption that STS will inactivate any unreacted drug present in patients.  
 
It is widely believed that, like endogenous sulfur-containing compounds found inside 
cells, exogenous compounds have the potential to bind and inactivate platinum 
complexes. STS is known to rapidly react with cisplatin, therefore it may have a greater 
potential than endogenous compounds such as glutathione in blocking second arm 
reactions. However, there is very limited data available on whether STS is able to enter 
cells, and whether STS has the potential to alter cisplatin-DNA adducts. There is 
evidence suggesting STS remains extracellular, however this conclusion was drawn 
from indirect evidence from studies in dogs (Gilman et al 1946), and more recently the 
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SLC13 family of sulfate transporters has been shown to have an involvement in 
thiosulfate transport into cells (Pajor 2006). 
 
The aim of this section was to test the hypothesis that, like endogenous sulfur-
containing compounds, STS has the potential to affect the formation of cisplatin-DNA 
adducts. This was investigated as follows: 
 
1. The hypothesis that STS has the ability to interact with platinated DNA to form 
novel cross-links was tested in two ways: 
a. Calf thymus DNA was incubated with cisplatin in the presence and 
absence of STS. Enzymatically digested platinum-DNA cross-links 
were separated by anion exchange chromatography and Pt-containing 
species detected by ICP-MS 
b. STS was incubated with monofunctionally bound cisplatin-dGMP (as 
described in chapter 3). Products were separated by anion-exchange 
chromatography and Pt-containing species were detected by AAS. 
 
2. The effects of concurrent/delayed administration of STS on the formation of 
platinum-DNA adducts in four human tumour cell lines was investigated in two 
ways: 
a. The effects of concurrent/delayed administration of STS on growth 
inhibition of cisplatin was measured by SRB assay 
b. The effects of concurrent/delayed administration of STS on total 
cisplatin-DNA adduct formation was measured by ICP-MS.  
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5.2: Results 
 
Pure calf thymus DNA (500 µg/ml) was mixed with 0, 0.1, 0.3, 1, 3 and 10 mM STS 
before addition of 15 µM cisplatin. The mixtures were incubated for 2hr and 24hr at 
37°C under anoxic conditions, and then stored at -80°C. DNA was then separated from 
low molecular weight products such as unreacted drug and products of the reaction of 
cisplatin with STS by gel filtration on a G-75 Sephadex column as described in section 
2.8 (and as used in chapter 4 to separate glutathione reaction mixtures). Collected 
fractions were analysed for DNA concentration by measuring OD at 254nm and Pt 
concentration by AAS (section 2.10). All fractions containing DNA were pooled 
together and concentrated by ultrafiltration as described in section 2.8. Pt-DNA adduct 
levels were determined by ICP-MS (section 2.11).   
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5.2.1: Gel filtration separation of platinated DNA 
 
Typical gel filtration chromatographic separations for reaction mixtures in the absence 
(A) and presence (B) of STS are shown in Figure 5.1. These results showed that DNA 
passed though the column rapidly typically eluting between 40 and 60 minutes post-
injection (Figure 5.1, peak 1). This is consistent with its exclusion from the G-75 
Sephadex beads because of its high molecular weight. Unbound platinum eluted 
typically between 115 and 155 minutes (Figure 5.1 – Graph A peak 2). Following 2 
hour incubation, 37.2% of the total platinum eluted was associated with the DNA 
(Figure 5.1 – Graph A peak 1). These findings are consistent with similar separations in 
this thesis for glutathione reactions (see chapter 4). 
 
The presence of 0.1 mM STS in the incubation caused a decrease from 37% to 17% of 
the total platinum associated with DNA (Figure 5.1 – Graph B peak 1). An additional 
optical density peak was observed between 110 and 140 minutes that eluted slightly 
earlier than unbound platinum (Figure 5.1 – Graph B peak 2), a phenomenon also seen 
with glutathione (see chapter 4). This product is likely to be a conjugate between 
cisplatin and STS. Typical Pt recovery was greater than 90% of the total Pt loaded for 
all separations. 
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Figure 5.1: Typical Sephadex G-75 gel elution profiles of calf thymus DNA (500 µg/ml) 
incubated for 2hr at 37°C with cisplatin (15 µM) alone (A) and with 0.1 mM STS (B). 
(), Optical density was measured at OD 254 nm. (), Platinum concentrations 
determined by AAS. Peaks are: 1, DNA; 2, low molecular weight products such as 
unreacted cisplatin or STS; 3, possible cisplatin-STS conjugate 
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5.2.1.1: Effect of STS on total Pt-DNA adduct level 
 
Pt-DNA adducts levels for calf thymus DNA mixed with increasing concentrations of 
STS and incubated with 15 µM cisplatin for 2hr or 24hr are shown in Table 5.1. Total 
adduct levels as a percentage of control for 2 hours (A) and 24 hours (B) incubation are 
plotted in Figure 5.2. 
 
When no STS was added, a total adduct level of 10.5 (+/- 0.7 SD) µmol Pt g
-1
 DNA 
was observed after a 2hr incubation with cisplatin. This increased to 20.8 (+/- 0.4 SD) 
µmol Pt g
-1
 DNA when incubated for 24 hours. Incubation with 0.1 mM STS decreased 
the total adduct level to 4.1 (+/- 0.2 SD) and 5.8 (+/- 0.5 SD) µmol Pt g
-1
 DNA (39% 
and 28% of control) for the 2hr and 24hr incubations respectively. Incubation with 1 
mM STS caused a decrease to less than 5% of the control value. Data interpolated from 
the graph (first order exponential decay line fitted in Prism) suggests concentrations of 
values of 0.07 and 0.05 mM STS are required to achieve a 50% decrease in total Pt-
DNA adducts levels for 2hr and 24hr respectively.  
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Table 5.1: Overall Pt-DNA adducts levels formed by the reaction of cisplatin with pure DNA in the presence of varied concentrations of STS. 
DNA was reacted with 15 µM cisplatin for 2hr and 24hr. Each value represents the mean of 3 individual experiments. Standard deviation is 
shown in brackets. 
 
 Concentration of STS (mM) 
Control (0) 0.1 0.3 1 3 10 
2 hours µmol Pt g
-1
 DNA 10.5 (0.7) 4.1 (0.2) 1.6 (0.1) 0.5 (0.01) 0.2 (0.01) 0.03 (0.01) 
% Control  39.2 (1.6) 14.9 (0.5) 4.3 (0.1) 1.5 (0.1) 0.3 (0.01) 
24 hours µmol Pt g
-1
 DNA 20.8 (0.4) 5.8 (0.5) 2.6 (0.1) 0.8 (0.1) 0.2 (0.01) 0.06 (0.01) 
% Control  28.0 (2.4) 12.4 (0.5) 3.6 (0.3) 0.8 (0.02) 0.3 (0.03) 
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Figure 5.2: Effect of increasing STS concentration on the level of total adducts formed 
on DNA by cisplatin. 500 µg/ml calf thymus DNA was reacted with 15 µM cisplatin for 
2 hours (A) and 24 hours (B) with increasing concentrations of STS. () Total platinum 
levels determined by ICP-MS. Solid line indicates one phase exponential decay curve 
fitted by Prism software. Each point represents the mean of 3 different experiments and 
error bars reflect standard deviation. Where not shown, error bars lie within the points. 
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5.2.1.2: Reaction of cisplatin with STS 
 
Cisplatin was initially reacted alone with STS to determine the chromatographic 
properties of cisplatin-TS. This was important to ensure any novel chromatographic 
products formed in reactions involving dGMP, cisplatin and STS were not cisplatin-TS 
conjugates. Cisplatin was dissolved in water to a concentration of 2 mM. STS was 
dissolved in water to a concentration of 4 mM, and pH adjusted to 7.0. Cisplatin and 
GSH were incubated for 24hr in a 1:2 molar ratio (1:2 mM). Products of the reaction 
were analysed using the standard MonoQ system (section 2.9). The concentration of Pt 
in each fraction was determined by AAS. A typical MonoQ elution profile is shown in 
Figure 5.3. 
 
Cisplatin had previously been shown to elute very rapidly from the MonoQ column (see 
chapter 3). However, it was unclear where cisplatin-TS conjugates would elute. Three 
peaks were detected by UV absorbance eluting at approximately 21 minutes, and 28-29 
minutes (Figure 5.3). The latter peaks were the only detected species associated with Pt, 
and these were therefore attributed to be Pt-TS conjugates. The earlier peak eluting at 
approximately 21 minutes was unreacted STS in the mixture and not an impurity. This 
had previously been determined by injecting STS alone into the chromatographic 
system. UV absorbance for STS (injected alone) was higher at 230 nm than at 254 nm, 
and this fits in with data published showing TS has a UV absorbance, maximum at 212 
nm (Krull and LaCourse 1987). 
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Figure 5.3: Typical MonoQ elution profile for 1 mM cisplatin incubated with 2 mM 
STS for 24hr: 100 µl was applied to the MonoQ column and eluted with increasing 
NaCl concentrations. Pt concentration in collected fractions was determined by AAS. 
(●) Pt concentration; dotted red line: OD 254 nm; dotted blue line: OD 230 nm. 
Overall Pt recovery was always with 10% of total Pt loaded. 
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5.2.2: Effect of STS on the formation of Pt-DNA adducts in pure DNA 
 
Calf thymus DNA was incubated with 15 µM cisplatin in the presence and absence of 2 
mM STS as described earlier, and separated from low molecular weight material by gel 
filtration and concentrated by ultrafiltration. This DNA was enzymatically digested and 
the products by MonoQ anion exchange chromatography. Platinum eluted in collected 
fractions was measured by ICP-MS. 
 
Chromatographic separation and analysis of platinum in collected fractions of calf 
thymus DNA incubated with 15 µM cisplatin for 2 hours (Figure 5.4) confirmed the 
formation of the four known major adducts as described in chapters 3 and 4. In order of 
elution these were: Pt(NH3)2(R)(dGMP), cis-Pt(NH3)2d(ApG), cis-Pt(NH3)2d(GpG) and 
cis-Pt(NH3)2(dGMP)2.  
 
Analysis of Pt-DNA adducts present on the first preparation of DNA that had been 
reacted with cisplatin in the presence of STS revealed a clear additional Pt-containing 
peak which eluted at approximately 16 minutes (Figure 5.5, graph A). This was 
confirmed by further hydrolysis and chromatographic analysis of the same DNA 
preparation and was thought to potentially represent a cross-link between DNA and 
thiosulfate (TS). However, when further preparations of DNA were made (3 individual 
preparations) in subsequent reactions of DNA with cisplatin and STS under exactly the 
same conditions, these failed to confirm the presence of the additional peak (Figure 5.5, 
graph B).  
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Figure 5.4: Typical MonoQ elution profile for enzymatically digested calf thymus DNA 
(500 µg/ml) digested after reaction with 15 µM cisplatin. Solutions (100 µl) of DNA 
were injected onto the MonoQ column and eluted at 1 ml/min with increasing NaCl 
concentrations. Platinum levels in collected fractions was determined by ICP-MS. (●) 
Platinum concentration; dotted line: OD 254 nm. Peaks are 1: cis-
Pt(NH3)2(R)(dGMP); 2: cis-Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4: cis-
Pt(NH3)2(dGMP)2. Overall Pt recovery was greater than 90% of total Pt loaded. 
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Figure 5.5: Typical MonoQ elution profiles for enzymatically digested calf thymus 
DNA (500 µg/ml) digested after reaction with 15 µM cisplatin and 2 mM STS for 2hr. 
Figures A and B are individual analyses of separate DNA preparations. Solutions (100 
µl) of DNA were injected onto the MonoQ column and eluted at 1 ml/min with 
increasing NaCl concentrations. Platinum levels in collected fractions was determined 
by ICP-MS. (●) Platinum concentration; dotted line: OD 254 nm. Peaks are 1: cis-
Pt(NH3)2(R)(dGMP); 2: cis-Pt(NH3)2d(ApG); 3: cis-Pt(NH3)2d(GpG) and 4: cis-
Pt(NH3)2(dGMP)2. The putative identity of 5 is cis-Pt(NH3)2(dGMP)(TS). Overall Pt 
recovery was greater than 90% of total Pt loaded.  
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5.2.3: Effect of STS on the reaction of cisplatin with dGMP 
 
The initial experiment with calf thymus DNA showed evidence of a potential cis-
Pt(NH3)2(DNA)(STS) cross-link. As the evidence for such a product was very limited, 
experiments similar to those described in chapter 3 with dGMP were carried out to 
determine if it was plausible that STS-nucleotide cross-links could form and, if so, to 
determine their chromatographic behaviour.  
 
Incubation of equimolar (1 mM) cisplatin with dGMP led to the formation of three 
monofunctional products and one bifunctional platinum product. The identification of 
these products is described in detail in section 3.3. Figure 5.6 (graph A) shows a typical 
MonoQ elution profile for the products formed by reaction of cisplatin with dGMP for 
24hr in the present series of experiments. The identities of the peaks are cis: unreacted 
cisplatin; 1: cis-Pt(NH3)2(OH2)(dGMP); 2: cis-Pt(NH3)2(OH)(dGMP); 3: cis-
Pt(NH3)2(Cl)(dGMP)  and 4: cis-Pt(NH3)2(dGMP)2. Interestingly, peak 5 appeared to 
elute quicker in the reaction with STS, although this is probably reflective of subtle 
variations in chromatographic buffer conditions as discussed in chapter 3. 
 
After the initial incubations of cisplatin with dGMP for 24hr to generate the products 
shown in Figure 5.6 (graph A), STS (1 mM) was added to the reaction mixture and 
further incubated at 37°C for 24hr. The products present at that time were analysed by 
chromatography using the MonoQ column Figure 5.6 (graph B). Trace levels of the cis-
Pt(NH3)2(OH2)(dGMP) species of cisplatin (peak 1) were still detectable, as was the 
bifunctional cis-Pt(NH3)2(dGMP)2 species (peak 4). There was no evidence of any 
unreacted cisplatin. An additional platinum-containing species was detected that eluted 
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at approximately 16 minutes (Figure 5.6 – Graph B). This product was observed in 3 
MonoQ analyses each of an individual reaction. It is proposed that this product is a cis-
Pt(NH3)2(dGMP)(STS) cross-link. 
 
Interestingly, the levels of the bifunctional cis-Pt(NH3)2(dGMP)2 peak were lower (10 
nmoles/ml (Figure 5.6 – Graph A peak 4) to 4 nmoles/ml (Figure 5.6 – Graph B peak 
4)). This is further complicated by the appearance of detectable levels of dGMP (Figure 
5.6 – Graph B, peak dGMP). The reason for this phenomenon is unknown, but it 
suggests a possibility that STS may have the capacity to displace dGMP bound to 
platinum. The work in this thesis does not address that possibility.  
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Figure 5.6: MonoQ elution profile for 1mM cisplatin and dGMP 24hr (A) and with STS 
(1 mM) for a further 24hr (B): Solutions (100 µl) were applied to the MonoQ column 
and eluted with increasing NaCl concentrations. Platinum concentration in collected 
fractions was determined by AAS. (●) Platinum concentration; dotted line: OD 254 nm. 
Peaks are 1: unreacted cisplatin; 2: cis-Pt(NH3)2(OH2)(dGMP); 3: cis -
Pt(NH3)2(OH)(dGMP); 4: cis-Pt(NH3)2(Cl)(dGMP)  and 5: cis-Pt[(NH3)2d(GMP2. 
Overall Pt recovery was greater than 90% of total Pt loaded. 
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5.2.4: Effect of STS on the antiproliferative activity of cisplatin in human tumour 
cell lines 
 
As discussed in section 5.1, an aim of the work described in this chapter was to 
investigate the effects of STS on cisplatin-induced DNA adduct formation in cells. 
Initially the effects of STS on cisplatin sensitivity of the cells to be used for adduct 
studies was confirmed. 
 
Three incubation schedules were chosen for measuring the effects of STS on human 
tumour cells exposed to cisplatin. The individual schedules are described in Figure 5.7. 
In the SIOPEL 6 clinical trial, cisplatin is infused i.v. over a 6hr period with 
accompanying hydration, followed by a further 6hr hydration period. At this 12hr point, 
STS infusion begins over a 6hr period, although the actual infusion is 125 mg/ml STS 
i.v. for 15 minutes. In patients with normal renal function, STS has a half-life in serum 
of 15 minutes (Schulz 1984, Araya et al 2006). The delayed schedule used in this study 
most clearly mimics this setup. A lower concentration of STS (12.6 mM) was chosen 
for these incubations to that used in the clinical trial. This equates to 2 mg/ml STS, 
which is the concentration of STS used in earlier experiments (Neuwelt et al 1996). The 
concurrent schedule is expected to demonstrate the greatest effect but this could result 
from extracellular as well as intracellular interactions of STS and cisplatin. The 
sequential schedule should eliminate the effects resulting from extracellular reactions of 
STS with cisplatin and any effects should result from inactivation of intracellular 
cisplatin or its reactive derivatives.   
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Figure 5.7: Incubation schedule for exposure of human tumour cell lines to cisplatin in 
the presence and absence of STS. Incubation schedule for growth inhibition 
experiments is shown in panel A and for determination of total Pt-DNA adducts in 
panel B. 
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5.2.5: Effect of STS on growth inhibition by cisplatin 
 
Human tumour cells 833K, A2780, LoVo and Mor/CPR were seeded into 96 well 
plates at 8000 cells/well and incubated with various concentrations of cisplatin. STS 
concentration was constant at 12.6 mM. Cisplatin and STS were added at various times 
as described in Figure 5.7 (panel A). Growth inhibition experiments were terminated at 
72hr post-cisplatin addition. This is the same endpoint used in growth inhibition 
experiments with cisplatin alone in chapter 4. Growth inhibition was assessed using the 
SRB assay as described in section 2.4. The effects of concurrent, sequential and 
delayed administration of STS are shown in Figure 5.8 - Figure 5.10. GI50 values for 
the four cell lines are given in Table 5.2. 
  
Co-incubation of cisplatin and STS led to 35, 21, 22 and >17-fold increases in GI50 
values for 833K, A2780, LoVo and Mor/CPR cells respectively. Sequential and 
delayed exposure to STS had no significant effect on growth inhibition in any of the 
four cell lines tested.  
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Figure 5.8: The effect of concurrent administration of STS on growth inhibition by 
cisplatin in 833K (A), A2780 (B), LoVo (C) and Mor/CPR (D) cells. Cells were 
incubated with cisplatin alone () or cisplatin and 12.6 mM STS (). Each point 
represents the mean of 3 different experiments and error bars reflect standard 
deviation. Where not shown, error bars lie within the points. 
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Figure 5.9: The effect of sequential administration of STS on growth inhibition by 
cisplatin in 833K (A), A2780 (B), LoVo (C) and Mor/CPR (D) cells. Cells were 
incubated with cisplatin alone () or cisplatin and 12.6 mM STS ().Each point 
represents the mean of 3 different experiments and error bars reflect standard 
deviation. Where not shown, error bars lie within the points. 
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Figure 5.10: The effect of delayed administration of STS on growth inhibition by 
cisplatin in 833K (A), A2780 (B), LoVo (C) and Mor/CPR (D) cells. Cells were 
incubated with cisplatin alone () or cisplatin and 12.6 mM STS (). Each point 
represents the mean of 3 different experiments and error bars reflect standard 
deviation. Where not shown, error bars lie within the points. 
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Table 5.2: GI50 values for 833K, A2780, LoVo and Mor/CPR cells incubated with 
cisplatin +/- STS and respective ratio’s. Ratios are calculated as : GI50 cisplatin + STS/ 
GI50 cisplatin.  
Cell Line Incubation Concurrent Sequential Delayed 
833K 
Cisplatin 1.4 µM 1.5 µM 1.3 µM 
Cisplatin + STS 50.3 µM 1.6 µM 1.3 µM 
Ratio 35 1 1 
A2780 
Cisplatin 2.2 µM 2.3 µM 2.2 µM 
Cisplatin + STS 45.5 µM 2.4 µM 2.2 µM 
Ratio 21 1 1 
LoVo 
Cisplatin 2.7 µM 2.9 µM 2.9 µM 
Cisplatin + STS 59.9 µM 3.0 µM 2.7 µM 
Ratio 22 1 1 
Mor/CPR 
Cisplatin 29.4 µM 30.5 µM 30.5 µM 
Cisplatin + STS > 500 µM 30.3 µM 29.7 µM 
Ratio > 17 1 1 
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5.2.6: Effect of STS on total Pt-DNA adduct formation 
 
Human tumour cells 833K, A2780 and LoVo cells were incubated with 3 µM cisplatin 
in the presence and absence of 12.6 mM STS. Mor/CPR cells were incubated with 30 
µM cisplatin +/- STS. The choice of concentrations was based on GI50 concentrations 
determined in chapter 4. Incubation times are shown in Figure 5.7 (panel B). 
Immediately after the endpoint, cells were harvested and tubes containing pellets were 
frozen at -80°C. DNA was extracted using the hydroxyapatite method as described in 
section 2.5. DNA extracted from cells was hydrolysed overnight at 70°C in 3.5% nitric 
acid. Total Pt-DNA adducts levels were determined by ICP-MS as described in 2.11. 
 
For the incubation schedules described earlier (Figure 5.7) the three treatment 
schedules resulted in sets of samples where cells were all exposed to cisplatin for 6hr 
but were harvested at three different time points. The data (Figure 5.11) shows a 
general decline in total adduct level with time, although there appears to be a transient 
rise in adduct levels at the 12hr time point for 833K cells. This will be discussed further 
at the end of this chapter. 
 
Concurrent incubation of human tumour cells with cisplatin and STS led to 2.4, 3.6, 3.1 
and 10.1 fold reductions in adduct level for 833K, A2780, LoVo and Mor/CPR cells 
respectively (Figure 5.12, Table 5.3). These values were significant (p = < 0.0001, 0.02, 
0.0002 and 0.0034 for 833K, A2780, LoVo and Mor/CPR cells respectively). No 
significant decreases in Pt-DNA adducts levels were observed in any of the four cell 
lines when STS was added in the sequential or delayed regimes (Figure 5.12, Table 
5.3).  
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Figure 5.11: Changes in total Pt-DNA adducts formed in 833K (), A2780 (), LoVo 
() and Mor/CPR () cells following incubation with cisplatin at 3, 3, 3 and 30 µM 
respectively. Cells were incubated with cisplatin and harvested at varying timepoints. 
Total Pt-DNA adducts levels were determined by ICP-MS. Each point represents the 
mean of 3 different experiments and error bars reflect standard deviation. Where not 
shown, error bars lie within the points. 
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Figure 5.12: Analysis of total cisplatin-DNA adduct level in 833K, A2780, LoVo and 
Mor/CPR cells following concurrent (A), sequential (B) and delayed (C) incubation 
with cisplatin +/- STS. Each bar represents the mean of 3 different experiments and 
error bars reflect standard deviation. Where not shown, error bars lie within the points. 
*, p = <0.05, **, p = < 0.01, ***, p = < 0.001 
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Table 5.3: Effect of STS of cisplatin-DNA adducts formation in four cell lines exposed to cisplatin using three different schedules. 833K, A2780, 
LoVo and Mor/CPR cells were incubated (6hr) with (3, 3, 3 and 30 µM cisplatin respectively. STS (12.6 mM, 6hr) was present concurrently, 
immediately after of or after a 6hr delay relative to the exposure of cisplatin. Each value represents the mean of 3 individual experiments. 
Standard deviation is shown in brackets. 
 Concurrent Sequential Delayed 
Cisplatin Cisplatin + STS Cisplatin Cisplatin + STS Cisplatin Cisplatin + STS 
833K nmol Pt g
-1
 DNA 39.6 (1.9) 16.6 (1.7) 50.8 (2.7) 47.5 (1.5) 31.5 (1.4) 33.5 (3.1) 
% Cisplatin Alone  41.9 (4.2)  93.3 (3.8)  106.1 (7.9) 
A2780 nmol Pt g
-1
 DNA 35.6 (4.3) 10.0 (2.2) 26.7 (3.8) 28.0 (2.6) 23.1 (1.0) 22.5 (2.0) 
% Cisplatin Alone  28.0 (6.1)  105.2 (7.2)  97.4 (5.6) 
LoVo nmol Pt g
-1
 DNA 22.6 (1.6) 7.4 (1.8) 16.3 (0.6) 17.3 (1.3) 14.6 (1.2) 15.6 (1.2) 
% Cisplatin Alone  32.5 (8.2)  106.4 (6.0)  106.9 (5.2) 
Mor/CPR nmol Pt g
-1
 DNA 81.7 (7.9) 8.0 (1.0) 50.4 (5.4) 54.4 (2.3) 44.5 (2.9) 46.0 (5.9) 
% Cisplatin Alone  9.8 (1.2)  107.8 (2.8)  103.5 (7.3) 
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5.3: Discussion 
 
STS is currently in a phase III clinical trial (SIOPEL 6) to investigate its ability to 
reduce ototoxicity in patients receiving cisplatin for standard risk hepatoblastoma. It is 
hypothesised that STS binds to unreacted platinum compounds in extracellular 
compartments, inactivating the drug before it interacts with DNA. Although there is 
recent evidence suggesting that thiosulfate ions are transported into cells by the SLC13 
family of sulfate transporters (Pajor 2006), it is generally assumed that STS does not 
enter cells and this view is based on pharmacokinetic data from dogs (Gilman et al 
1946). In the clinical trial, STS is administered 6 hours after cessation of cisplatin 
infusion. This was based on data showing that delayed administration of STS can 
significantly reduce toxicity without affecting platinum drug antitumour efficacy 
(Howell and Taetle 1980, Neuwelt et al 1996, Muldoon et al 2000). 
 
There is however no conclusive data to eliminate the possibility of STS entering cells. 
Also, it is not clear whether or not, if STS did accumulate intracellularly, it might affect 
the quantity or quality of the DNA adducts that were formed by cisplatin. Other sulfur-
containing compounds such as glutathione and thiourea have previously been shown to 
bind DNA via Pt (Burchenal et al 1978, Filipski et al 1979, Micetich et al 1983, 
Eastman 1987). It was therefore hypothesised that STS could potentially alter the types 
of Pt-DNA adducts formed in cells if it were able to enter cells. 
 
The data presented in this chapter showed that STS is able to inhibit the binding of 
cisplatin to purified DNA (Table 5.1). The extent of this inhibition is concentration 
dependent. For 2hr incubations it was estimated that 0.07 mM STS would cause a 50% 
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decrease in DNA adduct formation. In contrast, data in chapter 4 shows that 3.9 mM 
GSH was needed to cause a similar effect under exactly the same conditions of DNA 
and cisplatin concentration. For 24hr incubations, the equivalent concentrations were 
estimated to be 0.05 mM STS and 2.7 mM GSH. Thus, to achieve similar effects of 
adduct formation STS needed to be present at concentrations of approximately 55-fold 
lower than GSH. This implies that if a small quantity of STS entered cells it could, in 
principle, exert a strong effect on the intracellular pharmacology of cisplatin. 
 
Chromatographic separation and analysis of individual platinum adducts on calf thymus 
DNA by ICP-MS failed to give consistent evidence for the formation of cross-links 
involving STS. Although there was evidence for a novel platinum-containing product in 
some analyses (Figure 5.5), the majority of experiments failed to show the presence of 
detectable quantities of this product. A platinum-containing product with the same 
chromatographic properties as the novel Pt-containing product detected in hydrolysates 
of one of the DNA preparations was observed when dGMP was incubated with 
cisplatin, followed by incubation with STS (Figure 5.6). It is therefore concluded that 
although such novel products could not be reproducibly induced, the possibility that 
STS is able to form novel products with DNA can be excluded. 
 
Growth inhibition experiments confirmed that in four cell lines, concurrent incubation 
with cisplatin and STS is detrimental to the anti-tumour efficacy of cisplatin, with 35-, 
21- and 22-fold increases in GI50 concentrations observed for 833K, A2780 and LoVo 
cells. This data is consistent with previous experiments which showed that STS has an 
antagonistic effect on platinum drugs when exposed simultaneously or within a short 
period of time after (Howell and Taetle 1980, Neuwelt et al 1996, Muldoon et al 2000). 
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Neither sequential nor delayed administration of STS had any effect in this study on the 
antiproliferative effects of cisplatin as reported previously (Neuwelt et al 1996, 
Muldoon et al 2000). 
 
The incubations schedules described above for the study of total Pt-DNA adducts 
resulted in a consistent 6hr exposure to cisplatin, but varying time points at which cells 
were harvested. The data for all cell lines showed a decrease in overall adduct level 
with increase in time after the end of cisplatin incubation (Figure 5.11). This could 
reflect the effects of DNA repair processes. It is however possible that this could be a 
result of dilution of DNA adducts levels due to increases in the amount of total DNA in 
the culture as a result of continued DNA replication. Although DNA damage can halt 
DNA replication (e.g. via p53 mediated G1 arrest) or stalling at replication sites, this 
does not always occur. The p53 pathway is likely to be inactivated in cancer cell lines 
and DNA replication can by-pass Pt-DNA adducts. 
 
A general decline is seen in total adduct level over although there appears to be a 
transient rise in adduct levels at the 12hr time point for the 833K cells. This 
phenomenon is seen in both the cells incubated with cisplatin alone and the cells 
incubated with cisplatin followed by STS. Adduct levels decrease at the 18hr timepoint. 
It is possible therefore that in the 833K cells Pt-DNA adduct levels continue to increase 
during the time between the 6hr and 12hr timepoints. As the 833K cells are the most 
sensitive to cisplatin of the four cell lines studied it is possible that they were more 
strongly inhibited during the first few hours after drug exposure hence the lower values 
in the 6hr incubation. 
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The data presented in this chapter support the hypothesis that STS is unable to enter 
cells, and is effective in the extracellular compartment. The data also support the 
previous findings that delaying administration of STS has no effect on the antitumour 
effects of STS. Neither sequential nor delayed administration of STS had any 
significant effect on GI50 values in any of the four human cell lines analysed (Table 
5.2). However, concurrent incubation of human tumour cells with cisplatin and STS 
caused significant increases in GI50 values (Table 5.2). A similar trend was seen when 
total Pt-DNA adducts levels were measured, with significant decreases in total Pt-DNA 
adducts levels observed when human tumour cells were incubated with cisplatin and 
STS concurrently, and no significant effect observed when administration of STS was 
delayed (Table 5.3). 
 
What is not apparent however is the discrepancy between the fold changes observed for 
GI50 values and those found for total Pt-DNA adducts? Adduct levels are normally 
linearly related to drug dose, and higher levels of adducts observed at higher drug 
doses. In this study, 2.4-, 3.6-, 3.1- and 10.1-fold decreases in total Pt-DNA adducts 
levels were observed for 833K, A2780, LoVo and Mor/CPR cells respectively when 
cisplatin and STS were incubated with cells concurrently. However, GI50 values 
increased by 35-, 21- and 22-fold for 833K, A2780 and LoVo cells respectively. One 
potential explanation for this phenomenon is that Pt-DNA adducts formed in cells in the 
presence of STS are of a different nature to those formed when exposed to cisplatin 
alone. This is discussed further in chapter 7. 
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Chapter 6 
Investigation of adducts formed in biopsies from ovarian 
cancer patients following treatment with carboplatin 
 
6.1: Introduction 
 
Understanding of Pt drug pharmacology in vitro has provided substantial information 
on the formation of Pt-DNA adducts. Suitable techniques have been developed and 
optimised that have shed light on the nature of adducts formed, although their 
individual contribution to the cytotoxic mechanism of Pt-containing anticancer drugs 
remains unclear. However, there has been very little investigation into the formation of 
Pt-DNA adducts in patients receiving Pt-based chemotherapy clinically. Such studies 
are limited by the difficulties in obtaining tumour samples, especially from patients 
immediately after chemotherapy, which is critical to allow accurate reporting of drug 
levels in tumours at times that are clinically relevant to drug administration. The 
inability to repeatedly remove such biopsies is an additional constraint resulting in 
studies limited to small sample sizes and numbers. Investigating intra-tumoural Pt 
levels is also limited by the inherently low levels of Pt-DNA adducts. For this reason 
analysis of clinical samples has required the development of highly sensitive assays for 
studying Pt-DNA adducts. 
 
Early investigations indicated associations between adducts formed in PBLs and 
clinical response and toxicity (Reed et al 1988, Reed et al 1990) and showed 
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correlations between adducts formed in PBLs in patients receiving cisplatin 
chemotherapy and PBLs incubated with cisplatin in vitro (Fichtinger-Schepman et al 
1995, Oshita et al 1995). However, contradictory evidence has been published (Bonetti 
et al 1996). Unfortunately these earlier studies did not investigate the pharmacokinetics 
of Pt drugs. When pharmacokinetics was studied along with Pt-DNA adduct formation 
in PBLs poor correlation was found between in vivo adduct levels and unbound or total 
cisplatin plasma concentrations, leading to the conclusion that variations in Pt-DNA 
adduct formation is not predominantly determined by free drug concentration in the 
circulation (Peng et al 1997, Veal et al 2001, Veal et al 2007).  
 
It is important to note however that the studies mentioned above investigated Pt-DNA 
adduct formation in normal blood cells. Studies on tumour tissue are much less 
common. Drug exposure in tissues is intrinsically more complex than in the blood 
stream and factors such as differences in vasculature access, blood flow, capillary 
permeability, interstitial pressure and lymphatic drainage may vary in tumours (Jain 
1996). Drug access is also limited by the surrounding tissues (Hobbs et al 1998). 
 
One of the first reported in vivo studies on solid tumour Pt levels was published by 
Fichtinger-Schepman et al (Fichtinger-Schepman et al 1989). This study involved 
administration of cisplatin to female LOU/M rats bearing either a cisplatin-resistant or 
sensitive IgM immunocytoma, with animals sacrificed at 1hr or 24hr after 
administration. Total levels of Pt were determined for the kidneys, liver, spleen, tumour 
and blood by ELISA and/or AAS. After a 1hr exposure, total tissue levels of Pt were in 
the order of kidney > liver > tumour > spleen. After 24hr, Pt levels were in the order of 
kidney > liver > spleen > tumour. The greatest decrease in Pt levels was observed in the 
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resistant tumours. Cisplatin-DNA adduct levels determined by competitive ELISA 
showed the same ranking as Pt levels. Except for the kidneys, all samples showed a 
decrease in Pt-DNA adduct level between 1hr and 24hr. It was concluded from the data 
that the difference in susceptibility to cisplatin between sensitive and resistant tumours 
was not a result of decreased Pt content or lower levels of Pt-DNA adduct formation. In 
another study, Zamboni et al implanted human non-small cell lung cancer H23 cells 
into SCID mice and investigated Pt disposition in cells (Zamboni et al 2004). Total Pt 
in plasma ultrafiltrate and tissue homogenates (tumour, liver, kidney and spleen) was 
determined by AAS. Tumour extracellular fluid (ECF) was collected by microdialysis 
for determination of unbound Pt concentration. After microdialysis, tumour samples 
were collected (at the site of probe insertion). Total Pt in tumour samples was 
determined by AAS and levels of 1,2-intrastrand cis-Pt(NH3)2d(GpG) and cis-
Pt(NH3)2d(ApG) adducts determined using a 
32
P post-labelling assay. Zamboni et al 
found that the AUC of free cisplatin in the plasma increased with dose, but this was not 
consistent with the AUCECF. They also showed a considerable variability in total 
unbound Pt in both ECF and tumour homogenates, and no relationship between 
AUCECF and total Pt or Pt-DNA adduct formation. 
 
More recently, studies have been published investigating formation of Pt-DNA adducts 
in biopsies of head and neck squamous cell carcinoma (HNSCC) removed from 
patients (Hoebers et al 2006, Hoebers et al 2008). These studies investigated Pt-DNA 
adduct formation following two types of infusion – selective intra-arterial (IA) high 
dose cisplatin with systemic STS rescue and intravenous (IV) standard dose cisplatin. 
The hypothesis behind this approach was that adduct formation in the primary tumour 
would be significantly greater with the higher dose IA administration. However, no 
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significant difference was observed in primary tumours. Also, Pt-DNA adducts levels 
were found to be higher in white blood cells (WBC) following standard dose IV 
administration. No correlation was observed between Pt-DNA adducts levels in WBC 
and in tumour tissue. These findings further confirm data obtained from previous 
studies (Peng et al 1997, Veal et al 2001, Veal et al 2007), indicating that variation in 
Pt-DNA adducts formation cannot be attributed simply to drug dose or AUC of drug in 
the plasma, and suggest that WBC adducts levels may not be predictive markers for 
patient response to Pt drug chemotherapy. 
 
The aim of the work presented in this chapter was to determine Pt-DNA adduct levels 
in human ovarian tumour biopsies and compare these levels with Pt-DNA adduct levels 
in peripheral blood cells, and to compare adduct levels with plasma pharmacokinetics 
following carboplatin treatment. The techniques used here have not been previously 
applied to measuring Pt-DNA adducts levels in solid human tumour tissue and no data 
at all for adduct levels in clinical solid ovarian tumour has previously been reported. 
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6.2: Study Methods 
6.2.1:  Ovarian Cancer Overview and Patient Details 
 
Ovarian cancer is a term used to describe over 30 different types of malignancies, each 
with its own unique characteristics and responses. Ovarian tumours are divided into 
three major categories based on the cell types they originated within: epithelial 
tumours, germ-cell tumours and sex-cord stromal tumours. Epithelial tumours arise in 
the cells that cover the ovaries. All four patients in this study presented with epithelial 
tumours. 
 
Epithelial ovarian tumours are further classified by the cells from which they originate. 
The most common are serous tumours, accounting for 40% of the total epithelial 
tumours. Serous tumours typically occur in patients between the ages of 40 and 60. 
Endometrioid tumours account for 20% of total epithelial tumours and typically occur 
in patients between the ages of 50-70. Clear cell (6%) and mucinous (1%) tumours 
occur to a lesser extent and typically occur between the ages of 30-50 and 40-80 
respectively. The remaining 30% of epithelial tumours is comprised of Brenner 
tumours, undifferentiated tumours (cannot be classified by microscopy) and borderline 
ovarian tumours (occur on the surface of the ovary, not inside). 
 
Two of the most important details about a tumour are the stage and the grade of the 
cancer. Doctors use the FIGO system for determining the stage of ovarian tumours and 
assign a value of 1-4 based on how far the tumour has spread, and use this information 
to determine suitable treatment regimes (specifics of the FIGO staging system for 
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ovarian cancer are summarised in the appendix of this thesis). Lower stage tumours are 
generally considered to have a more favourable outcome.  
 
Ovarian tumours are also graded, measuring how normal/malignant the cells look under 
the microscope. Grade 0 tumours are undifferentiated/borderline ovarian tumours. 
Grade 1 tumours have well differentiated cells (similar to normal, healthy epithelial 
cells), Grade 2 tumours consist of moderately differentiated cells and Grade 3 tumour 
cells are poorly differentiated. Grade 3 tumours have the worse prognosis. 
 
Patient 1 was initially diagnosed in 2001 at the age of 47 and presented with serous cell 
ovarian cancer (stage 1C, grade 1). Patient 1 was treated with carboplatin and 
therapeutic outcome was classified as complete. Patient 1 subsequently relapsed in 
2007 at the age of 52 and was treated with carboplatin/taxol as per the adduct study 
treatment schedule. Patient 1 is still alive with disease (last recorded status 13
th
 
November 2008). 
 
Patient 2 was initially diagnosed in 2005 at the age of 74 and presented with 
endometrioid cell ovarian cancer (stage 1C, grade 3). Patient 2 was treated with 
carboplatin and therapeutic outcome was classified as complete. Patient 2 subsequently 
relapsed in 2007 at the age of 76 and was treated with carboplatin/taxol as per the 
adduct study treatment schedule. The subsequent status of Patient 2 is unknown. 
 
Patient 3 was initially diagnosed in 2004 at the age of 65 and presented with clear cell 
ovarian cancer (stage 3C, grade 3). Patient 3 was treated with carboplatin and taxol, 
therapeutic outcome was classified as optimal. Patient 3 subsequently relapsed in 2007 
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at the age of 68 and was treated with carboplatin/taxol as per the adduct study treatment 
schedule. The therapeutic outcome was classified as complete. Patient 3 subsequently 
died of the disease. 
 
Patient 4 was initially diagnosed in 2002 at the age of 62 and presented with clear cell 
ovarian cancer (stage 1C, grade 3). Patient 4 was treated with carboplatin and taxol, 
therapeutic outcome was classified as optimal. Patient 4 subsequently relapsed in 2007 
at the age of 68 and was treated with carboplatin/taxol as per the adduct study treatment 
schedule. The therapeutic outcome was classified as complete. Patient 4 is still alive 
with disease (last recorded status 6
th
 July 2010). 
 
6.2.2: Treatment Schedule and Sampling Time 
 
All samples were collected according to a protocol and using a patient information 
sheet and consent that had been approved by the Local Regional Ethics Committee. All 
samples were stored in accordance with the Human Tissue Act in a secure freezer in the 
NICR. 
 
Patients initially received a 3 hour taxol infusion i.v. followed by a 45 minute rest 
period. During this rest period a pretreatment blood sample (20 ml) was taken as a 
control for determining background levels of Pt bound to DNA in peripheral blood 
mononuclear cells (PB-MNC) and for measuring pharmacokinetics at defined 
timepoints following administration. Carboplatin was infused i.v. over a 30 minute 
period. The dosing in this time was calculated taking into account renal function to 
achieve a target AUC of 5.5 mg/ml.min. Blood samples (2 ml) for pharmacokinetic 
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analysis were taken pre-infusion, 15 minutes after the start of infusion and at 30 
minutes at the end of infusion. Further blood samples (2 ml) for pharmacokinetics were 
taken at 30, 60, 120 and 180 minutes after the end of infusion. At 180 minutes an 
additional blood sample (20 ml) was collected to determine Pt-DNA adducts levels in 
PB-MNC. At the same time biopsies were removed from accessible ovarian tumour for 
determining intra-tumoural Pt-DNA adduct levels and for histological analysis. 
Biopsies for adduct measurement were placed in 2 ml vials and maintained on dry ice 
pending transfer to the NICR and storage at -80°C. 
 
6.2.3: Preparation of blood samples at the Queen Elizabeth Hospital 
 
Determination of pharmacokinetic parameters 
Blood samples were collected into lithium heparinised tubes and were immediately 
centrifuged at 1200 x g for 10 minutes at room temperature to separate plasma. A 1 ml 
aliquot of plasma was transferred to an Amicon Centrifree micropartition unit with a 
MW cut-off of 30 kDa (Millipore, UK). The remaining plasma was transferred to a 
screw-capped 1.5 ml microfuge tube and stored on dry ice. The micropartition unit 
containing the plasma sample was centrifuged at 1900 x g for 15 minutes at 4°C, and 
the cup containing the plasma ultrafiltrate was removed, capped, and stored on dry ice. 
Samples were transferred to the NICR and stored at -80°C. Pt levels were determined 
by AAS by Dr Gareth Veal as described in section 2.10. 
 
Measurement of Pt-DNA adducts levels 
Blood samples (20 ml) were collected into lithium heparinised tubes which were 
maintained at room temperature. Samples were immediately transferred to Leucosep 
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tubes (Greiner Bio-One) containing 15 ml sterile Lymphoprep solution, centrifuged 
(1000 x g, 15 minutes at room temperature) and then plasma removed. The 
plasma/cells/lymphoprep layer was transferred into a clean 50 ml tube, diluted with a 2-
fold excess of cold PBS, and centrifuged (1000 x g, 5mins at room temperature). PB-
MNCs were washed twice with cold PBS and mononuclear cells collected as pellets by 
further centrifugation (1000 x g, 5 minutes at room temperature). Tubes containing the 
pellets were placed in dry ice. Samples were transferred to the NICR and maintained at 
-80°C prior to DNA extraction.  
 
6.2.4: Sample Handling in the NICR 
 
Pt levels in the patient samples were predicted to be very low, and therefore precautions 
were taken to ensure that external Pt was not introduced into the sample preparations at 
any time. All sample handling was carried out in a dedicated Pt-free laminar flow 
cabinet in a designated Pt-free room. All equipment used in sample preparation was 
unique to this analysis to prevent contamination from external sources, and was stored 
in a locked Pt-free cabinet when not in use.  
 
Dedicated reagents were prepared for this analysis and stored in a locked Pt-free 
cabinet when not in use. Ultrapure nitric acid (Romil, UK) was used for all preparations 
with a certified Pt content of less than 0.1 PPT. Ultrapure water (Elga, UK) was used 
throughout. All reagents (including QIAGEN kit reagents) were analysed by ICP-MS to 
confirm no external Pt content was present. 
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DNA concentration was determined using the NanoDrop spectrophotometer as 
described in section 2.5.3. An additional quality control DNA sample (50 µg/ml) was 
analysed with every sample batch to ensure accuracy. The concentration of DNA 
measured in this sample was always within 5%.  
6.2.5: Samples for checking the techniques and reagents to be used 
 
Control samples not treated with carboplatin were used to confirm both the techniques 
and reagents used in this study did not introduce external Pt into the analysis which 
could affect the results. These samples were also used to determine the background 
levels of Pt as an indicator of the significance of the results obtained from the clinical 
samples. Four kidneys obtained from (individual) female CD-1 nude mice that had not 
been treated with any drugs were used. Pre-carboplatin blood samples obtained from 
three of the four study patients, and blood from healthy volunteers incubated with 
saline were also included. An additional set of mouse kidneys which had been treated 
with 25 mg/kg carboplatin for either 30 or 60 minutes were pooled together and 
aliquots of the tissue homogenate used as a quality control with each batch of samples 
for DNA extraction and analysis. DNA was extracted from all samples using the 
QIAGEN method described in section 2.5.2. DNA was hydrolysed overnight in nitric 
acid (3.5%) at 70°C, and total Pt levels determined by ICP-MS (section 2.11 and 
below). 
6.2.6: ICP-MS analysis 
 
All samples in this chapter were analysed using a Finnigan Element2 Magnetic Sector 
Field ICP-MS (section 2.11.2). Three isotopes of Pt (
194
Pt, 
195
Pt and 
196
Pt) were 
measured. Thallium (Tl) was added (1 PPB final concentration) to all samples and 
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standards to act as an internal reference to enable monitoring of instrumental 
performance and correction for variations due to matrix effects and instrumental 
variation, particularly variation in the rate of sample entry into the plasma torch. Two 
isotopes of thallium (
203
Tl and 
205
Tl) were measured on the ICP-MS. 
 
Isotopes of neodymium (
143
Nd), dysprosium (
161
Dy) and hafnium (
178
Hf and 
179
Hf) 
were also measured. These isotopes were chosen because they are known to have the 
potential to cause interferences if present in samples being analysed for Pt. In this study 
no correction for interference was required on any samples analysed as the measured 
concentrations of each isotope in the samples were significantly lower than measured 
values for Pt, and oxide interference readings therefore contributed significantly less 
than 1% of the detected Pt signal. 
 
At the beginning of each analysis, ultrapure water and ultrapure nitric acid samples 
were analysed to ensure Pt levels were low. These samples were always followed by 
the standards (0-500 PPT Pt), followed by a series of wash samples. During analysis of 
tumour/blood samples, routine analysis of the 5 PPT standard and blank nitric acid 
samples were incorporated to monitor instrument drift. 
 
6.2.7: Data Analysis 
 
During all analyses, the ratio of 
203
Tl:
205
Tl was calculated to monitor instrument 
sensitivity. An average ratio of 1:2.95 (range +/- 0.1) was observed confirming no drift 
in instrument performance. The natural abundances are 29.524% 
203
Tl and 70.476% 
205
Tl so a ratio of 1:2.3 was expected. Counts-per-second (CPS) values for 
205
Tl were 
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chosen to correct the Pt data. CPS values for 
205
Tl varied by less than 10% across all 
analyses. 
 
CPS values for the ultrapure nitric acid wash samples often drifted down slightly during 
the analyses. This was most probably a result of continued flushing of residual Pt out of 
the instrument during analysis of a series of blanks and samples with low levels of Pt.  
Therefore where necessary drifts in instrumental background was corrected by 
subtracting the drift in CPS from the CPS values for the standards used to generate the 
standard curve. The ratio of 
194
Pt:
205
Tl, 
195
Pt:
205
Tl and 
196
Pt:
205
Tl were calculated for all 
blanks and standards, and this was plotted against Pt standard concentration to generate 
a standard curve for each Pt isotope and for each analysis batch (section 2.11.2, Figure 
2.4).  
 
The concentration of Pt (PPT) in each sample was calculated in Prism4 (GraphPad 
Software) using the appropriate standard curve. This value was converted to moles/ml 
by multiplying the value (PPT) by 5.13e
-15
. An average value for the three Pt isotopes 
was determined, and subsequently divided by the concentration of DNA in the sample 
(5.0e
-5
 g/ml) to determine an overall Pt-DNA adduct level in nmol Pt g
-1
 DNA.  
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6.3: Results 
6.3.1: Patient Pharmacokinetics 
 
The antitumour effects of carboplatin have previously been related to its 
pharmacokinetics, which vary markedly between patients, mainly as a result of 
variation in kidney function (Newell et al 987, Harland et al 1991, Horwich et al 1991). 
Doses of carboplatin are therefore typically adjusted to each individual patient taking 
into account a measurement of renal function, using a dosing formula (Calvert et al 
1989, Newell et al 1993) to target the desired area under the plasma drug concentration 
time curve (AUC). Individualised dosing results in a more consistent exposure to 
carboplatin than dosing based on surface area alone, as is typically applied for cisplatin. 
Typically a range of 4-7 mg/ml.min AUC is targeted for conventional carboplatin 
dosing (Veal et al 2007). In this study, the target AUC was 5.5 mg/ml.min.  
 
Concentrations of Pt in plasma ultrafiltrates were determined by AAS by Dr Gareth 
Veal. Unbound (ultrafilterable) plasma Pt concentrations for the four patients are 
plotted in Figure 6.1. The maximum observed unbound plasma carboplatin for all four 
patients was at 30 minutes, with concentrations of 43.72 g/ml, 33.70 g/ml, 34.72 
g/ml and 23.56 g/ml reported for patients 1-4 respectively. There was an 
approximate two fold difference in peak plasma levels, which is common for patients 
receiving carboplatin following renal-function based dosing (Veal et al 1997).  
 
AUC values for each patient were calculated using the trapezoid rule. Patients 1, 2 and 
3 achieved AUC values of 5.1, 6.2 and 4.9 mg/ml.min. Patient 4 achieved a lower AUC 
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value of 3.0 mg/ml.min. The AUC values for patients 1-3 fell within -10 to +15% of the 
target AUC whereas; the AUC for patient 4 was 44% below the target value.   
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Figure 6.1: Concentrations of unbound Pt in the plasma of four patients after a 30 
minute infusion of carboplatin. (), patient 1; (), patient 2; (), patient 3; (), 
patient 4. AUC values were 5.1 mg/ml.min for patient 1, 6.2 mg/ml.min for patient 2, 
4.9 mg/ml.min for patient 3 and 3.0 mg/ml.min for patient 4. 
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6.3.2: Determination of background Pt levels in control samples 
 
Initial test samples (not treated with carboplatin) were analysed to ensure that the 
methods and the batch of reagents to be used for the clinical tumour and blood samples 
gave low background levels of Pt associated with DNA. Confirmation that no platinum 
contamination was introduced was critical to maintain accuracy in evaluating the 
clinical samples, which were predicted to have very low Pt levels. Furthermore, the 
data from these samples helped form a basis to assess the statistics of the background 
readings against which the post-carboplatin samples could be compared. This was 
particularly important because the patient number was small, and therefore only a small 
number of pre-treatment blood samples were available and it was not possible to collect 
pre-treatment samples of tumour. Mouse kidney tissue was used as a blank to assess the 
methods for purification of DNA from solid tissue and blood samples (additional to the 
pre-treatment samples from the four patients) were used to assess methods for 
purification of DNA from blood cells. 
 
Pt concentrations were calculated for each sample from the values for each Pt isotope 
using the appropriate standard curve. Pt concentrations in DNA hydrolysates for the 
mouse tissues (Table 6.1) and volunteer blood samples (Table 6.2) were all low, close 
to the limit of detection typically seen with this instrument, with a mean of 1.4 PPT (+/- 
0.8 SD) for the mouse tissues and 0.5 PPT (+/- 0.5 SD) for the volunteer blood samples. 
This indicated that the methods and reagents used to process the biological samples 
were not introducing appreciable levels of Pt into the samples and therefore samples 
from the patients were analysed using the same batch of reagents. 
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The pre-treatment blood samples from patients 2-4 gave similarly low levels of Pt seen 
in the volunteer blood (Table 6.2) with a mean of 0.7 PPT (+/- 0.7 SD).  
 
The overall mean Pt concentration in the solutions analysed by ICP-MS was 0.8 PPT 
(+/- 0.5 SD), which equates to 4.4 fmoles/ml (+/- 2.4 SD). The overall background Pt-
DNA adducts level was 0.08 nmol Pt g
-1
 DNA (+/- 0.05 SD). 
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Table 6.1: Pt concentration and total adduct level in control mouse kidney tissues. Standard deviation is shown in brackets 
 
  
 
DNA Conc. 
(µg/ml) 
Pt Isotope 
Pt Concentration Adduct Level 
(nmol Pt g
-1
 DNA) PPT Fmoles/ml 
Mouse Kidney 1 418.4 
194
Pt 1.2 5.9  
0.15 
195
Pt 1.2 5.9 
196
Pt 1.2 6.2 
Average 1.2 (0.03) 6.0 (0.1) 
Mouse Kidney 2 348.3 
194
Pt 0.5 2.6 
0.14 
195
Pt 0.4 2.3 
196
Pt 0.7 3.6 
Average 0.6 (0.1) 2.8 (0.7) 
Mouse Kidney 3 430.2 
194
Pt 2.8 14.4 
0.15 
195
Pt 2.4 12.3 
196
Pt 2.5 12.6 
Average 2.7 (0.2) 13.1 (1.1) 
Mouse Kidney 4 322.2 
194
Pt 1.1 5.5 
0.13 
195
Pt 1.4 7.1 
196
Pt 1.3 6.6 
Average 1.3 (0.2) 6.4 (0.9) 
Overall Average 
 
1.4 (0.8) 7.1 (4.3) 0.14 (0.01) 
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Table 6.2: Pt concentration and total adduct level in control human blood. Hydrolysates from the same DNA preparation were prepared and 
analysed on three individual occasions for the patient samples or twice for the volunteer sample and average values presented. Standard 
deviation is shown in brackets 
 
DNA Conc. 
(µg/ml) 
 
Pt Concentration Adduct Level 
(nmol Pt g
-1
 DNA) PPT Fmoles Pt/ml 
Patient 2 147.74 
A 1.8 (0.3) 9.3 
0.16 (0.03) 
B 1.5 (0.5) 7.8 
C 1.3 (0.3) 6.5 
Average 1.5 (0.3) 7.8 (1.4) 
Patient 3 230.60 
A 1.2 (0.1) 6.0 
0.05 (0.06) 
B 0.2 (0.3) 1.1 
C 0.1 (0.2) 0.5 
Average 0.5 (0.6) 2.5 (3.0) 
Patient 4 281.75 
A 0.3 (0.1) 1.4 
0.01 (0.02) 
B 0.1 (0.2) 0.6 
C 0.2 (0.3) 1.0 
Average 0.2 (0.1) 1.0 (0.4) 
 
 
 Average 0.7 (0.7) 3.7 (3.7) 0.07 (0.08) 
Volunteer A 144.25 
A 0.9 (0.4) 4.4 0.09 
B 0.0 (0.0) 0.0 0.00 
Volunteer B 304.76 
A 0.5 (0.4) 2.7 0.05 
B 0.0 (0.0) 0.0 0.00 
Volunteer C 162.7 A 0.9 (0.1) 4.8 0.09 
 Average 0.5 (0.5) 2.4 (2.3) 0.05 (0.05) 
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6.3.3: Analysis of Pt-DNA adducts levels in patient blood samples 
 
PB-MNCs isolated from blood samples 15 minutes prior to carboplatin infusion (Pre) 
and 180 minutes after carboplatin infusion (Post) were analysed for determination of 
therapy-induced Pt-DNA adduct levels. Data for pre- and post-carboplatin blood 
samples are presented in Table 6.3 and Table 6.4 respectively. 
 
Pt concentrations in patient pre-treatment blood samples all fell within 2 SD of the 
overall mean background Pt concentration (Table 6.3). Pt concentrations in patient 
post-carboplatin blood samples ranged from 2.8-68.4 SD above overall mean 
background Pt concentration (Table 6.4). 
 
All patient post-carboplatin blood Pt-DNA adducts levels were significantly higher than 
overall mean background Pt-DNA adducts levels (p = 0.0008, <0.0001, <0.0001 and 
0.0029 for patients 1-4 respectively). Patients 2-4 had significantly higher Pt-DNA 
adducts levels in their post-carboplatin sample compared to their pre-carboplatin 
samples (p = <0.0001, 0.009 and 0.001 for patients 2-4 respectively). 
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Table 6.3: Pt concentration and adduct level in patient pre-carboplatin blood samples (repeat data from Table 6.2). Hydrolysates from the same 
DNA preparation were prepared and analysed on three individual occasions and average values presented. Number of SD above background is 
calculated as: ((Average patient Pt conc. (PPT) – Mean background Pt conc. (0.8 PPT)/ SD of background data (0.5)) SD is shown in brackets. 
  
 
DNA Conc. 
(µg/ml) 
 
Average Pt Concentration Number of SD 
above background 
Adduct Level 
(nmol Pt g
-1
 DNA) PPT Fmoles Pt/ml 
Patient 2 147.7 
A 1.8 (0.3) 9.3 
1.4 0.16 (0.03) 
B 1.5 (0.5) 7.8 
C 1.3 (0.3) 6.5 
Average 1.5 (0.3) 7.9 (1.4) 
Patient 3 230.6 
A 1.2 (0.1) 6.0 
0 0.05 (0.06) 
B 0.2 (0.3) 1.1 
C 0.1 (0.2) 0.5 
Average 0.5 (0.6) 2.5 (3.0) 
Patient 4 281.8 
A 0.3 (0.1) 1.4 
0 0.01 (0.02) 
B 0.1 (0.2) 0.6 
C 0.2 (0.3) 1.0 
Average 0.2 (0.1) 1.0 (0.4) 
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Table 6.4: Pt concentration and adduct level in patient post-carboplatin blood samples. Hydrolysates from the same DNA preparation were 
prepared and analysed on three individual occasions and average values presented. Number of SD above background is calculated as: 
((Average patient Pt conc. (PPT) – Mean background Pt conc. (0.8 PPT)/ SD of background data (0.5)) SD is shown in brackets. ND = no data 
available for sample. 
 
 
DNA Conc. 
(µg/ml) 
 
Average Pt Concentration Number of SD 
above background 
Adduct Level 
(nmol Pt g
-1
 DNA) PPT Fmoles Pt/ml 
Patient 1 66.21 
A 3.7 (0.6) 18.9 
6.4 0.8 (0.1) 
B 4.4 (0.2) 22.6 
C ND ND 
Average 4.0 (0.5) 20.7 (2.6) 
Patient 2 171.98 
A 31.3 (0.04) 160.5 
68 3.6 (0.3) 
B 36.1 (0.4) 185.2 
C 37.2 (0.1) 191.0 
Average 35.0 (3.2) 178.9 (16.2) 
Patient 3 319.14 
A 2.2 (0.2) 11.5 
2.8 0.2 (0.01) 
B 2.2 (0.5) 11.2 
C 2.1 (0.5) 10.8 
Average 2.2 (0.1) 11.2 (0.4) 
Patient 4 311.51 
A 2.7 (0.1) 13.6 
2.8 0.2 (0.04) 
B 1.8 (0.8) 9.4 
C 2.1 (0.7) 10.9 
Average 2.2 (0.4) 11.3 (2.1) 
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6.3.4: Analysis of Pt-DNA adducts in patient tumour biopsies 
 
Tumour biopsies, obtained from patients 180 minutes after carboplatin infusion, were 
analysed for determination of therapy-induced Pt-DNA adduct levels. Biopsies that 
were sufficiently large were subdivided to give 13 pieces of tissue that were processed 
and analysed separately. These are summarised in Figure 6.2. Only one sample was 
available for patient 4, due to the tumour being less surgically accessible than patients 
1-3. Histology of additional biopsy samples confirmed the obtained material was from 
the tumour (Dr Richard Edmondson, personal communication). Data is summarised in 
Table 6.5. 
 
Pt concentrations in the DNA preparations extracted from the 13 biopsy pieces ranged 
from 18.6 to 37.1 PPT Pt (Table 6.5). These Pt concentrations were between 36 and 62 
SD above the overall mean background Pt concentration (Table 6.5) 
 
All seven biopsy pieces analysed (by ICP-MS) on three separate occasions had 
significantly higher Pt-DNA adducts levels compared to overall mean background Pt-
DNA adducts levels: P1-A, p = 0.0002; P1-B, p = 0.0021; P2-A1, p= 0.0002; P2-B2, p 
= 0.0001; P3-B, p = 0.0006, P3-C, p = <0.0001 and P4-A, p = <0.0001.  
 
Only patient 3 demonstrated any significance between pieces of biopsy from the same 
tumour (P3-B and P3-C, p = 0.0242). No significant difference in Pt-DNA adduct level 
was observed between patients 1-3. Patient 4 had significantly higher Pt-DNA adducts 
levels than patients 1-3 (p = 0.0002, <0.0001 and 0.0096 respectively). 
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Figure 6.2: Summary of the source of the 13 biopsy pieces used in this study for 
measuring Pt-DNA adducts in patient tumours following carboplatin administration. 
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Table 6.5: Pt concentration and adduct level in patient biopsies. Individual hydrolysates were analysed either on one occasion, or hydrolysates 
from the same DNA preparation were prepared and analysed on three individual occasions and average values (+/- SD) presented. Number of 
SD above background is calculated as: ((Average patient Pt conc. (PPT) – Mean background Pt conc. (0.8 PPT)/ SD of background data (0.5)).  
 Biopsy Piece 
Pt Concentration Number of SD 
above background 
Adduct Level  
(nmol Pt g
-1
 DNA) PPT Fmoles/ml 
Patient 1 
P1-A 24.1 (0.4) 123.4 (15.8) 47 2.5 (0.3) 
P1-B 22.7 (0.1) 116.4 (26.4) 44 2.3 (0.5) 
P1-B2 18.6  95.2 36 1.9 
Patient 2 
P2-A1 21.6 (0.3) 110.7 (15.1) 54 2.2 (0.3) 
P2-A2 27.2 139.3 53 2.8 
P2-B1 23.7 121.4 46 2.4 
P2-B2 19.0 (0.4) 97.6 (10.8) 36 2.0 (0.2) 
P2-B3 20.1  103.0 39 2.1 
P2-B4 24.8  127.1 48 2.5 
Patient 3 
P3-A 31.7  162.7 62 3.3 
P3-B 31.7 (0.3) 162.4 (26.1) 62 3.2 (0.5) 
P3-C 19.9 (0.4) 102.3 (9.4) 38 2.0 (0.2) 
Patient 4 P4-A 20.6 (0.3) 105.8 (3.8) 40 4.2 (0.2) 
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6.4: Comparison of patient pharmacokinetic parameters with adduct levels 
 
AUC vs. PB-MNCs 
A very weak relationship was observed between plasma carboplatin AUC and post-
treatment Pt-DNA adducts levels in the PB-MNC. A weak correlation was observed 
between plasma carboplatin AUC and post-treatment Pt-DNA adducts levels in PB-
MNCs. (r
2
 = 0.5772, slope 0.9166) (Figure 6. 3A). This correlation was not significant 
(p = 0.2402).  
 
AUC vs. Tumour Biopsies  
A weak correlation was apparent between plasma carboplatin AUC and Pt-DNA adduct 
levels detected in the tumour biopsies (r
2
 = 0.7845, slope -0.5738) (Figure 6. 3B). This 
correlation was not significant (p = 0.1143). Furthermore, it was a negative trend which 
is opposite to what would be expected. 
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Figure 6. 3: Relationship between patient AUC and Pt-DNA adduct levels in PB-MNCs 
(A) and human tumour biopsies (B).  (), patient 1; (), patient 2; (), patient 3; (), 
patient 4. No significant correlation was observed (graph A, p = 0.2402; graph B, p = 
0.1143). 
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6.5: Comparison of adduct levels in blood cells and tumour 
 
No correlation was observed between Pt-DNA adducts levels in PB-MNCs and in 
tumour biopsies (r
2
 = 0.1960, slope -0.2377) (Figure 6. 4). Furthermore, it was a 
negative trend which is opposite to what would be expected. These findings suggest 
that Pt-DNA adduct levels in patient blood are not a good marker for Pt-DNA adduct 
levels in patient biopsies. 
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Figure 6. 4: Relationship between in vivo Pt-DNA adducts levels in PBLs and human 
tumour biopsies. (), patient 1; (), patient 2; (), patient 3; (), patient 4 
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6.6: Discussion 
 
There is currently limited data available on levels of Pt-DNA adducts in tumours of 
patients receiving Pt-based chemotherapy. Several factors have probably contributed to 
this, as described in section 6.1. A sensitive 
32
P post-labelling assay has recently been 
applied to investigations of intra-tumoural Pt-DNA adducts levels in patients receiving 
cisplatin-based chemotherapy for HNSCC (Hoebers et al 2006, Hoebers et al 2008). 
The results described in this chapter are the first application of ICP-MS to the analysis 
of therapy-induced Pt-DNA adducts levels in solid clinical tumours. 
 
Initially, an absolute background level of Pt was calculated using control human blood 
and mouse tissues. This was important to ensure the methods involved did not 
introduce external Pt to the clinical samples ensuring reliability in the measurements, 
and also to provide a value for background levels of Pt present resulting from the 
control samples and from the reagents and apparatus used, including the ICP-MS 
instrument itself. A background level of Pt of 0.8 PPT (+/- 0.5 SD) was measured in 
this study (4.1 fmoles/ml). The corresponding background Pt-DNA adducts level was 
0.08 nmol Pt g
-1
 DNA (0.05 SD). 
 
An AUC of 5.5 mg/ml.min carboplatin was targeted for the four patients studied, with 
dosing based on renal function. The range of AUC values for free Pt in plasma was 
within the range of values expected which, for a targeted AUC value in conjunction 
with renal-based dosing typically covers a 2-fold range (Dr Gareth Veal, personal 
communication). 
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Pt-DNA adducts levels in PB-MNCs obtained from patients post-carboplatin therapy 
ranged from 0.2-3.6 nmol Pt g
-1
 DNA and are comparable to previous studies (Peng et 
al 1997, Veal et al 2001). Peng et al had previously published Pt-DNA adduct levels in 
PBLs of patients receiving carboplatin therapy of 1-3.2 nmol Pt g
-1
 DNA 6hr after the 
end of infusion, and 1-5.9 nmol Pt g
-1
 DNA 24hr after the end of infusion (Peng et al 
1997). These values had been determined by ELISA. More recently Veal et al have 
published data on Pt-DNA adduct levels in children receiving high dose carboplatin for 
solid tumours using ICP-MS to measure Pt (Veal et al 2007). They found Pt-DNA 
adduct levels of 0.24-2.29 nmol Pt g
-1
 DNA in patients 24hr after the end of infusion. 
 
Hoebers et al had previously measured Pt-DNA adduct formation in patients receiving 
cisplatin-based chemotherapy using a 
32
P-post-labelling assay (Hoebers et al 2006, 
Hoebers et al 2008). Normal tissue (WBC) Pt-DNA adduct levels in all the regimes 
investigated ranged from 0.34-1.05 nmol Pt g
-1
DNA and 0.05-0.12 nmol Pt g
-1 
DNA for 
the intrastrand 1,2-d(GpG) and 1,2-d(ApG) adducts respectively. The background Pt-
DNA adduct level observed in the present work was 0.08 nmol Pt g
-1
 DNA (range 0.0-
0.19 nmol Pt g
-1
 DNA). Hoebers et al reported Pt-DNA adduct levels in tumour tissue 
ranging from 0.66-4.55 nmol Pt g
-1 
DNA and 0.1-0.43 nmol Pt g
-1 
DNA for the 
intrastrand 1,2-d(GpG) and 1,2-d(ApG) adducts respectively. Pt-DNA adducts levels in 
patient tumour biopsies in the present study ranged from 1.9-4.2 nmol Pt g
-1
 DNA. 
Comparable levels of Pt-DNA adducts were observed between this study and the 
studies of Hoebers et al. 
 
Pt-DNA adducts level in blood cells had previously been suggested as a marker for 
adduct levels in tumours (Reed et al 1988, Reed et al 1990). More recent published data 
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however has found no correlation was seen between Pt-DNA adduct levels in blood 
cells and tumour biopsies (Hoebers et al 2006, Hoebers et al 2008). The data obtained 
from the present investigation are in agreement with those recent findings. 
 
No significant differences in Pt-DNA adduct level in tumour biopsies was observed 
between patients 1-3. Patient 4 had significantly higher Pt-DNA adducts levels than 
patients 1-3 (p = 0.0002, <0.0001 and 0.0096 respectively). For patients 1 and 2, no 
significant differences in Pt-DNA adduct levels was observed in different biopsies 
obtained from the same tumour. Three pieces of biopsy were obtained from patient 3, 
and although two pieces (P3-A and P3-B) had comparable Pt-DNA adduct levels (3.17 
nmol Pt g
-1
 DNA), a third piece had significantly lower Pt-DNA adduct levels (1.97 
nmol Pt g
-1
 DNA, p = 0.0242). These data suggest that intratumour platination levels 
may vary depending on other factors than carboplatin dose, such as tumour location and 
vasculature access. When Pt-DNA adduct levels were compared with calculated AUC 
values for each patient, no correlation was observed. This suggests that patient AUC is 
not a reliable indicator of adduct levels in tumours. 
 
The application of ICP-MS in this study for measuring Pt-DNA adducts levels in solid 
tissues is novel, and has demonstrated that although material is hard to obtain, analyses 
of Pt adducts in clinical samples is possible.  
 
The very low levels of Pt detected in the DNA samples suggests that the application of 
ICP-MS to detect specific types of adducts will be challenging. However, recently a 
method has been published that does allow for detection of the low levels of the 1,2- 
intrastrand cis-Pt(NH3)2d(GpG) adducts in DNA from PBLs obtained from patients 
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after cisplatin-based chemotherapy (Harrington et al 2010). In this study, PBLs were 
isolated from 8 patients each receiving cisplatin chemotherapy (60 mg m
-2
) and DNA 
extracted. Levels of the cis-Pt(NH3)2d(GpG) adduct ranged from 0.58-6.4 nmol Pt g
-1
 
DNA, in the same range of values as reported in this chapter. The application of such a 
method for studying specific Pt-DNA adducts other than the cis-Pt(NH3)2d(GpG) or for 
studying Pt-DNA adducts in patient tumour biopsies is unknown. 
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Chapter 7 
Final Discussion 
7.1: Introduction 
 
Platinum-based anticancer drugs are believed to exert their action through chemical 
reactions with genomic DNA, forming adducts with DNA bases. Although the 
pharmacology of such adducts has been widely studied, many aspects of the cytotoxic 
mechanisms remain unclear. The possibility that non-DNA molecules have the 
potential to alter the types of adducts formed has received very little attention, and 
limited information is available on the levels of adducts formed in clinical tumours. 
Further understanding of platinum-DNA adduct formation may be important in 
explaining the efficacy of platinum-based drugs in different tumour types, providing 
insights into the cytotoxic mechanism, the development of clinical resistance and how 
to modulate response to therapy using additional drugs. 
  
The aims of the work described in this thesis were: a) to analyse the nature of DNA 
adducts formed in cells by three clinically used platinum-based anticancer drugs and to 
investigate the potential intracellular formation of additional types of adducts to those 
previously characterised on pure DNA; b) to determine platinum-DNA adduct levels 
formed in solid ovarian cancer tissue following treatment of patients with carboplatin 
and test the hypothesis that these levels are comparable to levels of DNA adducts 
formed in blood cells; and c) to determine whether STS impacts on DNA adduct 
formation.  
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7.2: Effects of GSH and STS on total Pt-DNA adduct formation in pure DNA 
 
Sulfur-containing molecules are known to react rapidly with Pt-containing compounds, 
due to the strong affinity of the metal for sulfur (Reedijk 1999, Reedijk 2003, Deubel 
2004). The effects of GSH, an endogenous sulfur containing compound found at 
millimolar concentrations in cells (Meister and Anderson 1983), and STS, an 
exogenous sulfur-containing compound currently in a phase III clinical trial 
investigating otoprotection, on the formation of cisplatin-DNA were therefore 
investigated. 
 
The data presented in chapters 4 and 5 shows that both GSH and STS were able to 
markedly inhibit the binding of cisplatin to purified DNA in a concentration-dependent 
manner. For 2hr incubations it was estimated that 0.07 mM STS would cause a 50% 
decrease in DNA adduct formation. In contrast, 3.9 mM GSH was needed to cause a 
similar effect under exactly the same conditions of DNA and cisplatin concentration. 
For 24hr incubations, the equivalent concentrations were estimated to be 0.05 mM STS 
and 2.7 mM GSH. Thus, to achieve similar effects on adduct formation STS needed to 
be present at concentrations approximately 55-fold lower than GSH. These data are 
consistent with published data suggesting that the reaction of the thiosulfate ion (TS) 
with cisplatin in solution is much faster than the reaction of cisplatin with GSH under 
similar conditions (Leeuwenkamp et al 1991, Dabrowiak et al 2002).  
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7.3: Can GSH and STS be cross-linked to DNA by cisplatin? 
 
Using a similar chromatographic separation to that of Fichtinger-Schepman et al 
(1985), Azim-Araghi (2003) investigated the formation of Pt-DNA adducts in lung 
cancer cell lines (H69/p and Mor/p), using ICP-MS to detect Pt species. Azim-Araghi 
provided evidence for an additional major class of Pt-DNA adducts in DNA from drug-
treated cells compared to those described previously on purified DNA. Analysis of 
cisplatin-DNA adducts formed in purified DNA in the presence of GSH showed further 
evidence of additional types of Pt-DNA adducts being formed. Interestingly, the 
additional adducts found in purified DNA displayed the same chromatographic 
characteristics as those detected in cellular DNA, leading to the hypothesis that GSH is 
able to cross-link to DNA in cells via cisplatin. Evidence that GSH is able to cross-link 
to monofunctionally bound Pt-DNA adducts was published over twenty years ago 
(Micetich et al 1983, Eastman 1987). Limited information is available regarding the 
formation of such adducts involving STS, but assuming that the putative cis-
Pt(NH3)2(DNA)(GSH) cross-link was formed via a Pt-S linkage, it seemed plausible 
that STS should react in a similar manner. If the existence of such Pt-S cross-links were 
to be proven, it would have a significant impact on our understanding of platinum drug 
pharmacology. 
 
The hypothesis for the formation of such Pt-S cross-links was through binding of either 
GSH or STS to cisplatin-bound monofunctionally to DNA. An alternative to this 
approach would be initial binding of GSH or STS to cisplatin, which then reacts with 
DNA. The data described above suggest that initial binding of cisplatin to either GSH 
or STS is more likely to lead to inactivation of drug as opposed to being an 
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intermediate step in adduct formation. However, as Pt-DNA adducts do still form this 
mechanism cannot be totally excluded. Initial experiments were carried out to 
investigate the plausibility of DNA-Pt-S cross link formation, and to identify their 
chromatographic behaviour. The latter information would be an important step to 
identifying novel products formed in cells. 
 
Following incubation of equimolar (1mM) cisplatin with dGMP (used as a surrogate for 
DNA) three monofunctional products were identified with the proposed chemical 
nature cis-Pt(NH3)2(R)(dGMP) where R could be any of Cl
-
, OH or OH2. Further 
incubations with GSH or STS provided evidence for the formation of cis-
Pt(NH3)2(dGMP)(GSH) and cis-Pt(NH3)2(dGMP)(STS) products, eluting from the 
MonoQ system at 21 and 16 minutes respectively. These products provided important 
information about the chromatographic behaviour of putative DNA-Pt-S cross-links, 
and indicated the times and conditions the predicted products would elute. Incubations 
of cisplatin and DNA in the presence of either GSH or STS however failed to provide 
consistent evidence for the formation of DNA-Pt-S cross-links.  
 
One possible reason for the lack of consistent evidence of putative DNA-Pt-S cross-
links was the use of a more robust and efficient gel filtration system to that used by 
Azim-Araghi (2003). The gel filtration column used in this study was somewhat more 
efficient at separating Pt-GSH and Pt-TS products from DNA. If Pt-GSH products 
contaminated previous DNA preparations they could have contributed to observations 
such as the apparent cross-linking of radioactive GSH to DNA by cisplatin. MonoQ 
chromatographic analysis showed that both Pt-GSH and Pt-TS eluted much later to the 
dGMP-Pt-S products so it seems unlikely that this would explain the discrepancy 
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between the data in this study and the new peak seen previously by Azim-Araghi 
(2003). 
 
Two factors that could influence the ability of either GSH or TS to interact with 
platinated DNA and might also explain the lack of consistent evidence of DNA-Pt-S 
products are steric hindrance and charge effects. GSH has a molar mass of 307.6 g/mol, 
and steric effects could inhibit the interaction of GSH with monofunctionally platinated 
DNA. As the thiosulfate ion is much smaller (molar mass of 112.12 g/mol) and more 
reactive, steric effects might be less pronounced. DNA is polyanionic in nature, and has 
an overall negative charge. At neutral pH, GSH has an overall -1 charge, and the 
thiosulfate ion -2. Since both GSH and TS possess negative charges, they should in 
theory be repelled from DNA. In cells DNA is complexed with positively charged 
proteins (such as histones) which would have effects on the ability of GSH and TS to 
interact with monofunctional adducts. While these factors could explain the lack of 
evidence in this study, they fail to address differences between the data presented here 
and in the work of Azim-Araghi (2003). 
 
The formation of Pt-GSH and Pt-TS products is an important issue in understanding the 
availability of Pt binding to DNA. It is believed that cisplatin will react with DNA in its 
aquated form, but not in its dichloro form. GSH and STS however are believed to be 
reactive with cisplatin in both forms. Aquation of cisplatin is the rate limiting step in 
reaction with DNA. It is possible therefore that such competition limits the amount of 
Pt available to bind DNA. Therefore, it is possible that changes to the reaction 
conditions such as altered ionic strength of Cl
-
 could increase the probability of GSH 
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reacting with monofunctionally bound drug through changes to ionic interaction and/or 
the state of aquation of cisplatin. 
 
A further possibility for a lack of evidence for DNA-Pt-S cross-link formation is that 
such cross-links lack stability. Attempts at analysing the putative dGMP-Pt-S products 
by MALDI-TOF mass spectrometry and NMR have proven unsuccessful and this might 
also be explained by lack of stability. However, the proposed DNA-Pt-GSH cross-link 
observed by Azim-Araghi was detected in purified DNA following 2hr and 24hr 
incubation. 
 
Incomplete digestion of DNA in the work of Azim-Araghi (2003) may also explain the 
discrepancy between these data and findings from the current study. Azim-Araghi 
provided evidence showing that increased concentrations of enzymes used in the 
digestion of DNA did not affect the results. However it is still possible that the novel 
products identified by Azim-Araghi were artefacts of incomplete digestion. The ratio of 
DNA to enzymes in this study was less than was used previously (100 μg versus 250 μg 
DNA per 20 units DNAase1 and 200 units/ml nuclease P1). Also, a different 
preparation of P1 was used as the previous supplier ceased its production. 
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7.4: Nature of Pt-DNA adducts formed in cells 
 
Although Pt complexes can interact with many molecules in the intracellular 
environment, it is commonly accepted that platinum binding to DNA is responsible for 
the major cytotoxic effects of platinum complexes. The formation of Pt-DNA adducts 
in purified DNA has been widely studied for cisplatin, and to a lesser extent for 
carboplatin, with more limited data available relating to oxaliplatin-DNA adducts 
formation. However, markedly less information has been published on the formation of 
Pt-DNA adducts in cells exposed to any of the three drugs has been published. In this 
study, the formation of Pt-DNA adducts in four human tumour cell lines (833K, A2780, 
LoVo and Mor/CPR) exposed to cisplatin, carboplatin or oxaliplatin was investigated. 
 
Analyses of adducts formed in cellular DNA incubated with cisplatin confirmed the 
presence of peaks corresponding to the four major previously identified Pt-DNA 
adducts. The percentage contribution of the two major Pt-DNA products was similar to 
previous studies (Fichtinger-Schepman et al 1985, Eastman 1986). Pt-DNA adducts 
formed in cells exposed to carboplatin or oxaliplatin showed very similar retention 
times and relative Pt levels to those seen in the incubation with cisplatin. It is possible 
that the use of a different chromatographic system, such as reverse-phase analysis of 
platinated nucleosides may have revealed differences between adducts formed by 
oxaliplatin compared to cisplatin. 
 
Of particular importance, however, was the lack of evidence for additional types of 
adducts in the regions where cis-Pt(NH3)2(dGMP)(GSH) products eluted or where the 
additional Pt-containing peak was identified in the analyses of Azim-Araghi (2003). 
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The reasons for this are unclear, but two possible factors might have contributed: 1, the 
use of different cell lines and 2, differences in cross-link repair. Potential issues with 
enzyme levels and stability of the proposed adducts have been discussed above. 
 
In the analyses by Azim-Araghi (2003), two non-small cell lung cancer cell lines 
(H69/p and Mor/p) were investigated, whereas in the current study three different cell 
lines were investigated (833K, A2780 and LoVo). Similar retention times of the 
identified peaks and relative proportions of Pt adducts were observed, therefore it 
seems unlikely that adducts formed in these cells differed to those formed in the H69/p 
and Mor/p cells in such a way as to explain the lack of novel products previously 
detected. Furthermore, one of the cell lines used in this study, Mor/CPR, is a cisplatin-
resistant sub-line of the Mor/p cells used by Azim-Araghi. The Mor/CPR cell line had 
been derived from the Mor/P line by selection for drug resistance (Twentyman et al 
1991). It is possible that the resistance mechanisms resulted in altered types of DNA 
adducts being formed in the Mor/CPR line compared to the cells used by Azim-Araghi, 
but it seems unlikely that a major class of adducts would be completely lost, especially 
since the extra peak could not be detected in analyses of DNA from the three other cell 
lines. 
 
Another possibility is that cis-Pt(NH3)2(DNA)(GSH) cross-links were repaired more 
efficiently than their classical counterparts. Analysing Pt-DNA adducts in cells with 
compromised repair capacity would be a way of investigating this. However, repair-
compromised cells demonstrate elevated sensitivity to cisplatin (Beck and Brubaker 
1973, Drobnik and Horacek 1973, Markham and Brubaker 1980, Brouwer et al 1981, 
Beck et al 1985, Fram et al 1985, Popoff et al 1987) so such investigations would 
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require careful decisions regarding drug concentration. In addition, as 2hr drug 
exposures were investigated in the present work, it seems unlikely that the proposed 
adducts would have been removed by DNA repair processes in that time, with the loss 
of total Pt adducts proceeding over a much longer timescale (Fraval and Roberts 1979, 
Roberts and Friedlos 1987). 
 
Overall, the failure to confirm the presence of additional Pt-DNA adducts in cells is 
consistent with the generally accepted model in which GSH protects cells against Pt 
drugs either directly by simple inactivation of the drug or indirectly by affecting the 
redox state of certain proteins. 
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7.5: Effect of STS on the antiproliferative activity of cisplatin in human tumour 
cell lines 
 
When STS was present concurrently with cisplatin it caused 35, 21, 22 and >17-fold 
increases in GI50 values for 833K, A2780, LoVo and Mor/CPR cells respectively 
(Table 5.2). Under the same conditions, 2.4, 3.6, 3.1 and 10.1 fold reductions in adduct 
level were observed (Table 5.3). In this study, the decreases in Pt-DNA adduct levels 
measured after concurrent incubation of cells with cisplatin and STS are lower than 
what would be expected based on the increase in GI50 concentrations. 
 
One potential explanation for this phenomenon is that Pt-DNA adducts formed in cells 
in the presence of STS are of a different nature to those formed when exposed to 
cisplatin alone. There is very limited data however to support the idea that STS is able 
to enter cells, and so it is unclear what to what extent, if any, STS is altering the nature 
of the adducts. Further investigations into the ability of STS to enter cells are required 
to determine the plausibility of STS affecting Pt-DNA adduct structure. Further 
incubations of human tumour cells with STS and cisplatin might permit analysis of 
adducts formed by chromatography/ICP-MS, but significantly higher levels of cisplatin 
would be required due to the effectiveness of STS in binding to and inactivating 
cisplatin. However, such an analysis seems not worthwhile in view of the lack of 
reliable evidence for the formation of altered cisplatin adducts in purified DNA in the 
presence of STS. 
 
A related possible explanation for the discrepancy between the effects of STS on GI50 
and adduct levels is that STS had a particularly strong effect at blocking formation of a 
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minor adduct which is strongly cytotoxic. The clear candidate for this would be the 
interstrand cross-links but this would require entry of STS into cells. This could be 
studied by alkaline elution analysis, but seems an unlikely mechanism because of the 
lack of any effect of delayed addition of STS on growth inhibition. 
 
Finally it is possible that STS was very effective at blocking the reaction of cisplatin 
with cell surface proteins which influence the way that cells respond to DNA damage. 
Such a mechanism could be relevant to the protective effects reports for STS on 
ototoxicity. 
 
Sequential and delayed exposure to STS had no significant effect on growth inhibition 
or adducts levels in any of the four cell lines tested. This is consistent with the proposed 
delayed administration of STS to patients to protect against ototoxicity without 
compromising the anti-tumour activity of cisplatin. 
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7.6: Analysis of Pt-DNA adducts in relation to growth inhibition data 
 
Factors known to affect the sensitivity of cells to Pt drugs can be grouped into three 
classes: 1, factors that affect access of drug to DNA, such as differences in uptake or 
intracellular thiols; 2, the properties of the adducts formed; and 3, factors that affect 
how the cell responds to the damage, such as repair or replication by-pass mechanisms. 
The latter factors are very dependent upon the nature of adducts formed.All of these 
factors contribute towards the GI50 values. However, if the level of adducts required to 
achieve a 50% growth inhibition (AL50) is determined, this data is independent of the 
first set of factors and so reflects the nature of adducts and how cells respond to them.  
 
Cisplatin and carboplatin are believed to form the same types of Pt-DNA adducts; with 
similar relative yields of major adduct types. In three of the four cell lines investigated 
here (A2780, LoVo and Mor/CPR), after 2hr incubations with equitoxic concentrations, 
carboplatin formed 2-fold lower levels of Pt-DNA adducts in cells than cisplatin. As the 
Pt-DNA adducts formed are believed to be the same, it would be expected that the 
levels of adducts required to achieve equal toxicity would be comparable. The 
differences presented here suggest that adducts formed by carboplatin can be slightly 
more toxic than those for cisplatin. However, chromatographic analysis of DNA 
adducts showed no detectable differences. 
 
Pt-DNA cross-links involving proteins were not analysed chromatographically. It is 
therefore possible that these adducts are contributing to cytotoxicity in a different 
manner in cells incubated with carboplatin or cisplatin. Another limitation of the 
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chromatographic separation is the lack of information about the distribution of adducts 
across the genome, and the implication of adducts forming at different sites. 
 
An alternative explanation could be that the drugs interact with other non-DNA 
molecules either intracellularly or on the cell surface, and this could have effects on the 
response of cells. It is possible that interactions of cisplatin or carboplatin with 
intracellular structures or proteins might have detrimental effects of cell signalling 
which could lead to variations in cytotoxicity. 
 
One unexpected finding was the large amount of oxaliplatin-DNA adducts tolerated by 
Mor/CPR cells. This increased tolerance might be a direct result of the cell line being 
resistant to cisplatin, and further understanding of the resistance mechanisms might 
provide evidence for this.  
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7.7: Analysis of Pt-DNA adducts formed in tumour biopsies and blood cells of 
ovarian cancer patients treated clinically with carboplatin  
 
Very few investigations of Pt-DNA adducts levels in solid tumours of patients 
receiving Pt-based chemotherapy have been published. Factors that may have 
contributed to this lack of data include difficulties in obtaining tumour samples at 
appropriate times after drug administration and the small size of such biopsies, 
combined with the inherent low levels of Pt-DNA adducts formed.  
 
In this study, Pt-DNA adducts levels in tumour biopsies and blood cells obtained from 
four patients receiving carboplatin-based chemotherapy were analysed. Pt-DNA 
adducts levels measured in tumour biopsies ranged from 1.9-4.2 nmol Pt g
-1
 DNA. 
These levels are comparable to Pt-DNA adduct levels detected in head and neck cancer 
patients receiving cisplatin-based chemotherapy by Hoebers et al (2006 and 2008). Pt-
DNA adducts levels in blood cells ranged from 0.15-3.5 nmol Pt g
-1
 DNA, comparable 
to previously published studies (Peng et al 1997, Veal et al 2001, Veal et al 2007). No 
correlation was observed between Pt-DNA adduct levels in tumour biopsies and adduct 
levels in blood cells. The lack of correlation between tumour adduct levels and blood 
cell adduct levels is in agreement with previous published findings (Hoebers et al 2006, 
Hoebers et al 2008) It is important to note however the small sample numbers used in 
this study, with only four patients investigated due to the inherent limitations in 
obtaining samples.  
 
In the most sensitive cell line studied (833K), adduct levels required to achieve 50% 
growth inhibition were 9.9 and 12.0 nmol Pt g
-1
 DNA for 2hr and 24hr incubations 
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respectively. The highest adduct level detected in the tumour biopsies was 4.2 nmol Pt 
g
-1
 DNA. These differences suggest that either the doses used clinically were 
ineffective, or the data obtained using cell line models or analysis by SRB assay is not 
directly relevant to the clinical situation. Investigations of drug sensitivity using a 
method such as a clonogenic assay might provide lower estimates of GI50 
concentrations and hence lower AL50 values. The patients studied were being treated 
for advanced metastatic ovarian cancer and had been previously treated with 
carboplatin. Importantly, all four patients had shown prior response to carboplatin-
based therapy as this was a pre-requisite in selection of suitable patients. It is possible 
therefore that resistance to carboplatin may have developed. Information on response of 
the patients has not yet been provided by the clinician. 
 
There is currently major interest in personalising cancer therapy to individual patients. 
A rationale for studying Pt-DNA adducts levels is that they could be used as a 
predictive assay for patient response, with higher levels of adducts potentially resulting 
in a more favourable outcome. Pt-DNA adducts level in blood cells had previously 
been suggested as a possible biomarker for adduct levels in tumours (Reed et al 1988, 
Reed et al 1990, Bonetti et al 1996). These studies were based on the assumption that 
normal tissue could act as a surrogate for tumour tissue. However, more recently 
published data found no correlation between Pt-DNA adduct levels in blood cells and 
tumour biopsies (Hoebers et al 2006, Hoebers et al 2008). The results obtained from the 
present investigation are in agreement with those recent findings. 
 
Welters et al (1999) investigated the formation of Pt-DNA adducts in biopsies taken 
from patients with head and neck or testicular cancer incubated ex vivo with cisplatin. 
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Adduct levels achieved were comparable between head and neck and testicular 
biopsies. These data suggest that analysis of Pt-DNA adducts achieved in patient 
tumour biopsies incubated ex vivo with Pt drugs is a feasible approach towards 
predicting patient response. However, this approach would require intensive laboratory 
work for each sample and it would need to be shown to produce clinically useful data. 
 
This study has demonstrated a successful application of ICP-MS for analysis of total Pt-
DNA adducts in solid ovarian tumour tissue. A major advantage of ICP-MS is the 
minimum preparation steps required from DNA extraction to analysis, improving 
sensitivity of detection. This is further supported by the comparable adduct levels 
detected in this study with those of Hoebers et al (2006 and 2008). A weakness of this 
approach however is that any Pt present in samples will appear to be a Pt-DNA adduct. 
Combining chromatographic separation with ICP-MS is a potential mechanism to 
overcome this, but might decrease sensitivity.   
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7.8: Overall Conclusions 
 
1. It was confirmed that adducts formed in cells incubated with cisplatin were of a 
similar nature to those described previously based on analysis of pure DNA 
incubated with cisplatin. 
2. No evidence was found to support the observations of Azim-Araghi 2003, that 
in cells exposed to cisplatin, an additional major class of Pt-DNA adducts is 
formed. 
3. The chromatographic behaviour of Pt-DNA adducts formed in cells exposed to 
either carboplatin or oxaliplatin are comparable to those of cisplatin, suggesting 
the nature of such adducts is broadly similar. 
4. STS was much more effective than GSH at limiting reaction of cisplatin with 
purified DNA. However, since no evidence of either forming additional adducts 
with platinated DNA was found the direct protective effect appears to result 
from inactivation of free Pt drug rather than modulation of adduct formation. 
5. STS protected cells against cisplatin but only when present concurrently. Effects 
on total adduct levels were not fully consistent with the effects on cytotoxicity. 
6. Pt-DNA adduct levels in tumour biopsies and blood cells obtained from patients 
receiving Pt-based chemotherapy were shown to be quantifiable by ICP-MS 
7. Pt-DNA adducts levels in tumour biopsies and blood cells showed no 
correlation indicating that blood cells have limited value as a marker of tumour 
response. 
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Appendix 
 
Section A: NMR 
 
 
Section 1: Reaction of cisplatin with dGMP 
 
Samples for NMR were prepared in ultrapure water. dGMP was dissolved at 10 mM, 
and cisplatin at 5 mM. For the NMR analyses of dGMP alone, samples were freeze 
dried then re-dissolved in 0.7 mL D2O. This was done twice. For the NMR analyses 
platinated dGMP samples were incubated with cisplatin (2:1 molar ratio) for 72hrs, and 
then freeze dried and re-dissolved in D2O. This was done once. 
 
NMR analysis of dGMP was predicted to detect 7 protons, as labelled in figure A1. 
1
H- 
and COSY-NMR analysis of dGMP alone is shown in figures A2 and A3. 
1
H- and 
COSY-NMR analysis of a reaction mixture of cisplatin with dGMP is shown in figures 
A4 and A5. 
 
NMR analysis of dGMP alone showed 7 detectable proton peaks. These were assigned 
as shown in figure A1 (assignment by Professors Bernard Golding and William 
McFarlane). NMR analysis of a mixture of cisplatin-dGMP showed 7 peaks 
comparable to those seen in the analysis of dGMP alone. 
  
361 
 
 
 
 
Figure A1: Structure of dGMP and 7 protons predicted detected by NMR 
  
362 
 
 
 
 
Figure A2:  
1
H-NMR analysis of 10 mM dGMP dissolved in water 
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Figure A3: COSY-NMR analysis of 10 mM dGMP dissolved in water 
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Figure A4: 
1
H-NMR analysis of a reaction mixture of 5mM cisplatin and 10 mM dGMP 
dissolved in water 
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Figure A5: COSY-NMR analysis a reaction mixture of 5mM cisplatin and 10 mM 
dGMP dissolved in water 
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Section 2: Reaction of cisplatin with GSH 
 
Samples for NMR were prepared in ultrapure water. GSH was dissolved at 10 mM, and 
cisplatin at 5 mM. For the NMR analyses of GSH alone, samples were freeze dried then 
re-dissolved in 0.7 mL D2O. This was done twice. For the NMR analyses platinated 
GSH samples were incubated with cisplatin (2:1 molar ratio) for 72hrs, and then freeze 
dried and re-dissolved in D2O. This was done once. 
 
NMR analysis of GSH was predicted to detect 7 protons, as labelled in figure A6. 
1
H- 
and COSY-NMR analysis of GSH alone is shown in figures A7 and A8. 
1
H- and 
COSY-NMR analysis of a reaction mixture of cisplatin with GSH is shown in figures 
A9 and A10. 
 
NMR analysis of GSH alone showed 6 detectable proton peaks. These were assigned as 
shown in figure A6 (assignment by Professors Bernard Golding and William 
McFarlane). NMR analysis of a mixture of cisplatin-dGMP showed multiple peaks, 
though it was not possible to draw any reliable conclusions from the data. 
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Figure A6: Structure of GSH and 6 protons predicted detected by NMR 
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Figure A7:
 1
H-NMR analysis of 10 mM GSH dissolved in water 
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Figure A8: COSY-NMR analysis of 10 mM GSH dissolved in water 
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Figure A9: 
1
H-NMR analysis of a reaction mixture of 5mM cisplatin and 10 mM GSH 
dissolved in water 
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Figure A10: COSY-NMR analysis a reaction mixture of 5mM cisplatin and 10 mM 
dGMP dissolved in water 
  
372 
 
Section B:  FIGO Staging for Ovarian Cancer 
 
The FIGO (International Federation of Gynaecological Oncologists) staging system is 
used to identify the spread of an ovarian cancer at the time of diagnosis and is used to 
determine appropriate therapy regimes. 
 
Stage 1: The tumour is confined to the ovary/ovaries 
 Stage 1A 
 Only one ovary is affected by the tumour, the ovary capsule is intact 
 No tumour is detectable on the surface of the ovary 
 No malignant cells are detected in the abdominal fluid 
 Stage 1B 
 Both ovaries are affected by the tumour, the ovary capsule is intact 
 No tumour is detectable on the surface of the ovary 
 No malignant cells are detected in the abdominal fluid 
 Stage 1C 
 The tumour occurs in one/both ovaries, the ovary capsule is ruptured 
 Tumour growth is detectable on the ovarian surface 
 Positive malignant cells are detected in the abdominal fluid 
 
Stage 2: The tumour involves one/both ovaries and has extended into the pelvic region 
 Stage 2A 
 The tumour has extended in the fallopian tubes and/or the uterus 
 No malignant cells are detected in the abdominal fluid 
 Stage 2B 
 The tumour has extended into another organ in the pelvis (such as the 
bladder or rectum) 
 No malignant cells are detectable in the abdominal fluid 
 Stage 2C 
 The tumour has extended into the pelvic region as defined in 2A/2B 
 Positive malignant cells are detected in the abdominal fluid 
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Stage 3: The tumour involves one/both ovaries with microscopically confirmed 
peritoneal metastasis (outside the pelvis) or regional lymph node metastasis 
 Stage 3A 
 Microscopic peritoneal metastasis beyond the pelvis 
 Stage 3B 
 Macroscopic peritoneal metastasis beyond the pelvis 
 Tumours less than 2 cm maximum diameter 
 Stage 3C 
 Macroscopic peritoneal metastasis beyond the pelvis ( > 2cm tumour 
diameter) and/or regional lymph node metastasis 
 
Stage 4: Distant metastasis beyond the peritoneal cavity 
 
 
 
 
 
 
 
